var title_f34_42_35488="Mitomycin: Patient drug information";
var content_f34_42_35488=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mitomycin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F13907015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F13907016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/33/10773?source=see_link\">",
"       Mitomycin (systemic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10903 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-49B032D4AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_42_35488=[""].join("\n");
var outline_f34_42_35488=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/33/10773?source=related_link\">",
"      Mitomycin (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_42_35489="Pill esophagitis CPC Endosc";
var content_f34_42_35489=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76438%7EGAST%2F55447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76438%7EGAST%2F55447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Medication-induced esophagitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 262px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEGAPwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5amlk86T52+8e/vTPNk/56P8AnRN/rpP940ygB/myf89H/OjzZP8Ano/50ynxRvNIkcSM8jkKqqMkn0FAFnTra+1O+gstPjnubudtkUMWWZ29AO9e/TQ+PNP8ReFtS0Pwr4jKWFlHa3kU2nvtkAPzDH8XHQ16b+zd8Io/CWnR+INdgDa9cpmONx/x7Ie2P7x717yBxWcqnK7IFqfMnxZ8RfEHU59NPgPQvFNpDGh+0rLpOMsT23BqofGw+JvGfhXRLTR/DHiz+0rZw9w8mmvECdmDgjrzX1XSVLr+Q7HzHqtpqet/CfSvDMmk+MtL1C2SLzJ00aWRSV6gFWBNeZRfDjXNL8SaZezaB4o8UWEb7rm3n0ya2LKP4QSWr7qFFHtvILH59eKfh74w1HX7y70XwJr+nafK+6G1+zyN5S+mcc1lf8Kw+IH/AEKev/8AgJJ/hX6NUhpOtboFj85v+FYfED/oU9f/APAST/CkHwy8fkkDwpr/AB/06Sf4V+iF60yxnyVLevNVrOae4RQS0ZU85XqPxrlnmCjK3KaKk3HmufnsPhr498wp/wAItr28dR9lk/wp/wDwrD4gf9Cnr/8A4CSf4V+iyoM5wM+tPxW0MRKW6IaPzm/4Vh8QP+hT1/8A8BJP8KP+FYfED/oU9f8A/AST/Cv0aorT2/kKx+cv/CsPiB/0Kev/APgJJ/hR/wAKw+IH/Qp6/wD+Akn+FfozRR7fyCx+c3/CsPiB/wBCnr//AICSf4Uf8Kw+IH/Qp6//AOAkn+FfozSGpeI8gsfnMfhj8QByfCmv/wDgJJ/hUb/Dnx0hw/hjXV+trIP6V+jpGagmt45R8y81lPFyW0SoxXU/Odvh544QAv4a1sA9zbP/AIVG3gLxooJPh3WQByc27/4V+hl1p0ZjbjGOnNc5dQrGx3dq53mMl9k7KOEhV2kfnhKZ4pGjkMiOpKspJBB9KZ5sn/PR/wA6+hfj58N0lM3iDQ4P3w+a6hQH5h/fA/nXzwQQcHg16FCtGtHmRz16EqMuVjvNk/56P+dHmyf89H/OmUVsYD/Nk/56P+dX7CWTyW+dvvevsKzav2H+pP8Avf4UAU5v9dJ/vGmU+b/XSf7xplAC19Ufsw/B4qbbxh4lhGfvWFrIvI/6aN/SuQ/Zt+ELeLNRXX/EVqf7Bt2zFHICBdOO3uo719pwxpFEiRqERFCqoGAAOgFZznyi30HKAOvWnZprOqjLHiqNxqtvDnJzXFOtCHxM1hTlLSKNDNJWBJ4mt1Bwh3D1NZs/jWKN+IQV9c1zzx9CO8jqhl+IntE7HIFKCK5e28Z6bLgSFkY/iK011/TWGftKD2Jq4YyjP4ZIieDrwdpQf3GrmiqaajZyAFbiIg/7VWlZWGVII9q2VRS2Zg4SjuhaMCiina5IUtJRRsAUUVVOoWQ1JdPN3bi/aMzC2Mg80oCAW25zjJAzTtcC1VS11Owu727s7S9tZ7uzKi5gjlVngLDK71ByuQCRnrXyJ45hsz4k+Il0LnSv7Xtdet5bWyEP/EyusFcrbyhtyLyScI3TqK6jWPE+u+HPE/xY1Tw/bmK6kvtIjuJXXd9iiaB98h+Vh8vAyVYDOcHGKv2YXPp6gkAZPSvm/UviD4z0/R4Vj8R6HqVrLq6Qy6zZTrKtlbsuQks4tRCDkffETY7gcVYi8feJUfwvp+teLdJj0y9vbyG58RaZ5csbCOMNFD5kkKxbySQWVMHAxghhScGFz3zStTsNXsUvdJvrW+s3JCT20qyxtg4OGUkHBBFWyK+RPhXrF3pmh/DJLP7Kpe016XzHtYpJEZEkZSjspZOeoUgHocium8PfEnxqkXha4fUW1ifV/D+oXzWklrEoNxCshj2eWitzsUEZOcnGOMKVILn0fcf6s8Vyuqry3FeVfDbx9rmteOvDOn3Hic6ta3+iPfX8HkW6i3utxBizGgZduAMMSecnqK9hv4N2TjNebiIcsrHfg5Wd2cTqgyrAjIIIINfMHxj8Cf2Tdvq2lRf6DK2ZY1H+qY9/oa+rdVQYIA+tcbrVkl1bywXESyQuCrowyCKjD1ZUZXR7NWhDE0+XqfF9JXb/ABJ8Gy+G9SaW3Rm06Ukxt/d/2TXEV78JqceZHzValKjJwkFX7D/Un/e/wqhV+w/1J/3v8KsyKc3+uk/3jXp/wH+F9x8Q/EYa6WSLQrQhrqYcb/RFPqf0rmfh34QufHPjW10O0ljhMzlnkf8AhQH5iPU4r9CPBnhnTvCXh+10fSIRHbW64z3du7H3NROSigNDSdNtNJ063sdPgSC0gQRxxp0UCrlFFcjd3dlJWK93GXiOOtcZrkUsTMK7usvVrOOZSxAyK83G4XnjdHdg8R7Keux5rLDMwJFUJ7WSQHb+tdRexLGXwT7YrDundcjGK+anhGnqz6uhWctjBe3uYmPByKV5ZduDkGrtxdGNCWzWXJegsSRkUvq9tmepDmnq0SJezwn5XP0zW7oviy4smAMhI7qeRXLSzKRkLtqnJcANxxUrng7xZc8FTrx5ZxPctF8XWV+yxSN5cp6A9DXTKwYAg5Br5qS9ZZVK5DA8EVJ8XfFvj218Ljw34d8Pa/Jd3UY+1ajb2ExEUZGfLjcLguR94j7oOPvZ2/RZXiq1eXJLp1PkM6ymGCSqQe/T/I+kxgjiuX1HxrpsV7Lp+kpca5qsZ2vaaaok8pvSWQkRxf8AA2B9Aa4T4c2934x8LWLeM3120WFBbNoslrJp0A2rgbud8wIx1faefkHSvWNNsrPTbKO0021gtLSIYSGCMRoo9lHAr2XOnGXK3qfPuLOZ/szxPr2TrOpJodk3/LlpL7p2Ho9yw4+kaqR/fNbegeHdJ8PxSJo9jFbGU7pZRlpZj6ySNlnPuxJrVzRmk6l9BWCg0ZpM1DkhhRURnQS+Xn5qeXAIycZrPnQ7Ds1FcqJIJEJYBlKkqxU8+hHIPuKkzSdetTKV1oCOQ0zwdoukatJqtrBcyam8PkG6vL2e7lEec7A0rsQM84GK0J5wMg1f1HMY3LxXNXk2WJB+tcdRu92ejhafOVNUQPuIxXNXsWc5HWuhnl3rgisq4QO3HB9DSij26MeVHHeIdGtdWsJrO8iEkMgKkdx7g9jXy/438M3PhnWJLaVS0DHdDJjhl/xr6+uYgS1cd408OWniHSZbS4XDHmOQdUb1rrw1Z0nZ7GGNwixEdNz5Pq/Yf6k/73+FGt6dLpOqXFjcFTJC5QlTkGiw/wBSf97/AAr2E01dHy8ouLsz1P8AZZ/5LVY/9c5v5V93nrXwh+y1/wAlqsP+uc38q+7z1rGtsCEpaSiucYHgVzGp6gHM53bVBworevpxFbuQfmxxXmOrSTtPISeM9K4sXXjGNkell2F9tO72RNJdB5GBbOazr64iZyqk5HWsq+uWh/iGfrXPalqMjZzIQPavD509WfZ4bAOTTRp6zexRx7M7m9qpWUlnPG32iby3x8oPC/ia5m4uXkDMW4HqaqPev5XlZAQ9eOaznrse7HBKMOVPU3ft4ywBO0HGfWq73G85z+NYhuvlwT9Kb9sHc81Kg7HTClGO+5uedu/iq3ZO6yhiufqKzdJ1hLfPm20c0QHPXIro/D95Y39wS7qnPCCqjRe5zYiryJrl0NzRL64iuo3iVwoOTivZtHuftNlG/OSOc1xvh6bSo2VGWMN712dneWTLthljAHbIFelhYSg73Pz7OayrS0g1bqX6MVi3mvw2rFWjLY7huMVSg8XWklyYwyH0GcEV6brU1uzx4YWtNXjE6c4AySAKSoLa5juotyEFT2zSqjx8Idydge1DmmrxMXFp2ZXv42Lq8Yy1RGaUnEowKW+upIpEWJN3PzZ4xSzOGUOB9c1zSV3c6IJ2V0Ec7eZt/I1aMpVc7c/So4Y0YZOCfarCxgU4RZnNxvsZmoXCSwlWDKfeuVvNiEsc112rRgxnA5xXEanIVLKamou56mXpS0QgZXGc/Q1VnIHJH41Rt7plypORmpWm3dG/A1nFntKm4kF2u9cjuOCKy3twetaUshHGMe1U5D15/CrTBxPkz4ljb421YD/nuaxbD/Un/e/wrb+J3/I8av8A9dzWJYf6k/73+Fe9R+BHyGK/jS9T1H9l04+NWne6Sj9K+8T1r4E/Ztm8j4y6W3qZBX3JcamVOFxk1hiqsaa1Ip0pT2NVmC9Tiq01xwQh/GsmSWac5JODWhaW+1QW615csTKb5Ym7oqmryYwW7S5Lk4PrWPqPhw3c+4NtSupVaJGCKWJ4FH1bmV5BTxVSk7wZ4p4u0H+z5WcyZUfwj1rzfU2YuQRg17f4uMFzcNI3zL2FeXa9DbAuWC4HfNcVXDRjoj7fJ8znKC9ocXK+EOTz2zVGWQjmrGrXEZcLFgDPX1rOuGCJ8rBvU+lYqlY+hWKTV0E820jB+pqJJ9z5YnA5wO9VJXz049/WoWHGcmuiFE46mNZeN4284O3/AGSasWeqy25Pl7cnuaw2LKeGz9atRTCaLCqEYfka1VFHDUx0u51um+L57ZwJlV/fvXSweLZFxJHGVRhndmvJ45WZyrckdxwK1NMvbeOUQXwl2HqVOcU3Q7HNLEqW6PRZfGUrD5CSD1yagj8QW9w4YuY5Ac1zctrZS/PaXO+M9AQQatJpEv2bPkEsed4bIx9KylRZpSq0j1TQPFMsUAxKTgdz1r0DQvFMd5FhgNw6jNfOuky3FmwRsvAT8wPauy8I3qQ37kyfI3QZog5QehxYzBUaybS1PbJ75LiFtvB7eorLOoyq4jZTjpmqFveCRRtPUUplfdyciupanjQwqhpY3dOn2P8AOdymttJEZchhiuPW424DHBqG4vpYW+8dp6VafKYVMG6stDr70qbdiCDXnPiIskzc4z2zwatSa48bEsSBWfqF7DdRFg4yexrOpUUjuwWCnQldmFJINu5eD9aas7EDnkVA12sc5DcL61ZBikGVPbtXOj25aDhMzqQSDUUudoPAqKT5RkcioJp/kxnmrsZPY+Xfif8A8jvq3/XY/wAhWHYf6k/73+FbnxNOfGuqk/8APY/yFYdh/qT/AL3+FfQUP4cfQ+Mxn8aXqd9+z6GPxe0kIcEyNX3LFYln3Nzivh39nb/ksekZ6b3r7rnvY4FyCMVx4+CklcuhKXLaJaigCgEjkVYUVgLrKLOdzDHuamufEVlAoPmKT9a4afJFlTw9VvY2mZUXcxAA7muK8VeJ44fMihbcqjnbzXP+L/HihGitSCfY15xPfXd+XLSlUf7wHetp1kkduDyudSXNU0Ro6z4oa4V/LbluPlritSuZLgFXY7PetyW2ihi3HgY4rltUuOWEYJz6VyO83c+kpRp0UlEzLogbuBz3Pas8kvKAzZqSUyysQeF7k1RmO1ztdiPXGM1SpG08VbQ3I7Ow/s5JPt6tqEkgRLYjaFGfvMxAA/OsrWd1rcSW7MjyIcfuyHB+hHB/CooUjc5mkKj0+8T/AIU67jhMQFtKsXY8bj+f+FdtONO1pI8yrjGrlSGK5Yh/liUfxSEfyqSQbmI+3wknqRGwH8qpyXH2OJo4rhpN3XIB/nVSKTfyXXCcgHvVKkjjliHI0Lz7UkSxO6SRdQVUA/n1qot2UbCbk9Tmn+abyXdOxA9FX9KUXIsmZo41y3A8xc8UcvkSqr6stWmqz20gaPDr3D969G8KeLLSVRDK4gduNj8A/SvJZp0kI2KF9QDUlvcZPTgevan7JNEyrvY95ksoLsko4XAzlT1rHuLS8sJBNasSAfWuB0nXb6xjzDNvjH8DmunsPFhvSkRiIkxwvPNYSo2OiliXax6f4P8AEyXKLDMwW4X7yHv9K7+GeKUKSvWvnNtQhkn3RMYbmM8kHBBruPDfjKRVWK+IB6BweDWVnHY0mo1Ndj1meESAFccetUbsSIuM59BVKy1eOYoUlUgjPWrD3QaYlumOPelzGcISi+5kTpI7PvQhT7Vzt8rRl9hauyu5EliI4Brl9QK7GBByOhrKUbno0arWjOanuWX/AF2Sp646io7PU/KuvJLEofuk8VU1puTtyMVjmYvtOMEdxWbXKdqSqI737V5seMcVAxPPp6Vk6Rd5UJL94cVtLtI4P6Va1OSfu3R8x/E0Y8Z6pxj97/QViWH+pP8Avf4Vu/FEY8b6oOn73+grCsP9Sf8Ae/wr6Cj/AA0fF4vWtL1Ot+Dl59g+Jmm3HPyyN0r6o1HxMZFJLFUHvXyB4HuDbeMLWVeokNex3Wpy3HBcmuHMbtJI93IacJxk5I7TUvFR5CufpmsS41y5uDhXauay0koXJJPet/TbBkhE0gwpOM15MYM+glyRQ6GGSaUPIevrWohitozuxnHFV55UgQZIrn9W1REUjzAW9BW6p3OSVa+iLGranvfG/Cjg1yl1fNvLE7Ih2Peq17fNIScmsuaRnPOc+9bRpmUp2RYur55TwSidgtV5ZnZcA8dMnrUGG5yTSbT/APWrojA4qlVsl8qaSMjISNerHvUEsuxRHHliP4z0qdQ8gCBePQVF5W5iqHIHBNapWOWU7lB0JGe9MCqMDHtV+SHCnbmoVXyyCse89celXsZtG9oehrcmB7q4EMMh4xwTU3izR9O06MPFdNLIeBGxzXPtf3c0axtIRGn3QD0qHcXlBmy3uxzUqLbvcTZDHAZDnHFWUt2j5AOKf55JxGgHuKkLvt+cgD3FURuKkhTAJ2t2JH9a67SLKze333MjwznBDkZSuc0sRl1aVPNXP3f/AK1dnBqFq1mIlIUjsy/pWU2UlJE11Z2s0aieRWlA/wBZjDY9vT9aqSabewozWsyzDGSjcNj+tZmqMWB2gbR27VFp2qX9j80U7Ff7rksv5Vny3NIzmjR07xXfadKVRshTzGxwRXY6d8TLbKreCSFv9vkfnXCapfafqcO+4tGguf8AnrGODWHPaPsEtvIZYx145/KplSUjop4hrc9zj8Y2NygMVwhz6GqWoa9CVJ81frmvFJIXfDcHj+EU2NHyF5yayeHa6nXDExvsek3+ofaCRGQRT/D1uZ5X3AMeu09TXHWcdwIgSW3DphjxW3omqNZSFnB3jjJ71hKmzvhiFbQ6hoTDdNERtJ5QelaNpdEfI5GR1qpNqtlcw+cEIYAY9apT3Cxz+aCDGex604wsYVJSlueG/E87vG2qH1l/oKw7D/Un/e/wrV+ITBvFmosOQZP6Csqw/wBSf97/AAr3aP8ADR8fiv40i74YOPEsGD/Ga9etULAHH5V5L4Pj83xVbr6ua9vt4BHGpNcuNV7HsZNV9nGQ/T9OeQeZkD0FbFwBFbYLgEDtVT7fHBDhetYep6o0gIU/LXDGCPUqVpS2K+q37klQ3HrXM3TlnJJqxdSlmI65Peq6xGQgmtYojnsivz2/E1G2AeTmr08IRfSqywsx6VpFHPUqshOT704R5IP3vYVI6bTgDB9qm8ry7Tf5q+cxwqAZ/XpWqOWTbIw0cdq6KGM7HHsBUCKANucepqwtsyYXrI3XJoNuV/1gIA6mjQVitnPHT0quyOX+X8ecVprGq5J5ZhhRiq8gMfBXBNCdyWig0IGNwGfanbFHapGOThcZ9alV4oVGV3v9arUhysR2cDXF1HEoKqTyTwK2/wCyLeczJHKqhOSG+9WBLc3EjALhQPQ4qSKQqpMjyBz3zSlCT6mTqWO/8K6D4ZvYjHdXslvck4xI23J9j0rvr3wNpiWUb2FzhQoykmHyfXJrwMzGJuHJ+hzV+z8U6xZIEtr2bYP4Ww38xWMqUnqmDrs9Wh8KWdxbSW8wE0gPEiNgD8KqN8NxFCQ10xY8jaeK4O1+IGs24kysEjP/ABMCCPy4qaDxvrk7r592Yl/v7QR/Ks/ZVE9RxrvZHQ3vg6G3Iie5dnIz97isq68P3Wnt5lq/mL7d6zra91TVtQklkv3JU8MQAD+ArXstZmhJguiGwcD3q9VuaqTZjuXD7ZYxE574xn6iqzRxib5gV9CDkV1F1La3ZEVwAjP9xx61zl1Y3EVxIuCyIfvr0+tNe8awbL2mSY3LKWUkYBxVw2xRCzr8p6N2NYsMzR878k8EdeK3LW5YQbD+9hPTJwRUTijspzktAty28RKMs3AGa0bcpLMLe7k8vb1P901i3W6BwdxGOVI7VraZEdYlihsUaW7fggck1zyT6HZCTtdnjHjf/kY77BB/enkVnWH+pP8Avf4Vo+OIZLbxLfwTKVkjlKsD1BrOsP8AUn/e/wAK9uj8CPkcY715W7mr4HBbxhahRz5hr3CSNyVXNeKeAOPGdsc/xtXukfzEEc1z4roduXSsmVLi1xHkmsC/QYIFdJfyjBUdawp13MAAMmuS1j1VMyVty79sVOYxAgJXI7VprGscefl96rXLy6k8a9VjG1QBgAU0iJzvoY9x+944UZoZRFFknNaslolsmTgtWNqUhPCnI960iYSZUlk3KWYEDPAHekt5JElBCoxPQelVZMnGeW7AVatnRBu2kP0AzmqlZEWbLrCU/NJ19F7VJEB5Z34+g61SlcSZ3scL1+tRwvcSSAW6n2GKg0ULl9GEMm5gCT0HpUkWnz6s8n2GMzFBz7Us3hvU5I1kbGG6g9q7z4evoPhqGdtUWWe+mULD5TYUN/tVM5pK6JnDlR5JqENxYTGGddkneq8aknO4/WvTfiBpUV+r3I2+eoLZXpXlyOOQxxjit6U+dXOSommTqQZFBXIz1ra1W3tYLdGjlAdhytc+HAbqMUy5uk27R1+taOLexje5N57b9sIQ+5FG4od8kmW/uqKoLKSAFJFTw/McHrTUSNCd5y5yUXj0GKt6dffZ2xcQCWBv4fQ+tV0UFSrYB/vU0qR8pwaHYpHUaXqFgt6rOQoYY2qcfmKuakmmn5rK4+YnJBPQ1xkaiQhWAxmrVnbL54QJnn86zlC5pGbR0Sq0jwsxDpkc1vaxbotudmfKlQHK+tcjOZLZAYpGVD1Wu88MxLqnhpyeZozjFYSi46o6FUOKtoliuFaYtgEEAfxD0z2roWkE0jXFtCsMTAKI0+6Pf61UubcGSWKUYkHSl0kyNdfZQcO3vQpux0xjzPmuS3KtLGFZeB1HeuutdI+wW2j3WnXiWzzfK0+cGLPUn2rCnO+4PmyeZL90se+Ku20720ig5eIdj2/CsWdV9PdZ4l8UIEtPHWsW0V4t6kc5/wBIXpJxnIrDsP8AUn/e/wAK1PiAyyeLdSdOhlP8qy7D/Un/AHv8K9al8CPmMRze0lzO7NXwQdvi+2P+2a93hcRw5JwOtfPvhyQw+IonHUOcV6UNYlC8sT9axxHQ7sBszpL+6Vs7SM1mG6WPJY81hzajI+cZyabbxy3MmXYge9ctj0tEaKTS31wI487O5FbAlisocbgCBWM92thHth2g9yKx7q/eViXY/Q1UYmc2at9qe9iFPBrEnnySSaqyXBJ44pikscsa0SsY31J1bPSpUIVG55+lLaRMys//ACzXqccfnU1uguryOBCApPLHpUyRpG5P4f02TVb1EYssOfmYenevZdJ8KaHLI39hhomhh3SLeOAzkd1OcfhmuHjurLT7URQlEUDkjjJrK1XxSohWKDc5Q53A1i05S12CdSSXuux2r3ULM6hdqg4Of8KyLm2s53ZyMOpyMV55feLLxkZYnKk9WPU1QXxHqIGBLwar2Em/dWhzOql8T1O18U6kY9LZBLwRt9zXnBkOPQ9eaku724vGzcyM+Og7CoOSME/jXXSpcq1OapWUth3muQAOn50LEWOTmnRKecHOasqvatdEY3ZGijp0qWIlHyB07VMsQVc4zQU4BHf1pblosmFnh37Cinuehp0mnyxBXBLrjt2pqTbrdopCzEfd54Famk3gZTBclTgcZrOV9ykzO0yykv7sRRnYo5LN0rQaJoLwKkisyn74Bx+tdF4ee3WSaUon90ZFT6rp0bgzybVc8Kq8YrF1OjRe7OXvH3puYgknqOhroPA+qnTb0Ryf6ibj6VmxaW0sgR2Owck1I9m0Lq0QbaD1xSk00bRRv+JgFndlHzdePSsuCPMXnRkGReoIrSu383S/PB3SYxWdZ8uJVyD0bFc9jtpPoX7WSJyqfMJsfKB0NaEMwZQJBiUHGPWsjCiUFANw5+lTxEyMuM4U9aTae52KGh4545x/wlGoYGP3hrPsP9Sf97/Cr/jc58S35P8Az0NULD/Un/e/wr1aXwI+XxP8WXqWfD/PiCIH++a9GSzD8kYFec+H/wDkYIucfOea9MRgI8Zx+NZ1+h14F2TGRaeGYnIwPWknZYFIQqBVW5vzExQNn2FZ81w7nFYWO67Fu58sQc/SqTsSeelPZTyWNRY7nNNJIlsVEzy1PdUC5JH4U1mH49qjA/vnHtVJEN2HfaXjUpETtPUZ4NNguJIX3xjJ96dlAATtAFVbm6UDaoBNUomU6uhPNeOzb5WYgds1Wub9pE2RqETvjkmqckjP9/8AKmhc84zWkYI5Z1W9EBJJ5qROlNC8jjjtVmFM8AEmrvYw1e4wISak8r16VKEPQDNSCJs0rlqJGiY+tTovPBoWJu9TrHnqKTLUQAGzg5NKy/L0+lG0r/8Aqp2C3rxUal2I40c/Njp+tblnFEtsWlj/AHzdGzWYMQJ5jcnHyinW5dkyzHdnI5pPUdjrNAhU2zyZ+6elW7+5NxcxRxqSPQc1k6UtzDalArfveldPo0MdoytIv7w9SwziuSokndlpdjpfA/h+CacvqUnlR9QCuab43t7CGYnRVcqFw+8DIP5dK0BII9OeRG7HkGudsbj7QjBz87NiuZVPeN6cXuzl7Yv9mZeiEnIPan2sWxDuHXkYrTvtMeJp2jIKe1VICAhUYLAcrWt0zsjboQWUb/bU3cqxwc9hW41qiO3ljCdveq+mxLvZpDggcCtiJA3pjsKl2OhN2PnXxuMeJb8ekpqhYf6k/wC9/hWp8QE2eLdSX0lP8qy7D/Un/e/wr1qXwI+ZxOtWXqWvDm0+Iot3Tea7a+u/mKoa4PSX2ayrf7RrqFclif1qapvhHuW02LyTlzzTCxcjgde1MXluhp59uK52dw1wWznioScA9cCpJCe2KiZSeR3poCJyWxjGKZuIHX86lK470zYzHgcdzWisYybKszEZJ5zVYqXbNaIhLEgL1qNIjkgjNVE553ZVWHrk1IkeRxVxYhjkfQ1L5WFGF/OqbIULlVLViM9BVyCJQvTmlBO0AnA9KejENwKlsr2aDYS3I/KpVUDAC4+tChzxg1YSN+u3j3pXHZEQiJ+4M+tOEJ9ADVqFGdwoq+trsUcgt6ip5hpXMR4TmnRwllwB8o/OtB4CW4PIqWGAnAUH6mp5x8rM6S1LgFwTjpiu1+F/w9vvHOptFas1rp0DAXd9tyI++xM8NIR26KOT2DZEOntNGwVivGMjrXonw38d654Q0vT7JWivNNNw6RWjQxxlbeIFZHDqoJd5XwGYnJhkz1zThKL36EVOZKyOa8HXEEmk2QOZJfKQuzHJJ2jNdelpDKAzR4Q9OK5rwdoq2Gl2Ul4PKlWFN6Zzg7RkZ+tauq68jj7NaZZ/7yjgV5td80rI6qcLFbxBqCadE1rA2WPQCs2ylZEUnCs4yfrVZbVpZ/MnbzJc1oJZNK6LwqjlmPGKIKx1pWRXur9iTBx71kQSH+1SRhl6CpNSY/bJI7Y5iU8sKgtfkuAV+8TWiR0U4o6K0dTKVB+b09K14tgK9j1rnYtySCX1bFbksm1Ux941N+5vy6Hz98RG3eMNTPrKf5Csmw/1J/3v8K0vHhz4p1An/nqazbD/AFJ/3v8ACvXpfAj5XFK1WXqLp3/IWXH9811wU9wK5HTeNXT/AHzXZKemcVNU1wrCNSe1SOhHTFOjYFhlsUj8gjIrA70hFiDKc/jTWTIwB8oqS3+YH5gMUMwY9fypNsvlKEkZbOOnvTnXYqgNmtKG3DRlgM+tZ8yuJSvpVxZlOJDCzrKCpxinsVLkkjcaMH0oY7R0/SruYNCqCTxzUm09ByRVywtTKAWBPritmDTYiN7bUUdBnk1LmkLlOcWBz2q1b2rh+QDWpdW5jKvEnBPepLeEnLysR7VPOUoMrRwBX+br6elWViJB2j8qntrcTSbVUls9a67SfC7yxBpDgkdBWcqiWrK5GjiFhYZG3bU8MZOFOcntXf3HhZbePezgD3FY8+kxx5c3GD24FZ+2TKUb7GItkBg8E+laVppTykbUwKSzeOKbMxBANdDHrESxYgiBx3rOVR9C/YyKL6ZJbWhFtGJbyVlht4/78rsFRfxYgU+wgtVDzW7+dboi2lo46yQxZAk/7aOZJf8AtrVO+1K4uBdXCr5f2ZBBbkf8/M6uin6pEJ5PZlT1FP06/hsIBHGobChFx0UAdKt8yppdWKFJzqN9F+ZDqlzfTHySvkQeveoIEtrKPc84z9c5NLfSXN8Tu+SP0FRW2moCDI30HWs0kjrVMuR6hGyMYInfA5YDFOMlzdxhXban91OPzqZLYKoXf+HSrHluq4hj/GldGigkZ89ooiEaYUd/eofsojyyKcgYzW5bWRBMlwQKmltwYRgED+dJs0hdMyNKhDcXBII5XvVmWXkg/eB4qyIliBK8k1QlJkkccZHQ5qDrjseEeNW3+JL5h3lNULD/AFJ/3v8ACrvjH/kYb3/roapWH+pP+9/hXtUfgR8hi/40vUZbSrBqIkfO0Oc12eN0COmGUjII9K4Ob/XSf7xrY0DU/s7C2nb9yx4J/hNOcboVCpyuzOphP7v3oPJwSBUeCp7gHvTo4yzYJAHqa5dj0oigDBBJz6ipoE29aaq4bBy1WkwGG8ECpbNkxUR/4eBUEkIPJq2SMfKTion68mhMTKy22/kYxUTFYpjwDirTAjkj6VA0WeT+NWZNJlvSr4RysH+6fStiK8iZwQCVHJHrXOJFx149cVPbSOshRXxkVnKN9jWNNG+97GzgoPlHbvSW8bXN0DglCeao20EjnKoWA71rWplVDvdFA6AVF0jRU7nRWYtLd1LBVC/rXQ/2/bQRfumGQOlcbYaPq2q720zT7298vG/7PA0m3OcZ2g4zg/lVG5gubS5khuoJYZ4zh4pUKsp9weRXPUi5am0KEW7NnSatrVxeoV3lU7c1jzXHmRAMxO2qJ8xvvHA9KYQeij8amEDVwjFDjKXkCqMZrQDCKAs0gVVGWJ4AAqna25zk5ra03TJtRuorK2iEstwwiRCQAxPGOePzrblMNXqUhG221hcFXijN1OG6+fOqttP+5CIE9m8z1NTwWm0lmGM9MVdj0YaTJLY/Z0tjBI6PGgGFcE7hxx1z0q2kBx04oqT5ncMPS5IW3M0xM3HQU5UCcKea0jZyOQACc9qig0+4urgwWcE08oBYiNCxAHU4HastWdUYrcqxfO3HQVq2oIUHBA9aZFYzQW8Vw9vKLeQlUlKkIxHXB6HFSyyEgIvfjNSbOmmiceW7dSwHeid8D5Rn0qOMqowfzpVU4OeSe1UmQ0kQSjjKjn0rLvvKs7eS5uZVjiQbmJPStx1VIy0jBUUFmJ7D1rwr4keLjq921nYnFjE2Mg/6wjv9PStKdJ1JWRhXxKw8OaRy/iW9jv8AWLq4hDBJHLDd1xUNh/qT/vf4VRPNXrD/AFJ/3v8ACvWjHlVkfLVKjqScn1Kc3+uk/wB40ynzf66T/eNMqiDrvC2pJchbC7YB/wDlk57+1dQ2mSIfk5X3rytGZHDKSGByCO1ereBdei1e2FpeSBb5OAT/AMtF9frXPWh1R2UK32WQCJo35QjFKSSfmU/lXTXlptJMQ3r9Ky5JY03Apg+lc/MegtTN8wKpyMCnrGZApG3noKnUCcj5QFq3DbojAr19aOYtRZCtmEGXqJ7dQDgfSrk8nO04NGWZMucD0pOZcaVzKkhYf4UWaqkuXGR71buJGIPGBUMEJkxjrnoKhyOmnSNFJXlwsR2J6gYq7DGAoIXp3p9jbYQcDNaKRbVAAyBWV9TRq2iOu8DNHL4H8YafLd2kN3drbCCO4uI4fM2uxOC5A4FdRDd+Hb/VrG01Se0vr+y0jyBcyOphkuAeFMjqytgdGYFee9eUeXzls1JE5V8qP0rT2vKloc7w3M277/5JHp8B8OPfak1xp2j22piyiFvALy3eJ3DNvO8xmBZCAvG0j0xk4uW1jpt3pWs32n6VoFrOLu2A3vBPDCCBvAdgExjOQvGenOK8mVC7ZYnPWtK3nuIrR7WO4mW2kYM8KuQjEdCV6E0lX7oJYTs+39bnQX6aHF8SfNso4DogvImK7cx7Mrv46Fc7vbFdxaw6JY3LSxyaQkn9vJNDJDJESlvwRgqflUc8dBXldvFyC361dQqOAKlV7X0CWG5klfpY7y+FlPBeSaOdKk1CTUbhp3uvJYshZthQy8bcY+7WhJDokOhRLZ2ljMr2eHeWaNJY5ccnBXzC2ewO32HWvP4Izwa0LeFj15qHX8g+rW0v/X9bHeXf9jz69DaW6aXb2qoJDcRxRtubZgqScr+Y6+9LB/ZWm69YXNt/Z9s81lLFcFTEVD/w7ioCgnnJAANcdHFtIJB/CrUu0xFduTjvTWIad7GTwy25ulixov8AYf2XRf7c/swXP2qf7T5Xl4zg7N/l8bM4xjj8Kn019CS401tXOjf2gILj7R5Zi8jr+7zt+Td6Y59a8+1eIwysQNoJrGnkUsAOfekq9uh2rCc6vzPX/g/5/gjuPFE2nS6RoFzai0F5JAwuVtwq4YEY3KvAPJ7Vz+89SBVCKQAgtnFcN8S/GAsLdtP0+T/S5BiV1P3F9PrVxTqvQKjjh6d5PRXM/wCKfjUyF9J0yb5BkTyKfvH+6PavJySTzSuxdixOSabXqU6apqyPmMTiJV58z2Cr9h/qT/vf4VQq/Yf6k/73+FaHOU5v9dJ/vGmU+b/XSf7xplABU1rcS2txHNA5SRDuUg1DRQB7F4e8Tx6zpe04S7QYkX19xUjPGqneMt715BZ3U1nOs1tIY5F6MK0G8Rao5y10xP8Auj/CuadC7vE9Chi4wVpo9EEjeaTHwPSp4rjj7vJrzQeItTHS5P8A3yP8KUeJNVBJF03/AHyP8KzeGm+p2xzKilsz0xp0UEsBu+lVZblpG+Tp71543iLU2XDXJI/3R/hTV17UR0uD/wB8j/Cl9Wn3KWZUOzPS/sbfK0kgLHoorXsLDGCwx7V5DH4l1WNspdEH/dX/AAq0vjTXl+7qDj/gC/4VP1Wfcf8AatFbJnuEMKhelLJ8gxjArxAeOPEI6ai//fC/4UjeNvEDfe1Fz/wBf8KHhJ9yf7UpXvZns7HLdeafGnPSvEv+Ey17Oft7/wDfC/4U5fGviBfu6g4/4Av+FT9Tn3NP7Wo9me8QRH05q9FbkcsMV8/L488SL93U3H/bNP8ACpP+FheKB/zFZP8Av2n+FH1Kfch5rTfRn0JsbICir1rak9QK+bR8Q/FIx/xNpP8Av2n/AMTUq/Erxap41iX/AL9p/wDE1LwM31Qf2rS7M+ooYQowACfWrka7Og/SvlQfE/xgBga1L/37j/8AiaUfFLxkP+Y3N/36j/8AiaX1Cfch5nTe6Z9VmX6UyebacYGTXyqfid4wJydalz/1zj/+JpD8TfF5OTrMv/ftP/iaPqM+6F/aNLsz6G8SS5jwPvH2rn4ovkB6k+teJTfELxPP/rtVkf6on+FRf8Jz4ixj+0X/AO+F/wAKf1Gfc6Keb0YLZnpvjnxMuhWbQwMrXsgwo67B6mvErmeS5meWVizsckk5JNPv764v7h57uUySucsx71WrtoUVSXmeXjca8TLTSIUUUVucAVfsP9Sf97/CqFX7D/Un/e/woAZNZyGWTlfvHv70z7HJ6p+dFFAB9jk9U/Oj7HJ6p+dFFAB9jk9U/Oj7HJ6p+dFFAB9jk9U/Oj7HJ6p+dFFAB9jk9U/Oj7HJ6p+dFFAB9jk9U/Oj7HJ6p+dFFAB9jk9U/Oj7HJ6p+dFFAB9jk9U/Oj7HJ6p+dFFAB9jk9U/Oj7HJ6p+dFFAB9jk9U/Oj7HJ6p+dFFAB9jk9U/Oj7HJ6p+dFFAB9jk9U/Oj7HJ6p+dFFAB9jk9U/Oj7HJ6p+dFFAB9jk9U/Oj7HJ6p+dFFAB9jk9U/Oj7HJ6p+dFFAB9jk9U/Or9haSeS3Kfe/oKKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy revealed superficial ulcerations with bleeding localized in the proximal esophagus at the level of the aortic arch. The mid and distal esophageal mucosa appeared normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud, MD and Kenneth Falchuk, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Medication-induced esophagitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 249px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy revealed superficial ulcerations with bleeding localized in the proximal esophagus at the level of the aortic arch. The mid and distal esophageal mucosa appeared normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud, MD and Kenneth Falchuk, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_42_35489=[""].join("\n");
var outline_f34_42_35489=null;
var title_f34_42_35490="Patient information: Counting carbs if you do not use insulin (The Basics)";
var content_f34_42_35490=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16435\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/2/40\">",
"         Nutrition label: Counting carbohydrates",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/40/36483\">",
"         Patient information: Diabetes and diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/35/11827\">",
"         Patient information: Diet and health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?14/12/14531\">",
"         Patient information: Low blood sugar in people with diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/40/22144\">",
"         Patient information: The ABCs of diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?15/49/16147\">",
"         Patient information: Treatment for type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/44/33475\">",
"         Patient information: Type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/37/36436\">",
"         Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?30/32/31239\">",
"         Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Counting carbs if you do not use insulin (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/counting-carbs-if-you-do-not-use-insulin-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H14019701\">",
"      <span class=\"h1\">",
"       What are carbs?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Carbs (short for &ldquo;carbohydrates&rdquo;) are sugars that come from food. When we eat, our body breaks the food down into different nutrients. These nutrients are carbohydrates, proteins, and fats. The body uses carbohydrates for energy.",
"     </p>",
"     <p>",
"      Foods with a lot of carbs include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bread, pasta, rice, and cereal",
"       </li>",
"       <li>",
"        Fruits and starchy vegetables",
"       </li>",
"       <li>",
"        Milk and other dairy foods",
"       </li>",
"       <li>",
"        Foods with added sugar (such as many cookies and cakes)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14019708\">",
"      <span class=\"h1\">",
"       What does &ldquo;counting carbs&rdquo; mean?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Counting carbs (also called &ldquo;carb counting&rdquo;) is a type of meal planning that many people with diabetes use. It involves figuring out the number of carbs you eat. When people count carbs, they keep track of how many carbs they eat for each meal and snack.",
"     </p>",
"     <p>",
"      People with diabetes need to know how many carbs they eat because eating carbs raises a person&rsquo;s blood sugar level.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14019715\">",
"      <span class=\"h1\">",
"       How do I count carbs?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your food has a nutrition label, you can look at the information on the nutrition label. You need to look at the:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        &ldquo;Total carbohydrate&rdquo; number &mdash; This tells you how many carbs are in 1 serving size of the food. If you eat 1 serving, then the number of carbs you eat is the same as the number of total carbohydrates.",
"       </li>",
"       <li>",
"        &ldquo;Serving size&rdquo; &mdash; This tells you how much food is in 1 serving. If you have 2 servings, the number of carbs will be 2 times the number of carbohydrates listed.",
"       </li>",
"       <li>",
"        &ldquo;Dietary fiber&rdquo; &mdash; Fiber is a carbohydrate that is not digested, which means it does not raise blood sugar. Foods with a lot of fiber can help control a person&rsquo;s blood sugar. If a food has more than 5 grams (g) of fiber, less insulin is needed for that food (",
"        <a class=\"graphic graphic_figure graphicRef76576 \" href=\"mobipreview.htm?0/2/40\">",
"         figure 1",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Many foods, such as fresh fruits and vegetables, don&rsquo;t have a nutrition label. For these foods, you will need to learn about the usual serving sizes of different foods. You will also need to learn how many carbs are in 1 serving.",
"     </p>",
"     <p>",
"      Your doctor, nurse, or dietitian (food expert) will tell you how many carbs you should eat in 1 day. It will depend partly on your height, weight, how active you are, and your medicines. You can divide this total number of carbs up over the day and eat some at each meal and snack.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14019722\">",
"      <span class=\"h1\">",
"       Can counting carbs help me manage my diabetes?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Counting carbs can help you manage your diabetes by keeping your blood sugar level under better control. Counting carbs can help keep your blood sugar level from getting too high (especially after meals) or too low.",
"     </p>",
"     <p>",
"      It&rsquo;s important to keep your blood sugar level under control, because blood sugar levels that are too high or too low can lead to immediate and serious problems. In addition, having high blood sugar levels for a long time can lead to kidney, nerve, and eye problems later on.",
"     </p>",
"     <p>",
"      Counting carbs can also help you plan your meals and snacks each day. Knowing how many carbs you can eat at each meal or snack can help you choose foods to eat.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14019729\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The following tips might help when you count carbs:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Spread out your carbs over 4 to 6 small meals each day instead of 3 big ones.",
"       </li>",
"       <li>",
"        Eat the same number of carbs at each meal, for example, at each dinner.",
"       </li>",
"       <li>",
"        Eat your meals at the same time each day.",
"       </li>",
"       <li>",
"        Plan your meals ahead of time.",
"       </li>",
"       <li>",
"        Check your blood sugar before you eat and 1 hour after you eat. This can help you learn how certain foods affect your blood sugar. You can check your blood sugar level at home using a device called a &ldquo;blood glucose monitor.&rdquo;",
"       </li>",
"       <li>",
"        Keep a record of your meals and blood sugar levels. Show it to your doctor or nurse so that he or she can change your treatment as needed.",
"       </li>",
"       <li>",
"        Remember that other things besides carbs can raise or lower your blood sugar level. These things can include exercise, getting sick, drinking alcohol, travelling, and stress.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have any questions about counting carbs or meal planning, ask your doctor, nurse, or dietitian. For more information, you can also get a book on counting carbs or look on the American Diabetes Association Web site (",
"      <a class=\"external\" href=\"file://www.diabetes.org/\">",
"       www.diabetes.org",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H14019736\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=see_link\">",
"       Patient information: Type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/49/16147?source=see_link\">",
"       Patient information: Treatment for type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/40/36483?source=see_link\">",
"       Patient information: Diabetes and diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/35/11827?source=see_link\">",
"       Patient information: Diet and health (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/40/22144?source=see_link\">",
"       Patient information: The ABCs of diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/12/14531?source=see_link\">",
"       Patient information: Low blood sugar in people with diabetes (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/32/31239?source=see_link\">",
"       Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/37/36436?source=see_link\">",
"       Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/42/35490?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16435 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-FD3AE0A3B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_42_35490=[""].join("\n");
var outline_f34_42_35490=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14019701\">",
"      What are carbs?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14019708\">",
"      What does &ldquo;counting carbs&rdquo; mean?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14019715\">",
"      How do I count carbs?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14019722\">",
"      Can counting carbs help me manage my diabetes?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14019729\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14019736\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16435\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/2/40\">",
"      Nutrition label: Counting carbohydrates",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/40/36483?source=related_link\">",
"      Patient information: Diabetes and diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/37/36436?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/35/11827?source=related_link\">",
"      Patient information: Diet and health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/12/14531?source=related_link\">",
"      Patient information: Low blood sugar in people with diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/40/22144?source=related_link\">",
"      Patient information: The ABCs of diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/49/16147?source=related_link\">",
"      Patient information: Treatment for type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/32/31239?source=related_link\">",
"      Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_42_35491="Amifostine: Patient drug information";
var content_f34_42_35491=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amifostine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/42/678?source=see_link\">",
"     see \"Amifostine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/51/36660?source=see_link\">",
"     see \"Amifostine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ethyol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ethyol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691353",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower the side effects of some chemo drugs or radiation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701486",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amifostine, aminothiol compounds, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697093",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking drugs for high blood pressure, talk with your doctor. Your doctor may ask you to skip that drug the day before and on the morning of care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697292",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low calcium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a stroke, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698275",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. You may need drugs to lower this side effect. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696069",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11455 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_42_35491=[""].join("\n");
var outline_f34_42_35491=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132861\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132862\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014480\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014479\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014484\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014485\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014487\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014482\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014489\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/42/678?source=related_link\">",
"      Amifostine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/51/36660?source=related_link\">",
"      Amifostine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_42_35492="TMJ dislocation reduction";
var content_f34_42_35492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    TMJ dislocation reduction technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 592px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Position of the patient, assistant, and physician in preparation for reduction.",
"    <br>",
"     (B) Application and direction of forces in the reduction of an anteriorly dislocated temporomandibular joint.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Pratt A, Loiselle JM. Reduction of temporomandibular joint dislocation. In: Textbook of Pediatric Emergency Procedures, 2nd Edition, King C, Henretig FM (Eds). Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"     </div>",
"     <div class=\"contractual\">",
"      <br/>",
"      <a href=\"file://www.lww.com\">",
"       file://www.lww.com",
"      </a>",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_42_35492=[""].join("\n");
var outline_f34_42_35492=null;
var title_f34_42_35493="Bloom syndrome";
var content_f34_42_35493=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bloom syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/42/35493/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/42/35493/contributors\">",
"     Andrew Gennery, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/42/35493/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/42/35493/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/42/35493/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/42/35493/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/42/35493/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of human genetic disorders cause chromosomal breakage, which is characterized by genome instability that occurs in the basal state (spontaneously) or in response to DNA-damaging agents (",
"    <a class=\"graphic graphic_table graphicRef82574 \" href=\"mobipreview.htm?16/58/17324\">",
"     table 1",
"    </a>",
"    ). These disorders cause defects in the recognition",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    repair of damage to DNA inflicted by different agents. In most cases, the genome instability is associated with immune deficiency, a predisposition to develop cancer, and premature aging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss Bloom syndrome (MIM 210900), one of the chromosomal breakage syndromes that is associated with immunodeficiency. Discussions relating to the other disorders are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/439?source=see_link\">",
"     \"Nijmegen breakage syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bloom syndrome is a rare disorder, with 265 cases reported in the Bloom's Syndrome Registry through 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/2\">",
"     2",
"    </a>",
"    ]. The exact incidence is unknown. It has been reported in a variety of ethnic groups. However, it is more common in the Eastern European Jewish (Ashkenazi) population (about 25 percent of the affected families in the Bloom syndrome registry), with a prevalence of approximately 1:48,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Parental consanguinity is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bloom syndrome (BS) is an autosomal recessive chromosomal instability disorder that is caused by mutations in the",
"    <em>",
"     BLM",
"    </em>",
"    gene at 15q26.1 (MIM 604610) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. This gene encodes a RecQ helicase, called the Bloom syndrome protein (Blm) that helps maintain the stability of DNA when the DNA duplexes are unwound during recombination repair and replication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/10\">",
"     10",
"    </a>",
"    ]. A significant increase in gene cluster instability and sister chromatid exchange (homologous recombination associated with crossover) is seen during mitotic recombination in patients with BS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Thus, Blm is believed to function primarily as an antirecombinase, mainly by acting as a Holliday junction dissolvase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. It also interacts with other molecules involved in the sensing and repair of DNA damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bloom syndrome is characterized by [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/2,7,8,20,21\">",
"     2,7,8,20,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Proportionate small stature with microcephaly",
"     </li>",
"     <li>",
"      Caf&eacute;-au-lait spots or hypopigmented skin lesions",
"     </li>",
"     <li>",
"      Predisposition to the early development of a wide variety of cancers",
"     </li>",
"     <li>",
"      Facial anomalies and sun-sensitive facial erythema",
"     </li>",
"     <li>",
"      Infertility",
"     </li>",
"     <li>",
"      Immunodeficiency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The affected fetus is typically small for gestational age and intrauterine growth retardation can be severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/2,20\">",
"     2,20",
"    </a>",
"    ]. There is a characteristic sparseness of subcutaneous adipose tissue, giving infants and young children a wasted appearance.",
"   </p>",
"   <p>",
"    The major physical feature of BS that usually brings these patients to medical attention is small stature with relatively normal body proportions. Thus, BS can be mistaken for certain forms of dwarfism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/22\">",
"     22",
"    </a>",
"    ]. The etiology for short stature in BS is not known, although it is not caused by growth hormone deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18376?source=see_link\">",
"     \"Diagnostic approach to short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other clinical features may or may not be present and vary in severity. There is a characteristic keel-shaped face with a slightly small dolichocephalic cranium, malar hypoplasia, nasal prominence, small mandible, protuberant ears, and absence of upper lateral incisors.",
"   </p>",
"   <p>",
"    Individuals are sun-sensitive and develop erythematous lesions on exposed regions of the face, often in a lupus-like butterfly distribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/23\">",
"     23",
"    </a>",
"    ]. The erythema may appear as a faint blush on the cheeks, but in extreme cases it may manifest as a bright, red disfiguring lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/7\">",
"     7",
"    </a>",
"    ]. The rash can also occur on other frequently sun-exposed areas of skin, such as the dorsum of the hands. In addition, patients may develop well-demarcated patchy areas of hypopigmentation and hyperpigmentation (caf&eacute;-au-lait spots), especially on the trunk, and skin and scleral telangiectasia.",
"   </p>",
"   <p>",
"    Other abnormalities include a high-pitched voice, male infertility (hypogonadism with failure of sperm production) and female subfertility (premature menopause), restricted intellectual ability, and a predisposition to develop late-onset non-insulin dependent diabetes mellitus. There is a high frequency of impaired glucose tolerance and insulin resistance, and these problems increase with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/22\">",
"     22",
"    </a>",
"    ]. Approximately 15 percent of BS patients develop diabetes mellitus type 2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Problems with vomiting and diarrhea leading to life-threatening dehydration are common in infancy. Gastroesophageal reflux may play a role in feeding issues and recurrent sinopulmonary infections. BS patients have an increased incidence of otitis media and pneumonia. Chronic lung disease is the second-leading cause of death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/22,25\">",
"     22,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with BS have a remarkable predisposition to the early development of cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/25\">",
"     25",
"    </a>",
"    ]. Approximately 50 percent of patients will develop cancer by age 25, and many will have two or more primary malignancies. Cancers of virtually all types and at all locations have been reported. In the first two decades of life, the predominant types are leukemia and non-Hodgkin lymphoma. Later in life, there are many carcinomas, especially of colon, skin, and breast. It is likely that genomic instability accounts for the majority of malignancies, although immunodeficiency could account for some of the cancers seen in this syndrome.",
"   </p>",
"   <p>",
"    Intellectual ability varies from normal to limited. An poorly defined learning disability, manifested by a lack of interest in learning and difficulty with coursework that requires abstract thought, is common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/2,20\">",
"     2,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heterozygous carriers of the defective BLM gene do not exhibit any of the BS clinical phenotype. As an example, they do not seem to have a higher risk of cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/26\">",
"     26",
"    </a>",
"    ]. However, cytologic evidence of chromosomal damage in spermatozoa has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of immunodeficiency has been reported in many BS patients, but it is highly variable and usually not severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The majority of patients have decreased levels of one or more serum immunoglobulin classes (IgM, IgA, and less commonly IgG), although the majority have normal antibody responses to vaccines.",
"   </p>",
"   <p>",
"    The presence of laboratory evidence of immunodeficiency is not highly predictive of risk for infection. Other factors leading to the development of chronic lung disease have not been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of BS is based upon the characteristic features of small, but well-proportioned, body size and a sun-sensitive, erythematous skin lesion affecting the butterfly area of the face. BS may go unrecognized or the affected child may be misdiagnosed when the facial lesion is absent.",
"   </p>",
"   <p>",
"    Once suspected on clinical grounds, the diagnosis is confirmed by finding excessive numbers of sister-chromatid exchanges (SCEs) on a standard karyotype or performing targeted mutation analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/30\">",
"     30",
"    </a>",
"    ], investigations that distinguish BS from other chromosomal breakage disorders with similar clinical phenotypes.",
"   </p>",
"   <p>",
"    A list of laboratories offering clinical testing for BS is available at",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/clinical_disease_id/2709?db=genetests\">",
"     file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/clinical_disease_id/2709?db=genetests",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;BS should be considered in the differential diagnosis of any child or adult with short stature, but normal weight for height. The combination of clinical and laboratory features should distinguish BS from skeletal dysplasia, growth hormone deficiency, or constitutional delay, among other possible explanations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18376?source=see_link\">",
"     \"Diagnostic approach to short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical features alone do not distinguish BS from other chromosomal breakage disorders, including Nijmegen breakage syndrome, DNA ligase IV deficiency, or Cernunnos deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/439?source=see_link\">",
"     \"Nijmegen breakage syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20362?source=see_link\">",
"     \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prenatal screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to prenatal screening in Ashkenazi Jews is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/24/12681?source=see_link&amp;anchor=H10#H10\">",
"     \"Prenatal screening for genetic disease in the Ashkenazi Jewish population\", section on 'Bloom syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following measures should be employed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/2,20\">",
"     2,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exposure to radiation should be minimized. MRI and ultrasound should be used instead for diagnostic purposes.",
"     </li>",
"     <li>",
"      Efforts should be made to protect the face from the sun. (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/60/33729?source=see_link\">",
"       \"Patient information: Sunburn prevention (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immune globulin replacement is indicated if there is significant hypogammaglobulinemia and deficiency of antibody production. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=see_link\">",
"       \"Immune globulin therapy in primary immunodeficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8633?source=see_link\">",
"       \"Medical management of immune deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Particular attention should be paid to the prevention of life-threatening dehydration, particularly in infants.",
"     </li>",
"     <li>",
"      Gastrostomy tube feedings may be useful for providing nutrition and hydration, although the long benefits of this approach are not proven.",
"     </li>",
"     <li>",
"      Infections should be promptly diagnosed and treated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8633?source=see_link\">",
"       \"Medical management of immune deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients and their families should be informed about the high risk for development of cancer so that appropriate surveillance can be performed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/49/41754?source=see_link\">",
"       \"Screening for breast cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35337?source=see_link\">",
"       \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=see_link\">",
"       \"Screening for colorectal cancer: Strategies in patients at average risk\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9881?source=see_link\">",
"       \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recommendations for screening, diagnosis, and treatment of malignancies are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/31\">",
"     31",
"    </a>",
"    ]. Earlier screening for breast and colon cancer is advised.",
"   </p>",
"   <p>",
"    Once diagnosed, the doses of cancer chemotherapeutic agents may need to be adjusted because of the underlying tendency for chromosomal breakage and recombination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with BS survive to adulthood. The Bloom's Syndrome Registry reported a mean age at death of 26 years (range &lt;1 to 49 years) in 2009 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/2\">",
"     2",
"    </a>",
"    ]. The cause of death is usually cancer, commonly leukemia or a malignancy of gastrointestinal origin. Their small size often presents a serious impediment to employment, as do learning disabilities in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35493/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bloom syndrome is a rare autosomal recessive chromosomal instability disorder that is caused by mutations in the BLM gene at 15q26.1 (MIM 604610). It occurs most commonly in patients of Eastern European Jewish (Ashkenazi) descent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bloom syndrome is characterized by small stature, predisposition to the early development of a wide variety of cancers, facial anomalies and sun-sensitive facial erythema, infertility, and immunodeficiency. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of Bloom syndrome is based upon the characteristic clinical features and is confirmed by finding excessive numbers of sister-chromatid exchanges on a standard karyotype or performing targeted mutation analysis. The differential diagnosis includes other causes of proportional short stature. Prenatal screening can be performed for this syndrome in Ashkenazi Jews. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18376?source=see_link\">",
"       \"Diagnostic approach to short stature\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Management includes avoidance of x-rays, adequate sun protection, treatment of infections, provision of adequate nutrition, prevention of dehydration, and performance of cancer surveillance when appropriate. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/1\">",
"      Kamenisch Y, Berneburg M. Progeroid syndromes and UV-induced oxidative DNA damage. J Investig Dermatol Symp Proc 2009; 14:8.",
"     </a>",
"    </li>",
"    <li>",
"     Bloom Syndrome Registry. file://weill.cornell.edu/bsr/ (Accessed on February 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/3\">",
"      Shahrabani-Gargir L, Shomrat R, Yaron Y, et al. High frequency of a common Bloom syndrome Ashkenazi mutation among Jews of Polish origin. Genet Test 1998; 2:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/4\">",
"      Li L, Eng C, Desnick RJ, et al. Carrier frequency of the Bloom syndrome blmAsh mutation in the Ashkenazi Jewish population. Mol Genet Metab 1998; 64:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/5\">",
"      Roa BB, Savino CV, Richards CS. Ashkenazi Jewish population frequency of the Bloom syndrome gene 2281 delta 6ins7 mutation. Genet Test 1999; 3:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/6\">",
"      German J, Sanz MM, Ciocci S, et al. Syndrome-causing mutations of the BLM gene in persons in the Bloom's Syndrome Registry. Hum Mutat 2007; 28:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/7\">",
"      German J. Bloom syndrome: a mendelian prototype of somatic mutational disease. Medicine (Baltimore) 1993; 72:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/8\">",
"      Ellis NA, German J. Molecular genetics of Bloom's syndrome. Hum Mol Genet 1996; 5 Spec No:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/9\">",
"      Amor-Gu&eacute;ret M, Dubois-d'Enghien C, Laug&eacute; A, et al. Three new BLM gene mutations associated with Bloom syndrome. Genet Test 2008; 12:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/10\">",
"      Ellis NA, Groden J, Ye TZ, et al. The Bloom's syndrome gene product is homologous to RecQ helicases. Cell 1995; 83:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/11\">",
"      Killen MW, Stults DM, Adachi N, et al. Loss of Bloom syndrome protein destabilizes human gene cluster architecture. Hum Mol Genet 2009; 18:3417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/12\">",
"      Chan KL, Palmai-Pallag T, Ying S, Hickson ID. Replication stress induces sister-chromatid bridging at fragile site loci in mitosis. Nat Cell Biol 2009; 11:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/13\">",
"      Naim V, Rosselli F. The FANC pathway and BLM collaborate during mitosis to prevent micro-nucleation and chromosome abnormalities. Nat Cell Biol 2009; 11:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/14\">",
"      Payne M, Hickson ID. Genomic instability and cancer: lessons from analysis of Bloom's syndrome. Biochem Soc Trans 2009; 37:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/15\">",
"      Bachrati CZ, Hickson ID. Dissolution of double Holliday junctions by the concerted action of BLM and topoisomerase IIIalpha. Methods Mol Biol 2009; 582:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/16\">",
"      Wechsler T, Newman S, West SC. Aberrant chromosome morphology in human cells defective for Holliday junction resolution. Nature 2011; 471:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/17\">",
"      Tikoo S, Sengupta S. Time to bloom. Genome Integr 2010; 1:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/18\">",
"      Russell B, Bhattacharyya S, Keirsey J, et al. Chromosome breakage is regulated by the interaction of the BLM helicase and topoisomerase IIalpha. Cancer Res 2011; 71:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/19\">",
"      Wang Y, Smith K, Waldman BC, Waldman AS. Depletion of the bloom syndrome helicase stimulates homology-dependent repair at double-strand breaks in human chromosomes. DNA Repair (Amst) 2011; 10:416.",
"     </a>",
"    </li>",
"    <li>",
"     GeneReviews: Bloom's syndrome. file://www.ncbi.nlm.nih.gov/books/NBK1398/ (Accessed on October 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/21\">",
"      Karalis A, Tischkowitz M, Millington GW. Dermatological manifestations of inherited cancer syndromes in children. Br J Dermatol 2011; 164:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/22\">",
"      Diaz A, Vogiatzi MG, Sanz MM, German J. Evaluation of short stature, carbohydrate metabolism and other endocrinopathies in Bloom's syndrome. Horm Res 2006; 66:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/23\">",
"      McGowan J, Maize J, Cook J. Lupus-like histopathology in bloom syndrome: reexamining the clinical and histologic implications of photosensitivity. Am J Dermatopathol 2009; 31:786.",
"     </a>",
"    </li>",
"    <li>",
"     German J. The immunodeficiency of Bloom syndrome. In: Primary immunodeficiency diseases: A molecular and genetic approach, Ochs HD, Smith CIE, Puck JM (Eds), Oxford University Press, New York 1999. p.335.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/25\">",
"      German J. Bloom's syndrome. XX. The first 100 cancers. Cancer Genet Cytogenet 1997; 93:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/26\">",
"      Baris HN, Kedar I, Halpern GJ, et al. Prevalence of breast and colorectal cancer in Ashkenazi Jewish carriers of Fanconi anemia and Bloom syndrome. Isr Med Assoc J 2007; 9:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/27\">",
"      Martin RH, Rademaker A, German J. Chromosomal breakage in human spermatozoa, a heterozygous effect of the Bloom syndrome mutation. Am J Hum Genet 1994; 55:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/28\">",
"      Taniguchi N, Mukai M, Nagaoki T, et al. Impaired B-cell differentiation and T-cell regulatory function in four patients with Bloom's syndrome. Clin Immunol Immunopathol 1982; 22:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/29\">",
"      Van Kerckhove CW, Ceuppens JL, Vanderschueren-Lodeweyckx M, et al. Bloom's syndrome. Clinical features and immunologic abnormalities of four patients. Am J Dis Child 1988; 142:1089.",
"     </a>",
"    </li>",
"    <li>",
"     Gene Test. www.ncbi.nlm.nih.gov/sites/GeneTests/lab/clinical_disease_id/2709?db=genetests (Accessed on April 05, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35493/abstract/31\">",
"      Thomas ER, Shanley S, Walker L, Eeles R. Surveillance and treatment of malignancy in Bloom syndrome. Clin Oncol (R Coll Radiol) 2008; 20:375.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3959 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-617C8121F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_42_35493=[""].join("\n");
var outline_f34_42_35493=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prenatal screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3959\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3959|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/58/17324\" title=\"table 1\">",
"      Characteristics of chromosomal breakage syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18376?source=related_link\">",
"      Diagnostic approach to short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/439?source=related_link\">",
"      Nijmegen breakage syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/60/33729?source=related_link\">",
"      Patient information: Sunburn prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/24/12681?source=related_link\">",
"      Prenatal screening for genetic disease in the Ashkenazi Jewish population",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9881?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20362?source=related_link\">",
"      T cell negative, B cell negative, NK cell positive severe combined immunodeficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_42_35494="Jugular venous sampling of PTH";
var content_f34_42_35494=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Jugular venous sampling of parathyroid hormone (PTH)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 544px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Differential jugular venous sampling has been used to lateralize the side of the neck harboring the most hyperfunctioning parathyroid gland(s) and thus avoid bilateral neck exploration. When performed intraoperatively, samples from both internal jugular veins, preferably guided by ultrasound, are taken before skin incision for rapid PTH measurement as shown here. This technique guides the surgeon to the side of the neck containing the highest PTH level. In this illustration, the PTH levels are higher on the right, which indicates that the disease is on the right side of the neck.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_42_35494=[""].join("\n");
var outline_f34_42_35494=null;
var title_f34_42_35495="Niacin and simvastatin: Drug information";
var content_f34_42_35495=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Niacin and simvastatin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/40/5765?source=see_link\">",
"    see \"Niacin and simvastatin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5925347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Simcor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5925351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antilipemic Agent, HMG-CoA Reductase Inhibitor;",
"     </li>",
"     <li>",
"      Antilipemic Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5925524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage forms are a fixed combination of niacin extended-release and simvastatin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dyslipidemia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Patients na&iuml;ve to niacin therapy:",
"     </i>",
"     Niacin 500 mg/simvastatin 20 mg once daily at bedtime; increase dose every 4 weeks as needed in increments of not more than 500 mg of niacin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Patients currently on immediate-release niacin products:",
"     </i>",
"     Niacin 500 mg/simvastatin 20 mg once daily at bedtime; increase dose every 4 weeks as needed in increments of not more than 500 mg of niacin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Patients currently on simvastatin (20-40 mg daily):",
"     </i>",
"     Niacin 500 mg/simvastatin 40 mg once daily at bedtime; increase dose every 4 weeks as needed in increments of not more than 500 mg of niacin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance dose: Niacin 1000-2000 mg/ simvastatin 20-40 mg once daily (maximum daily dose: niacin 2000 mg/simvastatin 40 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     If therapy is interrupted for &gt;7 days, reinstitution of therapy should begin with the lowest dose followed by retitration as tolerated. Not for use as initial therapy of dyslipidemias. May be substituted for equivalent dose of niacin extended-release, however, manufacturer does not recommend direct substitution with immediate-release preparations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment for simvastatin component with concomitant medications:",
"     </b>",
"     <i>",
"      Amiodarone, amlodipine, or ranolazine:",
"     </i>",
"     Dose should",
"     <b>",
"      not",
"     </b>",
"     exceed niacin 1000 mg/simvastatin 20 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5925525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment: No dosage adjustment required; use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe renal impairment: Use with extreme caution or avoid unless patient already tolerating simvastatin doses &ge;10 mg.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5925526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in active liver disease or unexplained persistent elevations of serum transaminases.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F5925527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Discontinue therapy if transaminases &gt;3 times ULN persist or are accompanied by symptoms (nausea, fever, malaise).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5925565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, variable release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Simcor&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     500/20: Niacin 500 mg [extended release] and simvastatin 20 mg [immediate release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     500/40:  Niacin 500 mg [extended release] and simvastatin 40 mg [immediate release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     750/20: Niacin 750 mg [extended release] and simvastatin 20 mg [immediate release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     1000/20: Niacin 1000 mg [extended release] and simvastatin 20 mg [immediate release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     1000/40:  Niacin 1000 mg [extended release] and simvastatin 40 mg [immediate release]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5925349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5925529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets must be swallowed whole; do not crush or chew. Administer with a low-fat snack at bedtime.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5925369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduce total cholesterol, LDL, Apo B, non-HDL, TG, and/or increase HDL in patients with primary hypercholesterolemia, mixed dyslipidemia, or hypertriglyceridemia in combination with standard cholesterol-lowering diet when simvastatin or niacin monotherapy is inadequate",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5925389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reactions/percentages reported with combination product; also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Cardiovascular: Flushing (&le;59%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (3%), nausea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Frequency not defined: Alkaline phosphatase increased, amylase increased, bilirubin increased, creatinine kinase increased, fasting blood glucose increased, GGT increased, LDH increased, phosphorus decreased, platelets decreased, prothrombin time increased, thyroid function test abnormalities, transaminases increased, uric acid increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5925375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to niacin, simvastatin, or any component of the formulation; active liver disease; unexplained persistent elevations of transaminases; active peptic ulcer disease; arterial bleeding; pregnancy; breast-feeding; concomitant use of strong CYP3A4 inhibitors (eg, clarithromycin, erythromycin, protease inhibitors including boceprevir and telaprevir, itraconazole, ketoconazole, nefazodone, posaconazole, voriconazole, telithromycin), amiodarone, cyclosporine, danazol, diltiazem, dronedarone, gemfibrozil, and verapamil",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5925376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes mellitus: Increases in Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     and fasting blood glucose have been reported with HMG-CoA reductase inhibitors; however, the benefits of statin therapy far outweigh the risk of dysglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Flushing/pruritus: Flushing and pruritus, common adverse effects of niacin, may be attenuated with a gradual increase in dose, and/or by taking aspirin or another NSAID (eg, ibuprofen) 30-60 minutes before dosing. Avoid concurrent ingestion of ethanol, hot liquids, or spicy foods to minimize flushing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Cases of severe hepatotoxicity have occurred when immediate release (crystalline) niacin products have been substituted with sustained-release (modified release, timed-release) niacin products at equivalent doses. Initiate niacin at lower doses and titrate to achieve desired response. Postmarketing reports of fatal and nonfatal hepatic failure with simvastatin are rare. If serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy. If an alternate etiology is not identified, do not restart simvastatin. Liver enzyme tests should be obtained at baseline and as clinically indicated; routine periodic monitoring of liver enzymes is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune-mediated necrotizing myopathy (IMNM): IMNM, an autoimmune-mediated myopathy, has been reported (rarely) with HMG-CoA reductase inhibitor therapy.  IMNM presents as proximal muscle weakness with elevated CPK levels, which persists despite discontinuation of HMG-CoA reductase inhibitor therapy; additionally, muscle biopsy may show necrotizing myopathy with limited inflammation.  Immunosuppressive therapy (eg, corticosteroids, azathioprine) may be used for treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy/rhabdomyolysis: Patients receiving HMG-CoA reductase inhibitors have developed rhabdomyolysis with acute renal failure and/or myopathy; patients should be monitored closely. This risk is dose-related and is increased with high doses (simvastatin 80 mg), concurrent use of other lipid-lowering medications (fibric acid derivatives, or niacin at doses &ge;1 g/day), other interacting drugs (eg, moderate-to-strong CYP3A4 inhibitors), age &ge;65 years, female gender, uncontrolled hypothyroidism, and renal dysfunction. Use with caution in patients taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute or serious condition predisposing to renal failure (eg, sepsis, hypotension, trauma, uncontrolled seizures). However, based upon current evidence, HMG-CoA reductase inhibitor therapy should be continued in the perioperative period unless risk outweighs cardioprotective benefit. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine. Discontinue treatment if CK levels rise to &gt;10 times ULN with concomitant muscle symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use niacin with caution in patients with unstable angina or MI; risk of arrhythmias at high doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use niacin with caution in patients with diabetes mellitus; niacin may increase fasting blood glucose, although clinical data suggest increases are generally modest (&lt;5%). Monitor glucose; adjustment of hypoglycemic therapy may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: Use niacin with caution in patients with active gallbladder disease; use can exacerbate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: Use niacin with caution in patients with gout; may increase uric acid levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment and/or ethanol use: Use with caution in patients who consume large amounts of ethanol or have a history of liver disease; use is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases. Transaminases should be monitored during therapy; if levels elevated, repeat test (confirmatory) and monitor frequently until transaminases return to normal; therapy should be discontinued if transaminase levels &gt;3 times ULN persist or are accompanied by symptoms (nausea, fever, malaise).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in renal impairment; use with extreme caution or avoid in severe impairment unless patient already tolerating simvastatin doses &ge;10 mg. Renal impairment may also increase risk for myopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: If concurrent use of a contraindicated interacting medication is unavoidable, treatment with simvastatin should be suspended during use or consider the use of an alternative HMG-CoA reductase inhibitor void of CYP3A4 metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chinese patients: Concomitant use of niacin (&gt;1 g/day) and simvastatin (&gt;20 mg/day) should be done with caution; may increase risk of myopathy in Chinese patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients &ge;65 years of age; these patients are predisposed to myopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product interchangeability: Bioavailability of niacin formulations vary (regular release versus extended release) and are not interchangeable; cases of severe hepatic toxicity, including fulminant hepatic necrosis, have occurred in patients who have substituted niacin products at equivalent doses. In addition, bioequivalence between different Simcor&reg; dosage strengths has not been evaluated and strengths should not be considered exchangeable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Prior to initiation, secondary causes for hypercholesterolemia (eg, poorly controlled diabetes mellitus, hypothyroidism) should be excluded.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5925426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5925425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Dose of HMG-CoA reductase inhibitor may need to be reduced (limit simvastatin adult maximum dose to 20 mg/day, limit lovastatin adult maximum dose to 40 mg/day).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AmLODIPine: May increase the serum concentration of Simvastatin. Management: Avoid the concurrent use of amlodipine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day (for adults).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Niacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Avoid use of statins metabolized by CYP3A4 (eg, simvastatin) and consider avoiding fluvastatin as well in patients receiving high dose cyproterone (300 mg/day). Consider use of pravastatin, rosuvastatin, or pitavastatin if statin therapy is needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Concurrent use of simvastatin with danazol is contraindicated.  Initiate lovastatin at an adult maximum dose of 10 mg/day, and do not exceed 20 mg/day, when danazol is given concomitantly.  Fluvastatin, pravastatin and rosuvastatin may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DAPTOmycin: HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: May increase the serum concentration of Simvastatin. Simvastatin may increase the serum concentration of Diltiazem. Management: Avoid concurrent use of diltiazem with simvastatin when possible.  If used together, limit adult maximum simvastatin dose to 10 mg/day, and avoid Simcor (simvastatin/niacin) because fixed simvastatin doses in the product exceed this maximum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May increase the serum concentration of Simvastatin. Management: Limit simvastatin to a max of 10 mg/day (in adults). Increase monitoring for signs of simvastatin toxicity (e.g., myositis, rhabdomyolysis).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Systemic): May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin, lovastatin and simvastatin. Conversely, levels of fluvastatin may be increased. Management: Dose adjustment of the HMG-CoA reductase inhibitor may be warranted. No interaction is expected with rosuvastatin, pravastatin, or pitavastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use of HMG-CoA reductase inhibitors (statins) with fusidic acid if possible.  If treatment with fusidic acid is necessary, consider temporarily stopping the statin.  With any concurrent use monitor patients closely for statin toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of Simvastatin. Gemfibrozil may increase the serum concentration of Simvastatin. Concentrations of the active simvastatin acid metabolite may also be increased by gemfibrozil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider avoiding concurrent use of GFJ (especially larger amounts) with lovastatin, simvastatin, or atorvastatin.  Consider using a lower statin dose or a statin that is less likely to interact when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Green Tea: May increase the serum concentration of Simvastatin. Specifically, Simvastatin lactone concentrations may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Niacin may enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.  Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: May decrease the metabolism of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: HMG-CoA Reductase Inhibitors may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: May increase the serum concentration of Simvastatin. Management: Reduce the recommended simvastatin dose by 50%. Generally, limit the maximum adult simvastatin dose to 20 mg/day. A 40 mg/day dose can be considered in patients who previously received 80 mg/day for at least a year without evidence of muscle toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Avoid lovastatin or simvastatin with erythro-, clarithro-, or telithromycin. Limit pitavastatin to a 1 mg/day maximum adult dose with erythromycin.  Atorvastatin dose adjustments may be required. Increase monitoring for toxicity with any such combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Simvastatin. Management: Avoid simvastatin during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of Pazopanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in this interaction.  There is a lack of data regarding the risk with other statins, but caution appears warranted with any statins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider using a lower starting dose and lower maintenance/maximum doses of atorvastatin, simvastatin, or lovastatin when used together with quinine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: May increase the serum concentration of Simvastatin. Management: Avoid the concurrent use of ranolazine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: May decrease the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: May increase the serum concentration of Simvastatin. Management: Avoid using doses of simvastatin greater than 40 mg/day with ticagrelor.  This specific recommendation is found in the U.S. prescribing information but not in the Canadian product monograph.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trabectedin: HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the serum concentration of Simvastatin. Management: Avoid concurrent use of verapamil with simvastatin when possible.   If used together, limit adult maximum simvastatin dose to 10 mg/day, and avoid Simcor (simvastatin/niacin) because fixed simvastatin doses in the product exceed this maximum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5925429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Consumption of large amounts of ethanol may increase the risk of liver damage with HMG-CoA reductase inhibitors. Concurrent ingestion of ethanol may increase the risk of flushing associated with niacin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Simvastatin serum concentrations may be increased when taken with grapefruit juice; avoid concurrent intake of large quantities (&gt;1 quart/day). Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg rice. Concurrent ingestion of hot liquids or spicy foods may increase the risk of niacin associated flushing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John&rsquo;s wort may decrease simvastatin levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5925370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5925371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5925373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5925374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5925528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Continue standard cholesterol-lowering diet during therapy. Should be taken with a low-fat snack.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F6179933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Simcor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-20 mg (90): $350.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-40 mg (90): $350.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750-20 mg (90): $500.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000-20 mg (90): $620.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000-40 mg (90): $620.41",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5925531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood glucose (in patients with diabetes), CBC, prothrombin time (surgical patients), and serum phosphorus (if predisposed to hypophosphatemia). Baseline CPK (recheck CPK in any patient with symptoms suggestive of myopathy; discontinue therapy if markedly elevated); baseline liver function tests (LFTs) and repeat when clinically indicated thereafter. Patients with elevated transaminase levels should have a second (confirmatory) test and frequent monitoring until values normalize; discontinue if increase in ALT/AST is persistently &gt;3 times ULN (NCEP, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Lipid panel (total cholesterol, HDL, LDL, triglycerides):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      ATP III recommendations (NCEP, 2002):",
"     </i>",
"     Baseline; 6-8 weeks after initiation of drug therapy; if dose increased, then at 6-8 weeks until final dose determined. Once treatment goal achieved, follow up intervals may be reduced to every 4-6 months. Lipid panel should be assessed at least annually, and preferably at each clinic visit.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5925483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin is a component of two coenzymes which is necessary for tissue respiration, lipid metabolism, and glycogenolysis; inhibits the synthesis of very low density lipoproteins.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin is a derivative of lovastatin that acts by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5925485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Castro C and Gourley M, \"Diagnosis and Treatment of Inflammatory Myopathy: Issues and Management,\"",
"      <i>",
"       Ther Adv Musculoskelet Dis",
"      </i>",
"      , 2012, 4(2):111-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/42/35495/abstract-text/22870499/pubmed\" id=\"22870499\" target=\"_blank\">",
"        22870499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Denus S and Spinler SA, &ldquo;Early Statin Therapy for Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2002, 36(11):1749-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/42/35495/abstract-text/12398573/pubmed\" id=\"12398573\" target=\"_blank\">",
"        12398573",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Elam MB, Hunninghake DB, Davis KB, et al, &ldquo;Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial Disease: The ADMIT Study: A Randomized Trial. Arterial Disease Multiple Intervention Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2000, 284(10):1263-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/42/35495/abstract-text/10979113/pubmed\" id=\"10979113\" target=\"_blank\">",
"        10979113",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyton JR and Bays HE, &ldquo;Safety Considerations With Niacin Therapy,&rdquo;",
"      <i>",
"       Am J of Cardiol",
"      </i>",
"      , 2007, 99(6A):22C-31C.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/42/35495/abstract-text/17368274/pubmed\" id=\"17368274\" target=\"_blank\">",
"        17368274",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LaRosa JC, Grundy SM, Waters DD, et al, &ldquo;Intensive Lipid Lowering With Atorvastatin in Patients With Stable Coronary Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(14):1425-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/42/35495/abstract-text/15755765/pubmed\" id=\"15755765\" target=\"_blank\">",
"        15755765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), &ldquo;Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 106(25):3143-421.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/42/35495/abstract-text/12485966/pubmed\" id=\"12485966\" target=\"_blank\">",
"        12485966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peto R, Emberson J, Landray M, et al, &ldquo;Analysis of Cancer Data From Three Ezetimibe Trials,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(13):1357-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/42/35495/abstract-text/18765432/pubmed\" id=\"18765432\" target=\"_blank\">",
"        18765432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ridker PM, Danielson E, Fonseca FAH, et al, &ldquo;Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(21):2195-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/42/35495/abstract-text/18997196/pubmed\" id=\"18997196\" target=\"_blank\">",
"        18997196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossebo AB, Pederson TR, Boman K, et al, &ldquo;Intensive Lipid Lowering With Simvastatin and Ezetimibe in Aortic Stenosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(13):1343-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/42/35495/abstract-text/18765433 /pubmed\" id=\"18765433 \" target=\"_blank\">",
"        18765433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sever PS, Dahlof B, Poulter NR, et al, &ldquo;Prevention of Coronary and Stroke Events With Atorvastatin in Hypertensive Patients Who Have Average or Lower-Than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 361(9364):1149-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/42/35495/abstract-text/12686036/pubmed\" id=\"12686036\" target=\"_blank\">",
"        12686036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, \"Intensive Lowering of LDL Cholesterol With 80 mg versus 20 mg Simvastatin Daily in 12,064 Survivors of Myocardial Infarction: A Double-Blind Randomised Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2010, 376(9753):1658-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/42/35495/abstract-text/21067805/pubmed\" id=\"21067805\" target=\"_blank\">",
"        21067805",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9469 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-F1EFE81ED1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_42_35495=[""].join("\n");
var outline_f34_42_35495=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925347\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925351\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925524\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925525\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925526\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925527\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925565\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925349\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925529\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925369\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925389\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925375\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925376\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925426\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925425\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925429\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925370\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925371\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925373\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925374\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925528\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6179933\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925531\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925483\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5925485\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9469\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9469|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/40/5765?source=related_link\">",
"      Niacin and simvastatin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_42_35496="Malignancy and rheumatic disorders";
var content_f34_42_35496=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Malignancy and rheumatic disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/42/35496/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/42/35496/contributors\">",
"     Yusuf Yazici, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/42/35496/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/42/35496/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/42/35496/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/42/35496/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/42/35496/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain rheumatologic diseases are associated with an increased risk of malignancy. Included in this group are dermatomyositis, polymyositis, rheumatoid arthritis, systemic lupus erythematosus, Sj&ouml;gren's syndrome, and systemic sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. On the other hand, some malignancies have rheumatologic symptoms and may present with joint, muscle, and soft tissue manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. The malignancies that have the most frequent musculoskeletal findings are leukemias and lymphomas, but paraneoplastic syndromes also occur with solid tumors.",
"   </p>",
"   <p>",
"    This topic will provide an overview of associations between the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Specific rheumatic diseases and malignant disorders",
"     </li>",
"     <li>",
"      Specific malignant disorders and rheumatic or connective tissue diseases",
"     </li>",
"     <li>",
"      Drugs used in the treatment of rheumatic diseases and their contribution to the risk of malignant disease",
"     </li>",
"     <li>",
"      Drugs used in the treatment of malignant diseases and rheumatic symptoms or diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RHEUMATIC DISEASES: ASSOCIATED MALIGNANT DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following discussion will briefly review the types of malignancies that occur in the different rheumatic disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Dermatomyositis and polymyositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer is of greatest concern in patients with dermatomyositis and, to a lesser degree, polymyositis. The spectrum of malignancies associated with these disorders parallels the distribution in the general population with a few possible exceptions. The strength of this association and recommendations for initial screening for malignant disease in patients with newly diagnosed inflammatory myopathy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38566?source=see_link\">",
"     \"Malignancy in dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of lymphoma is increased moderately by the presence of rheumatoid arthritis (RA). Drugs used to treat the disease, including alkylating agents,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and anti-tumor necrosis factor alpha therapy, may contribute to the risk, although not all patients with RA who develop malignancies have been treated with any of these drugs. The etiology of neoplasia in such patients may include immune dysregulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic immune activation. The risk of lymphoproliferative diseases in RA is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/11/184?source=see_link&amp;anchor=H10#H10\">",
"     \"Disease outcome and functional capacity in rheumatoid arthritis\", section on 'Lymphoproliferative disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a substantially increased risk of lymphoid malignancy, primarily non-Hodgkin lymphoma, among patients with SLE. Whether or not there is a higher risk of other malignancies is less certain. These associations are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41578?source=see_link&amp;anchor=H35#H35\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\", section on 'Is cancer risk increased?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sj&ouml;gren's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sj&ouml;gren's syndrome has an established association with the development of lymphoproliferative malignancy. The spectrum of malignant lymphoproliferation extends from an increased frequency of circulating monoclonal immunoglobulins, free light chains, and mixed cryoglobulins (type II mixed cryoglobulinemia) to non-Hodgkin lymphoma of the MALT (mucosa-associated lymphoid tissue) type. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/42/27306?source=see_link&amp;anchor=H31#H31\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\", section on 'Lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Scleroderma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most pronounced association between scleroderma disorders and malignancy has been with lung cancer. Patients with systemic sclerosis of either the diffuse or limited cutaneous types appear to be at higher risk of lung cancer than those with morphea or other localized sclerodermatous skin changes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29224?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\", section on 'Cancer risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Vasculitis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Leukocytoclastic vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small vessel vasculitis, often limited to the skin, causing palpable purpura or ulceration and having histologic features of fragmented leukocytes (leukocytoclastic), has been noted in the setting of a variety of malignant diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=see_link&amp;anchor=H20#H20\">",
"     \"Cutaneous manifestations of internal malignancy\", section on 'Vasculitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Systemic vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic necrotizing vasculitis has been seen in association with hairy cell leukemia. Polyarteritis nodosa has been associated with solid tumors, lymphoid malignancies, and myelodysplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20841?source=see_link\">",
"     \"Clinical features and diagnosis of hairy cell leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Polyarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyarthritis or symptoms that mimic polymyalgia rheumatica may be the presenting manifestation of a malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/1,6,7\">",
"     1,6,7",
"    </a>",
"    ]. Patients with polyarthritis are generally older than those with rheumatoid arthritis, have asymmetrical arthritis and an explosive onset, and are rheumatoid factor negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with myelodysplastic syndromes sometimes develop polyarthritis that may be confused with seronegative RA. A cohort study of 87 patients with myelodysplastic syndromes reported five with inflammatory arthritis resembling RA, one of whom had leukocytoclastic vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6010?source=see_link\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30393?source=see_link\">",
"     \"Neutrophilic dermatoses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Palmar fibromatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palmar fibromatosis (sometimes referred to as palmar fasciitis) is a rare disorder associated with a variety of malignant neoplasms. The most frequently reported tumor is ovarian cancer, but other primary sites including the stomach, pancreas, lung, and colon have also been described in association with this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Polyarthritis may sometimes accompany the fibrosis.",
"   </p>",
"   <p>",
"    The fibrosis or fibromatosis of the palms leads to progressive flexion deformities of the fingers, usually affecting all the digits of both hands. The changes in the palmar skin and fascia and the resulting flexion deformities are reminiscent of Dupuytren's contracture but are more wide spread than in that disease, and progressive changes lead to an appearance and texture of &ldquo;woody hands&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Treatment of an associated malignancy has led to improvement in some cases and has halted progression in others. Malignant disease has not been identified in all cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hypertrophic osteoarthropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic osteoarthropathy (HOA) is a syndrome characterized by abnormal proliferation of the skin and osseous tissue at the distal parts of the extremities. Clinical features of HOA include digital clubbing (",
"    <a class=\"graphic graphic_figure graphicRef52839 \" href=\"mobipreview.htm?42/58/43951\">",
"     figure 1",
"    </a>",
"    ), periostosis of tubular bones (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57502 graphicRef70330 \" href=\"mobipreview.htm?32/3/32816\">",
"     image 1A-B",
"    </a>",
"    ), and synovial effusions, which are most prominent in the large joints. Periostosis is usually accompanied by pain on palpation of the involved area. Some patients present with a painful arthropathy in advance of clubbing and may be thought to have an inflammatory arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a primary form of HOA (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Primary HOA'",
"    </a>",
"    below) not associated with any other medical disorders and a secondary form that is usually associated with lung cancer, pulmonary infections, cystic fibrosis, and right-to-left cardiac shunts and that is less often seen in other conditions (eg, Hodgkin lymphoma and cirrhosis).",
"   </p>",
"   <p>",
"    Among patients with lung cancer, HOA is most frequently associated with adenocarcinoma and least frequently with small cell carcinoma. In one series of 111 consecutive patients with pathologically proven lung cancer, clubbing was present in 29 percent; clubbing was more common among women than men (40 versus 19 percent) and in non-small cell compared with small cell lung cancer (35 versus 4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/13\">",
"     13",
"    </a>",
"    ]. In a study of 2625 Japanese patients with lung cancer, HOA was detected by bone scintigraphy in 19 patients (0.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, arterial vascular prosthesis infections may be associated with HOA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/15\">",
"     15",
"    </a>",
"    ]. Clinical features suggestive of vascular infection-related HOA include clubbing or periosteal new bone formation in a single limb (in the case of upper extremity arterial prostheses) or unilateral or bilateral lower extremity involvement (in the case of arterial grafts to the legs or aortic prostheses).",
"   </p>",
"   <p>",
"    When HOA is suspected, particular attention should be paid to the chest because the most frequent cause of acute onset of HOA is a lung neoplasm, either primary or secondary. Bone scintigraphy is a sensitive way to detect involvement.",
"   </p>",
"   <p>",
"    Treatment with nonsteroidal antiinflammatories or other analgesics may provide significant relief of symptoms. Removal of lung cancer or treatment of the other causes of HOA results in regression in the clinical manifestations in many patients but is not always effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. In patients with refractory disease, bisphosphonates, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    , have been reported to be highly effective in a number of case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clubbing and HOA appear to be different manifestations of the same disease process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. It is thought that localized activation of the platelet-endothelial cells, with the subsequent release of fibroblast growth factor(s) (eg, platelet-derived growth factor), plays an important role in the pathogenesis of HOA. The frequent association with lung disease raises the possibility that circulatory bypass of the lung may play an important role. One hypothesis is that megakaryocytes escape the normal fragmentation to platelets in the lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/21\">",
"     21",
"    </a>",
"    ] and reach the distal extremities where they release growth factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4458?source=see_link\">",
"     \"Megakaryocyte biology and the production of platelets\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another hypothesis involves tumor production and release into the circulation of a factor that promotes features of HOA such as vascular proliferation, edema formation, and new bone formation. One candidate is vascular endothelial growth factor (VEGF). Two case reports of patients with lung cancer and HOA noted elevated circulating concentrations of VEGF, with evidence of tumor production of VEGF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In one case, a marked decline in VEGF followed resection of tumor and was temporally correlated with the disappearance of the skeletal abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent to these observations, the pathogenesis of primary HOA was elucidated and raised the question of whether the central abnormality in primary HOA, elevations in circulating prostaglandin E2, may play a pathogenetic role in secondary HOA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Primary HOA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary or idiopathic HOA (also called pachydermoperiostosis and Touraine-Solente-Gole syndrome) is a hereditary disorder that presents in childhood and clinically mimics the secondary HOA associated with the acquired disorders described above. The genetic abnormality in primary HOA involves a mutation in the HPGD gene that encodes 15-hydroxyprostaglandin dehydrogenase, which is the primary enzyme response for prostaglandin degradation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/24\">",
"     24",
"    </a>",
"    ]. The following findings were noted in a study of three affected families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mutant protein had no detectable activity.",
"     </li>",
"     <li>",
"      The pattern of inheritance was not clearly defined as features consistent with both autosomal recessive and dominant or pseudodominant inheritance were noted.",
"     </li>",
"     <li>",
"      Homozygous individuals had persistently elevated prostaglandin E2 (PGE2) concentrations and HOA. Heterozygous individuals had less pronounced biochemical and clinical manifestations.",
"     </li>",
"     <li>",
"      Four of the 13 affected individuals had a persistent patent ductus arteriosus, which is not surprising since postnatal closure of the ductus arteriosus depends upon a rapid fall in circulating PGE2 that occurs when blood is exposed to high concentrations of HPGD in the neonatal lung after establishment of the pulmonary circulation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35656?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations and diagnosis of patent ductus arteriosus\", section on 'Fetal and transitional ductal circulation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors suggested that increased circulating PGE2 might also be pathogenetically important in secondary HOA, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with cystic fibrosis, serum prostaglandin concentrations are higher in those with clubbing compared with those without clubbing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Overproduction of PGE2 has been demonstrated in patients with unresectable lung cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MALIGNANT DISEASES: MUSCULOSKELETAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of malignancies can have musculoskeletal manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/1,27-29\">",
"     1,27-29",
"    </a>",
"    ]. Perhaps most common is bone pain in multiple myeloma and with bone metastases; this problem will not be discussed further.",
"   </p>",
"   <p>",
"    In some cases, the rheumatic symptoms are the presenting feature of the disease. In one series of patients admitted to a general hospital ward with a previously unclarified rheumatic disease, 23 percent had an occult malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/29\">",
"     29",
"    </a>",
"    ]. Remission of the tumor was associated with improvement in rheumatic symptoms. Symmetric polyarthritis affecting the wrists and small joints of the hands, mimicking rheumatoid arthritis, is a relatively rare presentation of paraneoplastic arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Articular symptoms in patients with lymphoma may result from secondary gout, a reaction to adjacent lymphomatous involvement, or lymphomatous infiltration of the synovium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/31\">",
"     31",
"    </a>",
"    ]. Joint involvement is unusual in lymphoma and is primarily seen with T cell types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/32\">",
"     32",
"    </a>",
"    ]. Synovial fluid may show atypical lymphocytes, and synovial biopsies may demonstrate infiltration by lymphoma cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/33\">",
"     33",
"    </a>",
"    ]. In rare cases, arthritis is a presenting feature of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lymphomas may also have clinical features that can cause diagnostic confusion with systemic rheumatic or connective tissue disorders, including those characterized by vascular and granulomatous inflammation. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with angioimmunoblastic T cell lymphoma may have arthritis, Coombs-positive hemolytic anemia, skin rash, fever, and weight loss that are suggestive systemic lupus erythematosus or systemic onset rheumatoid arthritis (Still's disease). Lymphohistiocytic vasculitis has been described as well. This type of T cell lymphoma is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/14/34023?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of angioimmunoblastic T cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Angiocentric and angioinvasive lesions of various organs may be due to large B cell lymphomas. When there is predominantly (or exclusively) extranodal disease, T cell rich tissue infiltrates, extensive necrosis, and inflammation, this disorder may be confused with granulomatosis with polyangiitis (Wegener&rsquo;s). This type of disease, usually with prominent pulmonary involvement, is referred to as lymphomatoid granulomatosis, and it is discussed in more detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/20/41287?source=see_link\">",
"       \"Pulmonary lymphomatoid granulomatosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24282?source=see_link&amp;anchor=H763094#H763094\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Lymphomatoid granulomatosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Up to 15 percent of patients with Hodgkin lymphoma have radiographic evidence of bone involvement. Bone pain, which may be worse at night, is the most common symptom attributable to osseous involvement. Pathologic fractures, particularly involving the vertebrae, may occur.",
"   </p>",
"   <p>",
"    Lymphoma involving the muscles is uncommon. In one report, for example, 472 cases of lymphomas arising from the soft tissues were reported from a review of more than 39,000 consecutive cases over a 10-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Large granular lymphocyte syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic lymphoproliferative disease related to clonal or nonclonal (&ldquo;reactive&rdquo;) expansion of large granular lymphocytes is characterized by mild to moderate lymphocytosis, bone marrow infiltration, splenomegaly, granulocytopenia (neutropenia), and anemia. Up to one-third of patients with the LGL syndrome also have rheumatoid arthritis (RA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/36\">",
"     36",
"    </a>",
"    ] and may fulfill the clinical criteria for Felty's syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5095?source=see_link\">",
"     \"Large granular lymphocyte leukemia in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/46/2793?source=see_link\">",
"     \"Treatment of large granular lymphocyte leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukemia can present with symmetric or migratory",
"    <span class=\"nowrap\">",
"     polyarthritis/arthralgia",
"    </span>",
"    as well as bone pain and tenderness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/1,37-39\">",
"     1,37-39",
"    </a>",
"    ]. The frequency of articular manifestations in acute leukemia is approximately 4 percent in adults and 14 percent in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/37\">",
"     37",
"    </a>",
"    ]. The predominant leukemia causing arthritis in children is acute lymphocytic leukemia, and polyarthritis can be the presenting complaint. In comparison, acute and chronic lymphocytic and myeloid leukemia can cause arthritis in adults.",
"   </p>",
"   <p>",
"    The pain in leukemic arthritis is usually severe and unresponsive to antirheumatic medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/34\">",
"     34",
"    </a>",
"    ]. Radiographs often reveal more osteopenia and earlier lytic lesions than one would expect in a child with juvenile idiopathic arthritis.",
"   </p>",
"   <p>",
"    Synovial infiltration by leukemic cells, hemorrhage into the joint and bony, and periosteal or capsular lesions all can account for the joint manifestations. Synovial biopsy can be diagnostic but may be negative because of the patchy nature of neoplastic involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/40\">",
"     40",
"    </a>",
"    ]. Immunocytological analysis of the synovial fluid can also be helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/41\">",
"     41",
"    </a>",
"    ]. Leukemic synovitis is a sign of systemic involvement and should prompt immediate and aggressive therapy even in the absence of signs of bone marrow involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Myelodysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of phenomena of suspected autoimmune pathogenesis has been reported in association with myelodysplastic syndromes. Among the rheumatic manifestations are monoarticular arthritis, relapsing polychondritis, Raynaud phenomenon, Sj&ouml;gren&rsquo;s syndrome, and vasculitis. These and other disorders that may be associated with myelodysplasia are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ANTIRHEUMATIC MEDICATIONS: RISK OF MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic therapy of rheumatic diseases may increase the risk of malignant disease. Alkylating agents, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and other immunosuppressive and antiinflammatory drugs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ), as well as certain biologic response modifiers (anticytokine therapies), may also increase the risk of hematologic and other malignancies. Discussion of the oncogenic potential of these drugs and biologic agents is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=see_link\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     RHEUMATIC DISORDERS: RELATION TO TREATMENT OF MALIGNANT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various musculoskeletal or other connective tissue disorders may arise as the result of treatment of malignant disease. Among those already alluded to are gouty arthritis resulting from hyperuricemia that accompanies a tumor burden. Arthralgia or arthritis may follow or, less often, occur during adjuvant chemotherapy. These phenomena are referred to as postchemotherapy rheumatism or chemotherapy-related arthropathy, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35496/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Some other rheumatic or connective tissue disorders are associated with the use of particular chemotherapeutic agents and radiation therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aromatase inhibitors (",
"    <a class=\"graphic graphic_table graphicRef61155 \" href=\"mobipreview.htm?5/6/5227\">",
"     table 1",
"    </a>",
"    ) used in the treatment of breast cancer are associated with an increased incidence of musculoskeletal complaints. Arthralgia and subjective joint stiffness are common complaints, occurring in 40 to 50 percent of women who are being treated with one of these agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link&amp;anchor=H2110938219#H2110938219\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Aromatase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Bleomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of scleroderma and Raynaud phenomenon have been noted in association with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/65?source=see_link&amp;anchor=H15#H15\">",
"     \"Risk factors for and possible causes of systemic sclerosis (scleroderma)\", section on 'Drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Taxanes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taxanes, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , can cause myalgia and arthralgia that is sometimes severe. Taxanes may also cause photodistributed skin rashes with clinical and histologic similarity to subacute cutaneous lupus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link&amp;anchor=H14#H14\">",
"     \"Cutaneous complications of conventional chemotherapy agents\", section on 'Photosensitivity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of high-dose glucocorticoids is associated with an increased risk of developing osteonecrosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/43/28346?source=see_link&amp;anchor=H3#H3\">",
"     \"Osteonecrosis (avascular necrosis of bone)\", section on 'Corticosteroids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Musculoskeletal pain, occasionally severe, rarely occurs with the use of these agents. Use of bisphosphonates has been associated with osteonecrosis of the jaw. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=see_link&amp;anchor=H1928329#H1928329\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Osteonecrosis of the jaw'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myalgia, stiffness, and elevation of serum creatine kinase following external neck irradiation may be the result of radiation-induced hypothyroidism. These symptoms may follow radiation therapy by months or even years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/47/42744?source=see_link&amp;anchor=H11#H11\">",
"     \"Disorders that cause hypothyroidism\", section on 'External neck irradiation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29093?source=see_link\">",
"     \"Hypothyroid myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    External beam irradiation may also increase the risk of osteonecrosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=see_link&amp;anchor=H3822453#H3822453\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Osteoradionecrosis and soft tissue necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11807533\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individual rheumatic diseases may be associated with increased risk of particular malignancies, including rheumatoid arthritis, Sj&ouml;gren&rsquo;s syndrome, and systemic lupus erythematosus with lymphoid malignancy; dermatomyositis and polymyositis with multiple malignancies; and scleroderma with lung cancer. Other associations include leukocytoclastic vasculitis with a variety of malignancies; systemic necrotizing vasculitis with hairy cell leukemia; polyarteritis nodosa with solid tumors, lymphoid malignancies, and myelodysplasia; nonspecific polyarthritis with myelodysplastic syndromes; and palmar fibromatosis with various malignancies, including ovarian cancer. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Rheumatic diseases: Associated malignant disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Secondary hypertrophic osteoarthropathy (HOA) is characterized by abnormal proliferation of the skin and osseous tissue at the distal parts of the extremities, resulting in clinical features that include digital clubbing, periostosis of tubular bones, and synovial effusions. Periostosis is usually accompanied by pain on palpation of the involved area. Secondary HOA is usually associated with lung cancer (especially adenocarcinoma), pulmonary infections, cystic fibrosis, and right-to-left cardiac shunts and is less often seen in other conditions (eg, Hodgkin lymphoma and cirrhosis). A hereditary primary or idiopathic form of HOA can occur in children. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Hypertrophic osteoarthropathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Primary HOA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of secondary HOA with nonsteroidal antiinflammatories or other analgesics may provide significant relief of symptoms. Removal of lung cancer or treatment of the other causes of HOA results in regression in the clinical manifestations in many patients but is not always effective. Bisphosphonates have shown benefit in patients with refractory disease. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Hypertrophic osteoarthropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malignancy can be associated with a number of rheumatic manifestations, depending upon the underlying disorder. Uncharacterized polyarthritis may occasionally occur as a paraneoplastic syndrome. Bone pain can be seen in multiple myeloma, and articular manifestation can occur by several mechanisms in patients with lymphoma. Leukemia can present with symmetric or migratory",
"      <span class=\"nowrap\">",
"       polyarthritis/arthralgia",
"      </span>",
"      as well as bone pain and tenderness. A variety of phenomena suspected to be autoimmune have been reported in patients with myelodysplastic syndromes. Up to one-third of patients with large granular lymphocytic leukemia also have rheumatoid arthritis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Malignant diseases: Musculoskeletal manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Lymphoma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Leukemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Myelodysplasia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Large granular lymphocyte syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacologic therapies used for the treatment of rheumatic diseases may increase the risk of malignancy. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Antirheumatic medications: Risk of malignancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various musculoskeletal or other connective tissue disorders may arise as the result of treatment of malignant disease, including gouty arthritis resulting from hyperuricemia that accompanies a tumor burden and arthralgia or arthritis that may follow or occur due to treatments including adjuvant chemotherapy. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Rheumatic disorders: Relation to treatment of malignant disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/1\">",
"      Naschitz JE, Rosner I. Musculoskeletal syndromes associated with malignancy (excluding hypertrophic osteoarthropathy). Curr Opin Rheumatol 2008; 20:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/2\">",
"      Carsons S. The association of malignancy with rheumatic and connective tissue diseases. Semin Oncol 1997; 24:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/3\">",
"      Naschitz JE, Rosner I, Rozenbaum M, et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum 1999; 29:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/4\">",
"      Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum 2007; 57:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/5\">",
"      Solans-Laqu&eacute; R, Bosch-Gil JA, P&eacute;rez-Bocanegra C, et al. Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases. J Rheumatol 2008; 35:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/6\">",
"      Brooks RC, McGee SR. Diagnostic dilemmas in polymyalgia rheumatica. Arch Intern Med 1997; 157:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/7\">",
"      Sidhom OA, Basalaev M, Sigal LH. Renal cell carcinoma presenting as polymyalgia rheumatica. Resolution after nephrectomy. Arch Intern Med 1993; 153:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/8\">",
"      Chandran G, Ahern MJ, Seshadri P, Coghlan D. Rheumatic manifestations of the myelodysplastic syndromes: a comparative study. Aust N Z J Med 1996; 26:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/9\">",
"      Enomoto M, Takemura H, Suzuki M, et al. Palmar fasciitis and polyarthritis associated with gastric carcinoma: complete resolution after total gastrectomy. Intern Med 2000; 39:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/10\">",
"      Alexandroff AB, Hazleman BL, Matthewson M, et al. Woody hands. Lancet 2003; 361:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/11\">",
"      Cox NH, Ramsay B, Dobson C, Comaish JS. Woody hands in a patient with pancreatic carcinoma: a variant of cancer-associated fasciitis--panniculitis syndrome. Br J Dermatol 1996; 135:995.",
"     </a>",
"    </li>",
"    <li>",
"     Martinez-Lavin M, Pineda C. Hypertrophic Osteoarthropathy. In: Rheumatology, Hochberg MC, Silman AJ, Smolen JS, et al. (Eds), Mosby, London 2003. p.1763.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/13\">",
"      Sridhar KS, Lobo CF, Altman RD. Digital clubbing and lung cancer. Chest 1998; 114:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/14\">",
"      Ito T, Goto K, Yoh K, et al. Hypertrophic pulmonary osteoarthropathy as a paraneoplastic manifestation of lung cancer. J Thorac Oncol 2010; 5:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/15\">",
"      Alonso-Bartolom&eacute; P, Mart&iacute;nez-Taboada VM, Pina T, et al. Hypertrophic osteoarthropathy secondary to vascular prosthesis infection: report of 3 cases and review of the literature. Medicine (Baltimore) 2006; 85:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/16\">",
"      Yao Q, Altman RD, Brahn E. Periostitis and hypertrophic pulmonary osteoarthropathy: report of 2 cases and review of the literature. Semin Arthritis Rheum 2009; 38:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/17\">",
"      Slobodin G, Rosner I, Feld J, et al. Pamidronate treatment in rheumatology practice: a comprehensive review. Clin Rheumatol 2009; 28:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/18\">",
"      King MM, Nelson DA. Hypertrophic osteoarthropathy effectively treated with zoledronic acid. Clin Lung Cancer 2008; 9:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/19\">",
"      Dickinson CJ. The aetiology of clubbing and hypertrophic osteoarthropathy. Eur J Clin Invest 1993; 23:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/20\">",
"      Mart&iacute;nez-Lav&iacute;n M. Digital clubbing and hypertrophic osteoarthropathy: a unifying hypothesis. J Rheumatol 1987; 14:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/21\">",
"      Pedersen NT. Occurrence of megakaryocytes in various vessels and their retention in the pulmonary capillaries in man. Scand J Haematol 1978; 21:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/22\">",
"      Abe Y, Kurita S, Ohkubo Y, et al. A case of pulmonary adenocarcinoma associated with hypertrophic osteoarthropathy due to vascular endothelial growth factor. Anticancer Res 2002; 22:3485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/23\">",
"      Ol&aacute;n F, Portela M, Navarro C, et al. Circulating vascular endothelial growth factor concentrations in a case of pulmonary hypertrophic osteoarthropathy. Correlation with disease activity. J Rheumatol 2004; 31:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/24\">",
"      Uppal S, Diggle CP, Carr IM, et al. Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet 2008; 40:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/25\">",
"      Lemen RJ, Gates AJ, Math&eacute; AA, et al. Relationships among digital clubbing, disease severity, and serum prostaglandins F2alpha and E concentrations in cystic fibrosis patients. Am Rev Respir Dis 1978; 117:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/26\">",
"      Murphey LJ, Williams MK, Sanchez SC, et al. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem 2004; 334:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/27\">",
"      Nashitz JE, Rosner I, Rozenbaum M, et al. Cancer-associated rheumatic disorders: clues to occult neoplasia. Semin Arthritis Rheum 1995; 24:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/28\">",
"      Mody GM, Cassim B. Rheumatologic manifestations of malignancy. Curr Opin Rheumatol 1997; 9:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/29\">",
"      Naschitz JE, Yeshurun D, Rosner I. Rheumatic manifestations of occult cancer. Cancer 1995; 75:2954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/30\">",
"      Morel J, Deschamps V, Toussirot E, et al. Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis 2008; 67:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/31\">",
"      Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/32\">",
"      Mariette X, de Roquancourt A, d'Agay MF, et al. Monarthritis revealing non-Hodgkin's T cell lymphoma of the synovium. Arthritis Rheum 1988; 31:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/33\">",
"      Savin H, Zimmermann B 3rd, Aaron RK, et al. Seronegative symmetric polyarthritis in Sezary syndrome. J Rheumatol 1991; 18:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/34\">",
"      Ehrenfeld M, Gur H, Shoenfeld Y. Rheumatologic features of hematologic disorders. Curr Opin Rheumatol 1999; 11:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/35\">",
"      Kransdorf MJ. Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location. AJR Am J Roentgenol 1995; 164:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/36\">",
"      Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood 1993; 82:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/37\">",
"      Avi&ntilde;a-Zubieta JA, Galindo-Rodriguez G, Lavalle C. Rheumatic manifestations of hematologic disorders. Curr Opin Rheumatol 1998; 10:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/38\">",
"      Rennie JA, Auchterlonie IA. Rheumatological manifestations of the leukaemias and graft versus host disease. Baillieres Clin Rheumatol 1991; 5:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/39\">",
"      Weinberger A, Schumacher HR, Schimmer BM, et al. Arthritis in acute leukemia. Clinical and histopathological observations. Arch Intern Med 1981; 141:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/40\">",
"      Fort JG, Fernandez C, Jacobs SR, Abruzzo JL. B cell surface marker analysis of synovial fluid cells in a patient with monoarthritis and chronic lymphocytic leukemia. J Rheumatol 1992; 19:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/41\">",
"      Fam AG, Voorneveld C, Robinson JB, Sheridan BL. Synovial fluid immunocytology in the diagnosis of leukemic synovitis. J Rheumatol 1991; 18:293.",
"     </a>",
"    </li>",
"    <li>",
"     Caldwell DS. Musculoskeletal syndromes associated with malignancy. In: Textbook of Rheumatology, Kelley WN, Harris ED, Ruddy S, Sledge CB (Eds), WB Saunders, Philadelphia 1997. p.1521.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/43\">",
"      Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol 1993; 11:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35496/abstract/44\">",
"      Kim MJ, Ye YM, Park HS, Suh CH. Chemotherapy-related arthropathy. J Rheumatol 2006; 33:1364.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5615 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7ADB670DEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_42_35496=[""].join("\n");
var outline_f34_42_35496=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11807533\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RHEUMATIC DISEASES: ASSOCIATED MALIGNANT DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Leukocytoclastic vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Systemic vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Polyarthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Palmar fibromatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hypertrophic osteoarthropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Primary HOA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MALIGNANT DISEASES: MUSCULOSKELETAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Large granular lymphocyte syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Myelodysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ANTIRHEUMATIC MEDICATIONS: RISK OF MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      RHEUMATIC DISORDERS: RELATION TO TREATMENT OF MALIGNANT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Bleomycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Taxanes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11807533\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5615\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5615|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?4/63/5119\" title=\"diagnostic image 1A\">",
"      Pulmonary osteoarthropathy I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/43/10942\" title=\"diagnostic image 1B\">",
"      Pulmonary osteoarthropathy II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5615|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/58/43951\" title=\"figure 1\">",
"      Clubbing of the fingers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5615|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/6/5227\" title=\"table 1\">",
"      Aromatase inhibitors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20841?source=related_link\">",
"      Clinical features and diagnosis of hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/52/35656?source=related_link\">",
"      Clinical manifestations and diagnosis of patent ductus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/42/27306?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/14/34023?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of angioimmunoblastic T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/11/184?source=related_link\">",
"      Disease outcome and functional capacity in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/47/42744?source=related_link\">",
"      Disorders that cause hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/26/29093?source=related_link\">",
"      Hypothyroid myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5095?source=related_link\">",
"      Large granular lymphocyte leukemia in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/42/38566?source=related_link\">",
"      Malignancy in dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4458?source=related_link\">",
"      Megakaryocyte biology and the production of platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/43/30393?source=related_link\">",
"      Neutrophilic dermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/20/41287?source=related_link\">",
"      Pulmonary lymphomatoid granulomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/65?source=related_link\">",
"      Risk factors for and possible causes of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/46/2793?source=related_link\">",
"      Treatment of large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_42_35497="Retinal hemorrhage types";
var content_f34_42_35497=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Types of retinal hemorrhage (RH) in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 664px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Aryan HE, Ghosheh FR, Jandial R, Levy ML. Retinal hemorrhage and pediatric brain injury: etiology and review of the literature. J Clin Neurosci 2005; 12:624.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_42_35497=[""].join("\n");
var outline_f34_42_35497=null;
var title_f34_42_35498="Prevention of contrast-induced nephropathy";
var content_f34_42_35498=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of contrast-induced nephropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/42/35498/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/42/35498/contributors\">",
"     Michael R Rudnick, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/42/35498/contributors\">",
"     James A Tumlin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/42/35498/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/42/35498/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/42/35498/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/42/35498/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/42/35498/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of radiocontrast media can lead to a usually reversible form of acute kidney injury (formerly called acute renal failure) that begins soon after the contrast is administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/1-11\">",
"     1-11",
"    </a>",
"    ]. In most cases, there are no permanent sequelae, but there is some evidence that its development is associated with adverse outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will provide an overview of the relative nephrotoxicity of different iodinated radiocontrast agents and the relative efficacy of various prophylactic strategies. The pathogenesis, clinical features and diagnosis of radiocontrast media-induced nephropathy, and a discussion of acute tubular necrosis, the most common cause of acute kidney injury in hospitalized patients, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/28/4553?source=see_link\">",
"     \"Renal and patient outcomes after acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Types of radiocontrast agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodinated radiocontrast agents are either ionic or nonionic and, at the concentrations required for arteriography or computed tomography, are of variable osmolality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First generation agents are ionic monomers; they are highly hyperosmolal (approximately 1400 to 1800",
"      <span class=\"nowrap\">",
"       mosmol/kg)",
"      </span>",
"      compared with the osmolality of plasma.",
"     </li>",
"     <li>",
"      Second generation agents, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30949?source=see_link\">",
"       iohexol",
"      </a>",
"      , are nonionic monomers with a lower osmolality than the first generation radiocontrast media; however, they still have an increased osmolality (500 to 850",
"      <span class=\"nowrap\">",
"       mosmol/kg)",
"      </span>",
"      compared with plasma. Until recently, all available nonionic agents were such \"low osmolality\" agents. In addition, there is an ionic low osmolal contrast agent (ioxaglate).",
"     </li>",
"     <li>",
"      The newest nonionic contrast agents are iso-osmolal, being dimers with an osmolality of approximately 290",
"      <span class=\"nowrap\">",
"       mosmol/kg",
"      </span>",
"      (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/63/13301?source=see_link\">",
"       iodixanol",
"      </a>",
"      is the first such agent). Thus, iso-osmolal agents have a lower osmolality than \"low osmolal\" second generation drugs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The nephrotoxic properties of these agents appear to vary, with low- and iso-osmolal agents being associated with a relatively decreased incidence of renal injury among high-risk patients. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Type of contrast agent'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific treatment once contrast-induced acute kidney injury develops, and management must be as for any cause of acute tubular necrosis, with the focus on maintaining fluid and electrolyte balance. The best treatment of contrast-induced kidney injury is prevention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of preventive measures may reduce the risk of contrast nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/1-3,14\">",
"     1-3,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use, if clinically possible, of ultrasonography, magnetic resonance imaging (see",
"      <a class=\"local\" href=\"#H23\">",
"       'Contrast-enhanced MRI as an alternative'",
"      </a>",
"      below) or CT scanning without radiocontrast agents, particularly in high-risk patients.",
"     </li>",
"     <li>",
"      The use of lower doses of contrast [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/4-7,15\">",
"       4-7,15",
"      </a>",
"      ] and avoidance of repetitive studies that are closely spaced (within 48 to 72 hours). Very small amounts of contrast (&lt;10 mL) have been safely used in patients with advanced kidney disease for examination of poorly maturing arteriovenous fistula [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Avoidance of volume depletion or nonsteroidal antiinflammatory drugs, both of which can increase renal vasoconstriction.",
"     </li>",
"     <li>",
"      The administration of intravenous saline or possibly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The administration of the antioxidant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The use of selected low or iso-osmolal nonionic contrast agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to appreciate that most of the clinical trials that have evaluated these factors have used small, transient elevations in the serum creatinine concentration (which are of dubious clinical significance) as end points (eg, &ge;0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [44.2",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    or &ge;25 to 50 percent above baseline) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/14\">",
"     14",
"    </a>",
"    ]. Nevertheless, there are an increasing number of reports that contrast-induced nephropathy defined in this manner is associated with significant in-hospital and long-term mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/8,9,17\">",
"     8,9,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Type of contrast agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;A decreased incidence of contrast nephropathy appears to be associated with nonionic agents which, as defined above, are either low osmolal (500 to 850",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    or iso-osmolal (approximately 290",
"    <span class=\"nowrap\">",
"     mosmol/kg).",
"    </span>",
"    Most studies have evaluated the relative effectiveness of nonionic low osmolal agents versus ionic hyperosmolal agents. The ionic low-osmolal agent ioxaglate also appears to be associated with a lower risk of contrast nephropathy compared to ionic hyperosmolal agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/10\">",
"     10",
"    </a>",
"    ]. However, there are few direct comparisons between the various agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Nonionic low osmolal agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, low osmolal agents are less hyperosmolal than conventional agents (600 to 850",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    versus 1500 to 1800",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    but still hyperosmolal to plasma. Although the optimal renoprotective role of nonionic low osmolal contrast agents may vary with the clinical setting, such agents are now administered for the majority of radiologic procedures using intravascular contrast media, as a result of cost reductions, increased patient tolerability, decreased hypersensitivity reactions, and, in patients at risk, a lower incidence of contrast nephropathy.",
"   </p>",
"   <p>",
"    There appears to be little or no advantage in the prevention of contrast nephropathy when compared to ionic hyperosmolal agents in patients with normal renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/1,2,4,11,13\">",
"     1,2,4,11,13",
"    </a>",
"    ], a group that is at low risk.",
"   </p>",
"   <p>",
"    In studies of patients with moderate renal insufficiency (serum creatinine concentration between 1.4 and 2.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [123 to 211",
"    <span class=\"nowrap\">",
"     micromol/L]),",
"    </span>",
"    some nonionic, low osmolality agents compared to hyperosmolal agents have been associated with a reduced incidence of a mild to moderate decline in renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/4,10,13,20-23\">",
"     4,10,13,20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best data come from a randomized trial of almost 1200 patients undergoing coronary angiography, which compared the low osmolal nonionic agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30949?source=see_link\">",
"     iohexol",
"    </a>",
"    with the high osmolal agent diatrizoate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/4\">",
"     4",
"    </a>",
"    ]. A benefit from iohexol was seen in patients with renal insufficiency alone or with diabetes mellitus. Among patients with a baseline serum creatinine above 1.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (123",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    a rise in the serum creatinine of at least 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (88",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    was seen less often after the use of iohexol (7.2 versus 15.8 percent with an ionic agent). The benefit was greater in diabetic patients (11.8 versus 27 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nonionic iso-osmolal agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/63/13301?source=see_link\">",
"     Iodixanol",
"    </a>",
"    , the only currently available iso-osmolal nonionic contrast agent (approximately 290",
"    <span class=\"nowrap\">",
"     mosmol/kg),",
"    </span>",
"    may be associated with a lower risk of nephropathy than some low osmolal agents, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30949?source=see_link\">",
"     iohexol",
"    </a>",
"    , among diabetic patients with chronic kidney disease (CKD) and a reduced glomerular filtration rate who are given intraarterial contrast, mostly for coronary angiography.",
"   </p>",
"   <p>",
"    In an initial trial that compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/63/13301?source=see_link\">",
"     iodixanol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30949?source=see_link\">",
"     iohexol",
"    </a>",
"    in 129 high risk patients with diabetes and chronic kidney disease (mean serum creatinine 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [133",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    who underwent angiography, iodixanol was associated with a lower incidence of a &gt; 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (44",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    rise in serum creatinine (3 versus 26 percent with iohexol) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/24\">",
"     24",
"    </a>",
"    ]. In contrast, three much larger subsequent trials that compared iodixanol to two other nonionic low osmolal contrast agents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34709?source=see_link\">",
"     ioversol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/45/36565?source=see_link\">",
"     iopamidol",
"    </a>",
"    ) in patients with diabetic and nondiabetic chronic kidney disease found no difference in the incidence of contrast nephropathy between the different agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 16 randomized trials also suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/63/13301?source=see_link\">",
"     iodixanol",
"    </a>",
"    was associated with a reduction in risk among patients with chronic kidney disease who received contrast when compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30949?source=see_link\">",
"     iohexol",
"    </a>",
"    (relative risk 0.19, 95% CI 0.07-0.56) but not when compared to other nonionic low osmolal contrast agents (relative risk 0.79, 95% CI 0.56-1.12) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, the data support a benefit of iso-osmolal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/63/13301?source=see_link\">",
"     iodixanol",
"    </a>",
"    compared to low osmolal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30949?source=see_link\">",
"     iohexol",
"    </a>",
"    among patients who have diabetes and chronic kidney disease, but not a benefit for iodixanol compared to other nonionic low osmolal agents. Thus, the positive findings in the initial trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/24\">",
"     24",
"    </a>",
"    ] may represent an adverse effect of iohexol rather than a beneficial effect of nonionic iso-osmolal agents. After considering all the published data, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on percutaneous coronary intervention were revised to suggest the use of either an iso-osmolal contrast agent or a low molecular weight contrast agent other than iohexol or the ionic low osmolal agent, ioxaglate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/29\">",
"     29",
"    </a>",
"    ]. The 2012 KDIGO guidelines recommended low-osmolal or iso-osmolal rather than high osmolal contrast agents but stated that the work group found no reliable evidence upon which to base a recommendation for either low versus iso-osmolal agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Carbon dioxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative contrast agent is carbon dioxide, which can be used alone or with small amounts of iodinated contrast. Satisfactory imaging and procedural results are obtained, particularly with modern imaging technology (digital subtraction angiography), with no or little nephrotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/31-36\">",
"     31-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important limitation is the risk of neurotoxicity when injected close to the cerebral circulation or if there is a right-to-left intracardiac shunt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Thus, it cannot be used for cerebrovascular imaging, and if to be used, its use should be limited to imaging below the diaphragm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary benefit of nonionic contrast agents, whether low or iso-osmolal, is seen in high-risk patients (eg, serum creatinine &ge;1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [132",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    or a GFR &lt;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2), particularly if they are diabetic. As a result, these agents should be used instead of ionic high osmolal agents.",
"   </p>",
"   <p>",
"    The iso-osmolal nonionic contrast agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/63/13301?source=see_link\">",
"     iodixanol",
"    </a>",
"    appears to reduce the risk of contrast nephropathy in high-risk patients, such as diabetic patients with renal insufficiency, compared to the low osmolal nonionic agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30949?source=see_link\">",
"     iohexol",
"    </a>",
"    , but not when compared to other low osmolal nonionic agents. However, additional randomized prospective trials comparing iodixanol (or other iso-osmolal agents if developed) to other low osmolal ionic or nonionic agents are required before it can be determined that iso-osmolal contrast agents are uniformly less nephrotoxic than low osmolal agents as a class, especially given the substantially greater expense of the only currently available iso-osmolal nonionic agent, iodixanol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Volume administration, mannitol, and diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous volume administration is beneficial, and the type of solution may be important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/1,2,14,39\">",
"     1,2,14,39",
"    </a>",
"    ]. In comparison, the role of diuretics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    and other renal vasodilators in this setting is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/39-42\">",
"     39-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several small trials have investigated the effect of diuretics. In one trial, 78 patients with stable chronic kidney disease (mean plasma creatinine concentration 2.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [186",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    about to undergo coronary angiography were randomly assigned to one of three regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      One-half isotonic (0.45 percent) saline at a rate of 1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour for 12 hours before and 12 hours after the angiogram",
"     </li>",
"     <li>",
"      One-half isotonic saline plus 25 g of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      infused intravenously during the one hour before the procedure",
"     </li>",
"     <li>",
"      One-half isotonic saline plus 80 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      infused intravenously during the 30 minutes before angiography",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of acute kidney injury (defined as a rise in the serum creatinine of at least 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [44",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    was lowest in the group treated with saline alone.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     Mannitol",
"    </a>",
"    was of no added benefit, while there was a suggestion that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    therapy slightly increased the risk. Why this might occur is not known, since volume depletion due to the diuresis was not seen.",
"   </p>",
"   <p>",
"    A subsequent randomized trial that compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    to placebo among 92 patients with moderate renal insufficiency (mean serum creatinine of 2.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (248",
"    <span class=\"nowrap\">",
"     micromol/L))",
"    </span>",
"    also showed an increased risk associated with diuretics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/42\">",
"     42",
"    </a>",
"    ]. In this trial, acute kidney injury (defined as a 25 percent increase in serum creatinine) occurred more frequently among patients who received mannitol and furosemide compared to placebo (23 of 46 versus 13 of 46, adjusted odds ratio 3.73, 95% CI 1.12-12.38). There was no difference in net fluid balance between the groups.",
"   </p>",
"   <p>",
"    Another study evaluated 50 patients (24 of whom were diabetic) with moderate chronic kidney disease (mean serum creatinine about 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 220",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    who were about to undergo coronary angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/41\">",
"     41",
"    </a>",
"    ]. The patients were randomly assigned to receive saline or one of three renal",
"    <span class=\"nowrap\">",
"     vasodilator/diuretic",
"    </span>",
"    drugs (dopamine [2",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per min],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    [15",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in a one-half isotonic saline solution given at 100",
"    <span class=\"nowrap\">",
"     mL/h]",
"    </span>",
"    or atrial natriuretic peptide). Contrast toxicity was defined as a rise in the creatinine of at least 25 percent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Saline hydration was associated with a 40 percent incidence of renal dysfunction in diabetic and nondiabetic patients.",
"     </li>",
"     <li>",
"      Dopamine,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      , and atrial natriuretic peptide were associated with a much higher incidence of renal dysfunction (75 to 83 percent) in diabetic subjects. On the other hand, there were no cases of contrast toxicity in the nondiabetic patients, suggesting a possible benefit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to not being of benefit,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    use is associated with significant complications, which are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32451?source=see_link\">",
"     \"Complications of mannitol therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Intravenous saline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal intravenous solution (isotonic saline, one-half isotonic saline, or isotonic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    ) for prevention of contrast nephropathy is unclear.",
"   </p>",
"   <p>",
"    Volume expansion with isotonic saline may be superior to one-half isotonic saline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/43\">",
"     43",
"    </a>",
"    ]. This was shown in a prospective randomized trial of 1620 patients treated with either isotonic or one-half isotonic saline at a rate of 1",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour starting the morning of the procedure and continued until 8 AM the next morning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/44\">",
"     44",
"    </a>",
"    ]. Baseline serum creatinine concentration was the same in both groups (0.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [81",
"    <span class=\"nowrap\">",
"     micromol/L]).",
"    </span>",
"    Patients in each group received approximately 450, 350, and 1200 mL of fluid prior to, during, and after the procedure. Contrast nephropathy was defined as an increase in serum creatinine of at least 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (44",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    within 48 hours.",
"   </p>",
"   <p>",
"    The overall incidence of contrast-induced nephropathy was 1.4 percent, and was significantly lower in patients given isotonic saline (0.7 versus 2.0 percent). The benefit with isotonic saline was more pronounced in diabetic patients (0 versus 5.5 percent) and those given more than 250 mL of contrast (0 versus 3 percent). However, there was no difference for those with significant renal dysfunction (serum creatinine &gt;1.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [&gt;141",
"    <span class=\"nowrap\">",
"     micromol/L],",
"    </span>",
"    14 and 17 in the saline and one-half normal saline groups). This is an important limitation, since it is patients with underlying renal dysfunction who are at increased risk for contrast nephropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Intravenous bicarbonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since alkalinization may protect against free radical injury, the possibility that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    may be superior to isotonic saline has been examined in a number of randomized trials and meta-analyses. The results were conflicting as some showed a significantly lower rate of contrast-induced nephropathy with sodium bicarbonate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/45-49\">",
"     45-49",
"    </a>",
"    ], while others found equivalent rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/50-54\">",
"     50-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variations in outcomes with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    may be due to the significant heterogeneity found in these studies. Several meta-analyses have noted differences due to wide variations in study size, treatment effect, and publication bias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. In general, studies that have examined outcomes with isotonic sodium bicarbonate versus isotonic sodium chloride have noted either equivalent or better outcomes with sodium bicarbonate. However, one randomized trial published after these meta-analyses comparing a prolonged infusion of isotonic saline (1",
"    <span class=\"nowrap\">",
"     mL/kg/h",
"    </span>",
"    for at least 12 hours prior to and after the procedure) to briefer infusions of isotonic bicarbonate (3",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    for one hour prior to procedure and 1",
"    <span class=\"nowrap\">",
"     mL/kg/h",
"    </span>",
"    for 6 hours after the procedure, or 3",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    over 20 minutes prior to procedure plus oral sodium bicarbonate 500 mg per 10 kg) observed a lower rate of contrast nephropathy with isotonic saline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/57\">",
"     57",
"    </a>",
"    ]. Thus, the data regarding the use of bicarbonate, and the optimal rate of fluid administration, remain equivocal.",
"   </p>",
"   <p>",
"    If there are no contraindications to volume expansion, we recommend isotonic intravenous fluids prior to and continued for several hours after contrast administration. The optimal type of fluid and timing of administration are not well established. We generally use isotonic bicarbonate rather than isotonic saline.",
"   </p>",
"   <p>",
"    One regimen is to administer a bolus of 3",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of isotonic bicarbonate for one hour prior to the procedure, and continued at a rate of 1",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour for six hours after the procedure. Currently there are no commercially available isotonic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    solutions available. To administer isotonic bicarbonate a solution can be prepared by adding 150 mEq of sodium bicarbonate (three 50 mL ampules of 1",
"    <span class=\"nowrap\">",
"     mEq/mL",
"    </span>",
"    sodium bicarbonate) to 850 mL of sterile water. Although the administration of sodium bicarbonate may be potentially superior to the administration of isotonic saline for the prevention of contrast-induced nephropathy, the 2012 KDIGO guideline Work Group did not make a specific recommendation for the use of bicarbonate preferentially to saline due to concern for potential harm from errors in compounding of the bicarbonate solutions at point of care or in the hospital pharmacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Oral hydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that an increasing number of individuals receive contrast as outpatients, three small trials have evaluated the effectiveness of oral hydration or salt loading in preventing contrast nephropathy. The one trial that included only unrestricted oral fluids (ie, no salt) found a much higher rate of acute kidney injury after contrast than those given isotonic saline. In this trial, 53 patients were randomly assigned to either unrestricted oral fluids or to normal saline at 1",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour for 24 hours beginning 12 hours prior to the scheduled catheterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/57\">",
"     57",
"    </a>",
"    ]. Acute kidney injury was significantly more common with oral hydration (35 versus 4 percent).",
"   </p>",
"   <p>",
"    The two trials that included salt loading as part of the protocol showed no difference in outcome compared to intravenous saline:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 36 patients with serum creatinine &ge;1.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&ge;124",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      who required cardiac catheterization were randomly assigned to an outpatient oral hydration followed by six hours of intravenous one-half isotonic saline for six hours before the procedure or an inpatient regimen of intravenous one-half isotonic saline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/58\">",
"       58",
"      </a>",
"      ]. There was no difference in the maximal change in creatinine between the two groups.",
"     </li>",
"     <li>",
"      The second trial compared salt loading with tablets (1",
"      <span class=\"nowrap\">",
"       g/10",
"      </span>",
"      kg per day in two or three doses for two days before contrast) and intravenous saline (15",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      for six hours prior to contrast) in 153 patients with CKD (mean serum creatinine 2.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [200",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/59\">",
"       59",
"      </a>",
"      ]. There was no difference in the proportion of patients with an increase in serum creatinine of &ge;0.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (44",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the safety and efficacy of oral hydration or salt loading for the prevention of contrast nephropathy remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H588321811\">",
"    <span class=\"h3\">",
"     RenalGuard system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RenalGuard system is a fluid management device that guides fluid replacement and may minimize the risk of volume depletion in the setting of a forced diuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/60\">",
"     60",
"    </a>",
"    ]. Two studies have evaluated the benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    -induced diuresis and matched saline infusion guided by the RenalGuard system among patients undergoing angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. In both trials forced diuresis and matched volume repletion decreased the incidence of contrast nephropathy.",
"   </p>",
"   <p>",
"    However, high volume forced diuresis raises some concerns even in the setting of carefully matched volume replacement. As an example, volume overload may ensue if isotonic saline is used to replace urine, which, following the administration of loop diuretics, generally has the tonicity of approximately half normal saline. In one of the trials cited above, such an increase in intravascular volume may have been sufficient to increase the estimated GFR in patients undergoing forced diuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, arrhythmia-inducing electrolyte abnormalities such as hypokalemia may result from forced diuresis in a vulnerable population. Additional studies that address these issues are necessary before forced diuresis and matched volume replacement is used clinically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following conclusions can be drawn from the current literature:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prophylactic diuretics or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      do not appear to be beneficial for the prevention of contrast-induced acute kidney injury.",
"     </li>",
"     <li>",
"      Intravenous volume administration is superior to oral hydration. Oral hydration with water alone should not be used.",
"     </li>",
"     <li>",
"      Intravenous volume administration with isotonic saline solution is superior to one-half normal saline, and isotonic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      may be superior to isotonic saline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients at risk for contrast nephropathy, we recommend isotonic intravenous volume administration for prophylaxis. The selection of fluid and rate of administration must take into consideration the patient's ability to tolerate the fluid load (eg, rapid volume expansion may be harmful to individuals with reduced left ventricular function), the ability to tolerate alkalinization, and the degree of underlying risk for nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the available clinical trial data concerning relative efficacy, we suggest the use of isotonic bicarbonate rather than isotonic saline.",
"   </p>",
"   <p>",
"    We do not recommend prophylactic use of diuretics or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    . However, diuretics may be required to treat volume overload. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Acetylcysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     Acetylcysteine",
"    </a>",
"    is a thiol compound with antioxidant and vasodilatory properties. Although not well understood, a possible mechanism of benefit in contrast-induced nephropathy involves minimizing both vasoconstriction and oxygen free radical generation after radiocontrast agent administration.",
"   </p>",
"   <p>",
"    There is great heterogeneity and conflicting results in the available clinical trials and meta-analyses examining the effectiveness of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    in the prevention of contrast nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Given the conflicting data regarding benefit, we cannot make a strong recommendation regarding the use of acetylcysteine. Since the agent is potentially beneficial, well tolerated and relatively inexpensive, we agree with the 2012 KDIGO guidelines that suggest administration of acetylcysteine to patients at high risk. However some clinicians may elect not to give this unproven therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This must be accompanied by intravenous isotonic fluid administration and use of a low or iso-osmolal contrast agent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H10\">",
"     'Volume administration, mannitol, and diuretics'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Type of contrast agent'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Numerous prospective trials examining the prophylactic effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    in contrast nephropathy have been performed, with substantial inconsistency in reported results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/65-78\">",
"     65-78",
"    </a>",
"    ]. A variety of factors probably contribute to these inconsistencies. These include the definition of contrast-induced acute kidney injury, baseline risk for acute kidney injury (eg, severity of renal dysfunction and proportion with diabetes), acetylcysteine dose and route of administration (eg, oral or intravenous), intravenous volume administration protocols, amount and type of contrast given, and type of procedure performed (eg, contrast CT, cardiac catheterization, or peripheral angiography) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/14,79,80\">",
"     14,79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     Acetylcysteine",
"    </a>",
"    for the prevention of Contrast-induced Nephropathy (ACT) trial, 2308 patients undergoing angiography received either acetylcysteine (1200 mg orally twice daily) or placebo on the day before and after angiogram [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/81\">",
"     81",
"    </a>",
"    ]. Patients had at least one of the following risk factors: age greater than 70 years, chronic kidney disease (CKD), diabetes mellitus, heart failure or LVEF less than 45 percent, or shock. There was no difference in the development of AKI defined as a 25 percent or greater increase above baseline in serum creatinine within 48 to 96 hours after angiography (12.7 percent in both groups). Secondary endpoints including death, the need for dialysis, or either at 30 days were also not different between groups.",
"   </p>",
"   <p>",
"    There was no difference between groups in several subgroups that were defined after the study ended, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with CKD defined as baseline serum creatinine greater or equal to 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (n = 367) (6.4 versus 5.6 percent in placebo).",
"     </li>",
"     <li>",
"      Patients with stage 3 CKD defined as an estimated GFR between 30 and 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2 (n = 823) (7.1 versus 6.8 percent in placebo).",
"     </li>",
"     <li>",
"      Patients with stage 4 CKD defined as an estimated GFR &lt;30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2 (n = 104) (10.7 versus 6.3 in placebo).",
"     </li>",
"     <li>",
"      Patients with diabetes mellitus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However this trial has several shortcomings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although 823 patients had CKD as defined by estimated GFR, only 367 patients had a serum creatinine &gt;1.5",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      Thus the majority of patients defined as having CKD had only a mild reduction in estimated GFR (ie, 45 to 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2). It is not clear whether such patients are at increased risk for contrast nephropathy. A benefit of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      would not be expected to be seen among patients who are not at risk.",
"     </li>",
"     <li>",
"      The incidence of AKI in patients with CKD defined by a serum creatinine &gt;1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (who are more likely to have estimated GFR&lt;45",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2) was low, suggesting that the trial was underpowered to exclude a benefit of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      for patients at highest risk for AKI.",
"     </li>",
"     <li>",
"      The baseline creatinine was obtained at any time within three months of angiography, thus may not have provided an accurate reference serum creatinine for assessing the post-procedural change.",
"     </li>",
"     <li>",
"      Over 20 percent of patients received high osmolal contrast media, which confers a greater risk for AKI compared to low- or iso-osmolal media. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Type of contrast agent'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The overall prophylactic efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    has been assessed in multiple meta-analyses. Several meta-analyses have suggested a substantial benefit, reporting risk reductions of up to 50 percent with acetylcysteine, whereas others have reported less substantial, and occasionally nonsignificant risk reductions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/52,81-86\">",
"     52,81-86",
"    </a>",
"    ]. In general, benefits have been reported in meta-analyses that did not consider the great heterogeneity between the trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, benefits have also been noted in some, but not all, meta-analyses that did recognize this heterogeneity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/85,86,88,89\">",
"     85,86,88,89",
"    </a>",
"    ]. In one meta-analysis that included 41 studies but was published before the ACT trial, N-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    significantly lowered the risk for contrast-nephropathy compared with saline alone (relative risk, 0.62, 95% CI 0.44 to 0.88) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential concern related to the interpretation of clinical trials is that administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    in typical doses (600 mg twice daily for two days) transiently reduces the serum creatinine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/65,66,72,90\">",
"     65,66,72,90",
"    </a>",
"    ]. However, the magnitude of the fall in serum creatinine is very small (eg, from 0.85 to 0.82",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [75 to 72",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    in a study in normal patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/90\">",
"     90",
"    </a>",
"    ]) in comparison to the &ge;25 to 50 percent increase used to define contrast nephropathy in clinical trials. Higher doses of acetylcysteine (1200 mg twice daily for two days) also had virtually no effect on serum creatinine among patients with estimated GFR &lt; 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h4\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of different dosing regimens for oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    have been studied. The most commonly studied dose is 600 mg orally twice daily. A subgroup analysis of 12 studies that evaluated this regimen reported a summary risk ratio of 0.73 (95% CI 0.46-1.2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/85\">",
"     85",
"    </a>",
"    ]. However, studies comparing 600 mg and 1200 mg twice daily suggested slightly better outcomes with the higher dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. A beneficial effect of high dose acetylcysteine compared to control has also been shown. The best data are from a meta-analysis of 1677 subjects that compared the effect of high dose acetylcysteine (defined as a daily dose greater than 600 mg or a single pre-procedural dose greater than 600 mg) to control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/92\">",
"     92",
"    </a>",
"    ]. The majority (greater than 70 percent) of subjects had chronic kidney disease at baseline. The risk of contrast nephropathy was lower among subjects who received high dose acetylcysteine compared to those who did not (odds ratio 0.46, 95% CI 0.33-0.64).",
"   </p>",
"   <p>",
"    Although data regarding the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    are conflicting, if it is to be used, the preferred dose is 1200 mg administered orally twice daily on the day before and the day of the procedure to patients at risk for contrast nephropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h4\">",
"     Intravenous therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients requiring emergent coronary angiography or procedures, in whom preventive therapy with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    cannot be given the day before, have been treated with intravenous acetylcysteine. The benefit of this approach remains uncertain, and comparison of the various trials is difficult because of differences in patient populations and dosing, or lack of an adequate control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/74-76\">",
"     74-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A placebo-controlled study of 487 patients with a mean baseline serum creatinine of 1.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (140",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    all of whom received isotonic saline (200 mL before the procedure, 1.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour for six hours after), found no benefit to therapy with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    (500 mg immediately before the procedure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, two trials reported a substantial reduction in the rate of a &ge;25 percent increase in serum creatinine with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    compared to pretreatment with intravenous saline or no pretreatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of 80 patients with a mean baseline creatinine of 1.8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (160",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      (150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      prior to the procedure followed by 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      over four hours after to the procedure) was compared with isotonic saline (1",
"      <span class=\"nowrap\">",
"       ml/kg",
"      </span>",
"      per hour for 12 hours pre- and post-contrast) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/75\">",
"       75",
"      </a>",
"      ]. Fewer patients in the acetylcysteine group (5 versus 20 percent in the control group) developed acute kidney injury. However, at the high doses used, 7 percent developed anaphylactoid reactions.",
"     </li>",
"     <li>",
"      Different intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      doses, compared to no acetylcysteine, were studied in 354 patients with acute myocardial infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/76\">",
"       76",
"      </a>",
"      ]. Fewer patients assigned to high dose (1200 mg) or low dose (600 mg) intravenous acetylcysteine (followed by the same oral dose twice daily for two days) developed acute kidney injury (8 and 15 percent, versus 33 percent of those in the placebo group).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the lower rate of acute kidney injury in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    group in this trial cannot be reasonably ascribed to treatment for the following reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/76\">",
"     76",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients had normal kidney function (baseline serum creatinine 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [88",
"      <span class=\"nowrap\">",
"       micromol/L]),",
"      </span>",
"      in whom the risk of contrast nephropathy is expected to be negligible. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link&amp;anchor=H6#H6\">",
"       \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A large proportion of patients, particularly in the control group, had severe complications that could explain the acute kidney injury (eg, intraaortic balloon pump, respiratory failure requiring mechanical ventilation).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the lack of convincing evidence of benefit, and the potential risk of anaphylactoid reactions, we do not advocate the routine use of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    for the prevention of contrast nephropathy.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/10/32937?source=see_link&amp;anchor=H5#H5\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\", section on 'Effectiveness of acetylcysteine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prophylactic hemofiltration and hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential that removal of the inciting compound from the circulation might prevent contrast-induced acute kidney injury led to the examination of the role of prophylactic hemofiltration and hemodialysis in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hemofiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of hemofiltration in high-risk patients undergoing procedures requiring contrast was compared with intravenous saline in two trials by the same group in Italy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/93,94\">",
"     93,94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first trial, 114 consecutive patients with a mean serum creatinine of 3.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [265",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      who required a coronary intervention were randomly assigned to isotonic saline infusion (1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour) or to hemofiltration (1000",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      fluid replacement rate) that was begun four to eight hours",
"      <strong>",
"       prior",
"      </strong>",
"      to the procedure and resumed after the procedure for 18 to 24 hours. Approximately 250 mL of a nonionic, low-osmolality contrast agent were used in each group.",
"      <br/>",
"      <br/>",
"      Compared with isotonic saline, patients in the hemofiltration group had significantly lower rates of a serum creatinine elevation &gt;25 percent above baseline (5 versus 50 percent) and a requirement for dialysis (3 versus 25 percent). There were also significant reductions in in-house (2 versus 14 percent) and one-year mortality (10 versus 30 percent).",
"     </li>",
"     <li>",
"      A second trial by the same group found that hemofiltration after contrast administration produced intermediate outcomes between hemofiltration before and after contrast and isotonic saline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reported benefits with hemofiltration in these trials in terms of increased serum creatinine and requirement for renal replacement therapy may be explained by other factors, given the following study design flaws and unusual clinical features of these trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Creatinine removal by the hemofiltration procedure may explain the decreased frequency of elevation in the serum creatinine.",
"     </li>",
"     <li>",
"      Hemofiltration or hemodialysis was started for oligoanuria persisting for 48 hours or longer, or earlier for overt heart failure. However, oligoanuria alone as an indication for replacement therapy is not usual clinical practice, particularly with contrast nephropathy since spontaneous resolution within a few days is common. This may have artificially increased the proportion dialyzed in the saline group.",
"     </li>",
"     <li>",
"      Patients in the hemofiltration group were cared for in an intensive care unit; their greater intensity of care relative to the control group (of evidently sick patients given the high in-hospital and one year mortality of the cohort) may explain why hemofiltration was associated with improved short- and long-term survival.",
"     </li>",
"     <li>",
"      The hemofiltration group received bicarbonate-containing replacement fluid which may have conferred a protective effect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2012 meta-analysis that included eight studies of hemodialysis and three studies of",
"    <span class=\"nowrap\">",
"     hemofiltration/hemodiafiltration",
"    </span>",
"    showed no benefit of renal replacement therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/95\">",
"     95",
"    </a>",
"    ]. A subset analysis limited to studies of",
"    <span class=\"nowrap\">",
"     hemofiltration/hemodiafiltration",
"    </span>",
"    also showed no benefit.",
"   </p>",
"   <p>",
"    Hemofiltration is expensive, logistically cumbersome and associated with significant risks, its effectiveness compared to other less expensive strategies is not well established, and the reported benefits are implausible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/96\">",
"     96",
"    </a>",
"    ]. We do not currently recommend prophylactic hemofiltration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another proposed method of protecting high-risk patients from contrast-induced acute kidney injury is removal of the contrast agent using prophylactic dialysis. The efficacy of this approach was assessed in a 2006 meta-analysis of eight studies (six randomized) which included 412 patients (with a mean baseline serum creatinine ranging from 2.5 to 4.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [221 to 354",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    who were treated with hemodialysis (six studies) or continuous dialysis modalities (two studies) compared to usual medical therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/97\">",
"     97",
"    </a>",
"    ]. There was no benefit and a suggestion of possible harm with hemodialysis.",
"   </p>",
"   <p>",
"    A subsequent trial suggested possible benefit from prophylactic hemodialysis in patients with substantially more severe renal disease than in the trials included in the meta-analysis. In this trial, 82 patients with a stable baseline serum creatinine of 4.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (433",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and a measured creatinine clearance of less than 15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 (mean 13",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) were randomly assigned to hemodialysis (as soon as feasible after angiography but within 12 hours) versus no hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared to the control group, reported benefits with prophylactic hemodialysis included significantly higher creatinine clearance levels on day four (12.8 versus 10.4",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    decreased need for temporary hemodialysis (2 versus 35 percent), shorter length of hospital stay (6 versus 13 days), and a lower rate of requiring long-term hemodialysis after discharge (0 versus 13 percent). Of these, the last outcome is the only benefit that may be due to the removal of contrast rather than performance of the initial dialysis procedure alone.",
"   </p>",
"   <p>",
"    The lower risk of requiring chronic dialysis in the prophylactic hemodialysis group may have been due to the prevention of the loss of only a few",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    of glomerular filtration via the removal of contrast. Among patients with such advanced renal disease at baseline, the preservation of even a small amount of renal function can delay the need for initiating chronic hemodialysis.",
"   </p>",
"   <p>",
"    Support for this hypothesis is also provided by the observation that, among those not requiring chronic hemodialysis, a significantly larger percentage of the control group had a significant increase in serum creatinine (defined as larger than 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [88",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    between baseline and discharge (37 versus 5 percent). However, an alternative explanation is that the higher rate of requiring chronic dialysis in the control group may simply reflect the higher rate of requiring temporary dialysis, with a subsequent reluctance to discontinue dialysis in patients with such severe underlying disease.",
"   </p>",
"   <p>",
"    In the 2012 meta-analysis cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/95\">",
"     95",
"    </a>",
"    ], a subset analysis limited to studies of hemodialysis suggested that hemodialysis was associated with an increased risk of contrast nephropathy. There was no benefit of renal replacement therapy among patients with estimated GFR &lt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do NOT recommend routine hemofiltration or hemodialysis for the prevention of contrast nephropathy in patients with stage 3 and 4 CKD. More data are needed in stage 5 CKD, as in the last trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/98\">",
"     98",
"    </a>",
"    ], before any firm recommendation can be made. We would consider the prophylactic use of hemodialysis in patients with stage 5 CKD, provided that a functioning access is already available. We would not place a temporary access for prophylactic hemodialysis in these patients.",
"   </p>",
"   <p>",
"    There is no indication for prophylactic dialysis for the prevention of volume overload in dialysis-dependent patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Contrast-enhanced MRI as an alternative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paramagnetic contrast agents, usually administered intravenously, have assumed a role in MR imaging similar to that played by iodinated contrast agents in CT imaging and angiography. Most MR contrast agents in clinical use are chelates of gadolinium, with the urine being the major route of excretion.",
"   </p>",
"   <p>",
"    However, there are two major concerns with gadolinium-based chelates:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with moderate and particularly severe kidney disease, the possible development of the severe syndrome of nephrogenic systemic fibrosis. This disorder is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"       \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The possible development of nephrotoxicity, similar to that seen with iodinated contrast agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple studies have found that MR contrast agents when used in small doses for MR examinations have little or no nephrotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/23,100-102\">",
"     23,100-102",
"    </a>",
"    ]. This has led some to promote the use of gadolinium-based chelates as an alternative to iodinated radiographic contrast agents for digital subtraction angiography or interventional procedures, particularly in patients with renal insufficiency or iodinated contrast allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/103-105\">",
"     103-105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there are emerging data from animal experiments, case reports, and small series that gadolinium-based contrast media can be associated with nephrotoxicity when given at high doses (greater than 0.3",
"    <span class=\"nowrap\">",
"     mmol/kg)",
"    </span>",
"    for use as a contrast agent in standard (non-MR) digital subtraction angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/106-110\">",
"     106-110",
"    </a>",
"    ]. Some have claimed that the nephrotoxic profile of gadolinium is similar to that of diluted iodinated contrast media [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest study, renal outcomes were reported for 21 patients with moderate to severe chronic kidney disease (average serum creatinine concentration of 3.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [283",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    undergoing digital subtraction angiography who were randomly assigned to iodinated nonionic contrast media (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30949?source=see_link\">",
"     iohexol",
"    </a>",
"    ) or gadolinium (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39141?source=see_link\">",
"     gadobutrol",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/106\">",
"     106",
"    </a>",
"    ]. The incidence of nephropathy (defined as a fall of &ge;50 percent in baseline glomerular filtration rate [GFR]) was 50 and 45 percent in the two groups, respectively; the mean fall in estimated GFR was 9 to 11",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in the two groups.",
"   </p>",
"   <p>",
"    However, this study has multiple limitations. These include the small number of patients evaluated, use of a high dose of gadolinium (0.34 to 0.90",
"    <span class=\"nowrap\">",
"     mmol/kg),",
"    </span>",
"    absence of clinically significant rises in mean serum creatinine concentration in either group, use of small volumes of iodinated contrast media to measure GFR, and a greater number of diabetics in the gadolinium group.",
"   </p>",
"   <p>",
"    More importantly, among patients with moderate to severe kidney disease (dialysis-dependent or estimated GFR less than 30",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    the administration of gadolinium has been associated with the potentially severe syndrome of nephrogenic systemic fibrosis. In such patients, gadolinium should be avoided if possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon this limited literature, it is difficult to be certain that gadolinium is completely free of important nephrotoxicity in high-risk azotemic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/111\">",
"     111",
"    </a>",
"    ]. Furthermore, as noted above, gadolinium-based imaging should not be performed, if at all possible, in patients with an estimated glomerular filtration rate less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    because of the risk of nephrogenic systemic fibrosis. In such patients, we prefer the risk of radiocontrast nephropathy with iodinated contrast media, using all of the preventive measures that are available, to the risk of the much more severe complication of NSF.",
"   </p>",
"   <p>",
"    A separate issue, which has not yet been studied, is the safety of gadolinium-based in patients with an estimated GFR of 30 to 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    who also have an increased risk of iodinated contrast nephropathy. No data are available and opinion among experts differs as to whether or not one would expose such patients to gadolinium if alternative imaging procedures were available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Inhibition of renal vasoconstriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute reduction in GFR induced by contrast agents may be minimized in some patients by agents that prevent vasoconstriction. Such agents include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    (presumably via inhibition of the effect of adenosine),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    , prostaglandin E or I2, low-dose dopamine, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/29/35284?source=see_link\">",
"     fenoldopam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/112-121\">",
"     112-121",
"    </a>",
"    ]. Some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/119,121\">",
"     119,121",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/122,123\">",
"     122,123",
"    </a>",
"    ] vasodilator agents may reduce the risk. The following studies have examined the effects of different agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis that included 13 studies and 1222 patients demonstrated a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      -associated reduction in risk for contrast nephropathy but not for dialysis or in-house mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/124\">",
"       124",
"      </a>",
"      ]. However there was significant heterogeneity between studies, which appears to have been due to differences in baseline creatinine and in the quality of studies. On further analysis, a protective effect of theophylline was not observed among high-risk patients when all studies were analyzed, nor in any group of patients when only higher quality studies were analyzed. These results suggest that theophylline has little or no effect on contrast nephropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/125\">",
"       125",
"      </a>",
"      ]. In addition, concurrent administration of the antiplatelet agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      may increase contrast toxicity by enhancing the action of adenosine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/112\">",
"       112",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The prostacyclin analog,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"       Iloprost",
"      </a>",
"      , was tested in a randomized placebo-controlled trial of 208 patients undergoing coronary angiography who had a serum creatinine concentration greater than 1.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [123.76",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/121\">",
"       121",
"      </a>",
"      ]. Intravenous Iloprost (1",
"      <span class=\"nowrap\">",
"       ng/kg",
"      </span>",
"      per min) or placebo was given 30 to 90 minutes before and 240 minutes after the procedure. Contrast nephropathy (defined as an increase in serum creatinine &gt;0.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [44.2",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      or &gt;25 percent, measured 2 to 5 days after the procedure) occurred less frequently among patients who received iloprost compared to placebo (8 versus 22 percent respectively). Severe hypotension required withdrawal of Iloprost in three patients. Although Iloprost may be effective in the prevention of contrast nephropathy, confirmation of these results in larger definitive trials is necessary before its use can be recommended [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/126\">",
"       126",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective randomized trial (CONTRAST) assessed the effectiveness of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/29/35284?source=see_link\">",
"       fenoldopam",
"      </a>",
"      in 315 patients (one-half diabetic) undergoing a cardiovascular procedure who had chronic kidney disease with an estimated creatinine clearance below 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      (mean 29",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      with a mean serum creatinine of 1.8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [159",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/122\">",
"       122",
"      </a>",
"      ]. All patients also received one-half normal saline as mentioned above, and contrast nephropathy was defined as an increase in serum creatinine of &ge;25 percent above baseline in the first four days. There was no reduction in the incidence of contrast nephropathy in the fenoldopam group (34 versus 30 percent with placebo). It has been proposed that direct intrarenal administration may be more beneficial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/127\">",
"       127",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A nonselective endothelin receptor antagonist was tested in a multicenter, double-blind randomized trial of high-risk patients undergoing coronary angiography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/123\">",
"       123",
"      </a>",
"      ]. Compared with those assigned to placebo, a significantly higher percentage of patients who received active therapy sustained contrast nephropathy (56 versus 29 percent); this observation raises the possibility that endothelin may actually provide an intrinsic protective effect rather than contributing to the development of acute kidney injury. Alternatively, selective endothelin receptor antagonists may be required to demonstrate prophylactic value in this setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other interventions have been tried, including remote ischemic preconditioning (RIPC), atrial natriuretic peptide, statins and ascorbic acid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H607423301\">",
"    <span class=\"h3\">",
"     Remote ischemic preconditioning (RIPC)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Remote ischemic preconditioning (RIPC) is a method by which the deliberate induction of transient nonlethal ischemia of an organ protects against subsequent ischemic injury of another organ. Some, but not all, studies have suggested that RIPC prior to cardiac surgery protects against AKI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=see_link&amp;anchor=H24236462#H24236462\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\", section on 'Remote ischemic preconditioning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One randomized double-blind trial has suggested that RIPC prior to the administration of contrast agents may prevent contrast-induced nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/128\">",
"     128",
"    </a>",
"    ]. In this study, 100 patients with serum creatinine &gt;1.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (124",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or estimated GFR &lt;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2 were subjected to RIPC or to a sham procedure prior to elective coronary angiography. RIPC was induced by intermittent arm ischemia generated by 4 cycles of 5 minute inflation of a blood pressure cuff to 50 mm Hg above individual systolic pressure within 45 minutes before angiography. The sham procedure consisted of inflation of a BP cuff to individual diastolic pressure followed by deflation to 10 mmHg. All patients received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    and a continuous saline infusion. The incidence of contrast nephropathy (defined as an increase in serum creatinine to &ge;25 percent or &ge;0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (44",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    above baseline within 48 hours) was decreased among patients who underwent RIPC compared with the sham procedure (6 versus 20, respectively, odds ratio 0.21, 95% CI 0.07 &ndash; 0.57). At 6 weeks of follow-up, a composite cardiovascular endpoint including death, rehospitalization or hemodialysis occurred less frequently in the RIPC group compared with sham (8 versus 19, respectively). These results require confirmation in a larger randomized trial and further studies to determine the underlying mechanism of protection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Atrial natriuretic peptide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial natriuretic peptide (anaritide) has been considered for prophylaxis in high-risk patients, since its administration has been beneficial in animal models of contrast nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/130\">",
"     130",
"    </a>",
"    ]. However,",
"    <strong>",
"     no benefit",
"    </strong>",
"    was observed in a multicenter, prospective, double-blind, placebo-controlled randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/131\">",
"     131",
"    </a>",
"    ]. In this study, 247 patients (with a serum creatinine greater than 1.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [159",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    or between 1.5 and 1.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [133 to 159",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    undergoing radiocontrast administration were randomly assigned to placebo or one of three intravenous doses of anaritide given 30 minutes before and continued for 30 minutes after the procedure. Compared to placebo, active therapy at any dose failed to reduce the incidence of nephropathy in all patient groups, including those with diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statins may improve endothelial function, reduce arterial stiffness (via improved endothelin-mediated vasodilatation), and reduce inflammation and oxidative stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/132,133\">",
"     132,133",
"    </a>",
"    ]. The possibility that statins may reduce the incidence of contrast-induced acute kidney injury has been suggested by several observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/134-136\">",
"     134-136",
"    </a>",
"    ] and in small randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/137,138\">",
"     137,138",
"    </a>",
"    ]. However one randomized trial that included 304 patients with estimated creatinine clearance &lt;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    showed no benefit of atorvastin compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/139\">",
"     139",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Statins merit further study for the prevention of contrast-induced nephropathy. At this time, there are conflicting and insufficient data to recommend initiation of statin therapy for the prevention of contrast-induced nephropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Ascorbic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascorbic acid can ameliorate renal damage in experimental models of ischemic or toxic injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/140,141\">",
"     140,141",
"    </a>",
"    ] and an initial randomized trial in humans suggested protection against contrast-mediated nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/142\">",
"     142",
"    </a>",
"    ]. However, a second large well-designed trial found that ascorbic acid did not provide added benefit to a prophylactic regimen of isotonic saline plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    among patients at high risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Intravenous saline'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In summary, data are insufficient to support the use of ascorbic acid for prevention of contrast nephropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Trimetazidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trimetazidine, a cellular anti-ischemic agent, provided added protection to isotonic saline from contrast-mediated nephropathy in an initial small randomized prospective study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/42/35498/abstract/143\">",
"     143",
"    </a>",
"    ]. Further study in a larger number of patients is required to better characterize the effectiveness of this agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal therapy to prevent contrast-induced acute kidney injury remains uncertain. Patients with near-normal renal function are at little risk and few precautions are necessary other than avoidance of volume depletion.",
"   </p>",
"   <p>",
"    We recommend the following preventive measures for patients at increased risk of contrast nephropathy, which is defined as a serum creatinine &ge;1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (132",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    or an estimated glomerular filtration rate &lt;60",
"    <span class=\"nowrap\">",
"     ml/1.73",
"    </span>",
"    m2, particularly in those with diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use, if possible, ultrasonography, MRI",
"      <strong>",
"       without",
"      </strong>",
"      &nbsp;gadolinium contrast, or CT scanning",
"      <strong>",
"       without",
"      </strong>",
"      radiocontrast agents. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend NOT using high osmolal agents (1400 to 1800",
"      <span class=\"nowrap\">",
"       mosmol/kg)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Type of contrast agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/63/13301?source=see_link\">",
"       iodixanol",
"      </a>",
"      or nonionic low osmolal agents such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/45/36565?source=see_link\">",
"       iopamidol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34709?source=see_link\">",
"       ioversol",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30949?source=see_link\">",
"       iohexol",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Nonionic iso-osmolal agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use lower doses of contrast and avoid repetitive, closely spaced studies (eg, &lt;48 hours apart). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Avoid volume depletion and nonsteroidal antiinflammatory drugs. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If there are no contraindications to volume expansion, we recommend isotonic intravenous fluids prior to and continued for several hours after contrast administration (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The optimal type of fluid and timing of administration are not well established. We suggest isotonic bicarbonate rather than isotonic saline (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Intravenous bicarbonate'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      A suggested regimen is a bolus of 3",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of isotonic bicarbonate for one hour prior to the procedure, and continued at a rate of 1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour for six hours after the procedure. This solution can be prepared by adding 150 mEq of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      (three 50 mL ampules of 1",
"      <span class=\"nowrap\">",
"       mEq/mL",
"      </span>",
"      sodium bicarbonate) to 850 mL of sterile water.",
"      <br/>",
"      <br/>",
"      If isotonic saline is chosen, a suggested regimen is:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Isotonic saline at a rate of 1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour, begun at least two and preferably 6 to 12 hours prior to the procedure, and continuing for 6 to 12 hours after contrast administration. The duration of administration of fluid should be directly proportional to the degree of renal impairment (eg, should be longer for individuals with more severe renal impairment).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite conflicting data, we suggest that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      be administered the day before and the day of the procedure, based upon its potential for benefit and low toxicity and cost (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If acetylcysteine is administered, we suggest giving 1200 mg orally twice daily rather than 600 mg twice daily the day before and the day of the procedure (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Acetylcysteine'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      Based upon the lack of convincing evidence of benefit and the potential risk of anaphylactoid reactions, we suggest not using intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"       acetylcysteine",
"      </a>",
"      for the prevention of contrast nephropathy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Intravenous therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend NOT using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      or other diuretics prophylactically (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Volume administration, mannitol, and diuretics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with stage 3 and 4 CKD, we recommend NOT performing prophylactic hemofiltration or hemodialysis after contrast exposure (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Prophylactic hemofiltration and hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with stage 5 CKD, we suggest prophylactic hemodialysis after contrast exposure if there is already a functioning hemodialysis access (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We would not place a temporary access for prophylactic hemodialysis in these patients. Some clinicians would not perform prophylactic hemodialysis in any of these patients, pending further data. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/1\">",
"      Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and atheroembolism--a critical review. Am J Kidney Dis 1994; 24:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/2\">",
"      Barrett BJ. Contrast nephrotoxicity. J Am Soc Nephrol 1994; 5:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/3\">",
"      Asif A, Epstein M. Prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 2004; 44:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/4\">",
"      Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995; 47:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/5\">",
"      Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989; 86:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/6\">",
"      Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990; 89:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/7\">",
"      McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/8\">",
"      Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000; 36:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/9\">",
"      Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105:2259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/10\">",
"      Lautin, EM, Freeman, NJ, Schoenfeld, AH, et al. Radiocontrast-associated renal dysfunction: a comparison of lower-osmolality and conventional high-osmolality contrast media. AJR Am J Roentgenol 1991; 157:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/11\">",
"      Schwab SJ, Hlatky MA, Pieper KS, et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med 1989; 320:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/12\">",
"      Rudnick M, Feldman H. Contrast-induced nephropathy: what are the true clinical consequences? Clin J Am Soc Nephrol 2008; 3:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/13\">",
"      Moore RD, Steinberg EP, Powe NR, et al. Nephrotoxicity of high-osmolality versus low-osmolality contrast media: randomized clinical trial. Radiology 1992; 182:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/14\">",
"      Pannu N, Wiebe N, Tonelli M, Alberta Kidney Disease Network. Prophylaxis strategies for contrast-induced nephropathy. JAMA 2006; 295:2765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/15\">",
"      Marenzi G, Assanelli E, Campodonico J, et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med 2009; 150:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/16\">",
"      Kian K, Wyatt C, Schon D, et al. Safety of low-dose radiocontrast for interventional AV fistula salvage in stage 4 chronic kidney disease patients. Kidney Int 2006; 69:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/17\">",
"      Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005; 95:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/18\">",
"      Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int 2005; 68:2256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/19\">",
"      McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 2006; 48:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/20\">",
"      Barrett BJ, Parfrey PS, Vavasour HM, et al. Contrast nephropathy in patients with impaired renal function: high versus low osmolar media. Kidney Int 1992; 41:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/21\">",
"      Harris KG, Smith TP, Cragg AH, Lemke JH. Nephrotoxicity from contrast material in renal insufficiency: ionic versus nonionic agents. Radiology 1991; 179:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/22\">",
"      Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993; 188:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/23\">",
"      Townsend RR, Cohen DL, Katholi R, et al. Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency. Am J Kidney Dis 2000; 36:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/24\">",
"      Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/25\">",
"      Rudnick MR, Davidson C, Laskey W, et al. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial. Am Heart J 2008; 156:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/26\">",
"      Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 2007; 115:3189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/27\">",
"      Laskey W, Aspelin P, Davidson C, et al. Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures. Am Heart J 2009; 158:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/28\">",
"      Reed M, Meier P, Tamhane UU, et al. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials. JACC Cardiovasc Interv 2009; 2:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/29\">",
"      Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/30\">",
"      Kidney Int Suppl 2012; 2:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/31\">",
"      Shaw DR, Kessel DO. The current status of the use of carbon dioxide in diagnostic and interventional angiographic procedures. Cardiovasc Intervent Radiol 2006; 29:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/32\">",
"      Liss P, Ekl&ouml;f H, Hellberg O, et al. Renal effects of CO2 and iodinated contrast media in patients undergoing renovascular intervention: a prospective, randomized study. J Vasc Interv Radiol 2005; 16:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/33\">",
"      Schreier DZ, Weaver FA, Frankhouse J, et al. A prospective study of carbon dioxide-digital subtraction vs standard contrast arteriography in the evaluation of the renal arteries. Arch Surg 1996; 131:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/34\">",
"      Spinosa DJ, Matsumoto AH, Angle JF, et al. Safety of CO(2)- and gadodiamide-enhanced angiography for the evaluation and percutaneous treatment of renal artery stenosis in patients with chronic renal insufficiency. AJR Am J Roentgenol 2001; 176:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/35\">",
"      McLennan G, Moresco KP, Patel NH, et al. Accuracy of CO(2) angiography in vessel diameter assessment: a comparative study of CO(2) versus iodinated contrast material in a porcine model. J Vasc Interv Radiol 2001; 12:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/36\">",
"      Kessel DO, Robertson I, Patel J 5th, et al. Carbon-dioxide-guided vascular interventions: technique and pitfalls. Cardiovasc Intervent Radiol 2002; 25:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/37\">",
"      Coffey R, Quisling RG, Mickle JP, et al. The cerebrovascular effects of intraarterial CO2 in quantities required for diagnostic imaging. Radiology 1984; 151:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/38\">",
"      Wilson AJ, Boxer MM. Neurotoxicity of angiographic carbon dioxide in the cerebral vasculature. Invest Radiol 2002; 37:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/39\">",
"      Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/40\">",
"      Anto HR, Chou SY, Porush JG, Shapiro WB. Infusion intravenous pyelography and renal function. Effect of hypertonic mannitol in patients with chronic renal insufficiency. Arch Intern Med 1981; 141:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/41\">",
"      Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994; 45:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/42\">",
"      Majumdar SR, Kjellstrand CM, Tymchak WJ, et al. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial. Am J Kidney Dis 2009; 54:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/43\">",
"      Weisbord SD, Palevsky PM. Prevention of contrast-induced nephropathy with volume expansion. Clin J Am Soc Nephrol 2008; 3:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/44\">",
"      Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/45\">",
"      Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/46\">",
"      Briguori C, Airoldi F, D'Andrea D, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 2007; 115:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/47\">",
"      Recio-Mayoral A, Chaparro M, Prado B, et al. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol 2007; 49:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/48\">",
"      Ozcan EE, Guneri S, Akdeniz B, et al. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J 2007; 154:539.",
"     </a>",
"    </li>",
"    <li>",
"     Hoste EA, De Waele JJ, Gevaert SA, et al. Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis. Nephrol Dial Transplant 2009 [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/50\">",
"      Brar SS, Shen AY, Jorgensen MB, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 2008; 300:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/51\">",
"      Maioli M, Toso A, Leoncini M, et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol 2008; 52:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/52\">",
"      Alonso A, Lau J, Jaber BL, et al. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 2004; 43:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/53\">",
"      Vasheghani-Farahani A, Sadigh G, Kassaian SE, et al. Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial. Am J Kidney Dis 2009; 54:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/54\">",
"      Brar SS, Hiremath S, Dangas G, et al. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/55\">",
"      Joannidis M, Schmid M, Wiedermann CJ. Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis. Wien Klin Wochenschr 2008; 120:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/56\">",
"      Zoungas S, Ninomiya T, Huxley R, et al. Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med 2009; 151:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/57\">",
"      Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 2003; 93:C29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/58\">",
"      Taylor AJ, Hotchkiss D, Morse RW, McCabe J. PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 1998; 114:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/59\">",
"      Dussol B, Morange S, Loundoun A, et al. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant 2006; 21:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/60\">",
"      Briguori C, Visconti G, Ricciardelli B, et al. Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design. EuroIntervention 2011; 6:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/61\">",
"      Briguori C, Visconti G, Focaccio A, et al. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation 2011; 124:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/62\">",
"      Marenzi G, Ferrari C, Marana I, et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. JACC Cardiovasc Interv 2012; 5:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/63\">",
"      Kshirsagar AV, Poole C, Mottl A, et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol 2004; 15:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/64\">",
"      Fishbane S. N-acetylcysteine in the prevention of contrast-induced nephropathy. Clin J Am Soc Nephrol 2008; 3:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/65\">",
"      Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002; 40:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/66\">",
"      Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003; 289:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/67\">",
"      Briguori C, Colombo A, Airoldi F, et al. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2004; 44:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/68\">",
"      Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002; 62:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/69\">",
"      Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002; 40:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/70\">",
"      Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002; 89:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/71\">",
"      Shah SJ, Hsu CY. Has acetylcysteine use changed the incidence of contrast nephropathy in hospitalized patients? A before-after study. Am J Med 2004; 117:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/72\">",
"      Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/73\">",
"      Coyle LC, Rodriguez A, Jeschke RE, et al. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics. Am Heart J 2006; 151:1032.e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/74\">",
"      Webb JG, Pate GE, Humphries KH, et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 2004; 148:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/75\">",
"      Baker CS, Wragg A, Kumar S, et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003; 41:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/76\">",
"      Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006; 354:2773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/77\">",
"      Briguori C, Colombo A, Violante A, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 2004; 25:206.",
"     </a>",
"    </li>",
"    <li>",
"     Berwanger O. LBCT III, Abstract 21843. Presented at: American Heart Association Scientific Sessions 2010; Nov. 13-17; Chicago",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/79\">",
"      Fishbane S, Durham JH, Marzo K, Rudnick M. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. J Am Soc Nephrol 2004; 15:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/80\">",
"      Shalansky SJ, Pate GE, Levin A, Webb JG. N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration. Heart 2005; 91:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/81\">",
"      ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation 2011; 124:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/82\">",
"      Birck R, Krzossok S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003; 362:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/83\">",
"      Pannu N, Manns B, Lee H, Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 2004; 65:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/84\">",
"      Liu R, Nair D, Ix J, et al. N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J Gen Intern Med 2005; 20:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/85\">",
"      Nallamothu BK, Shojania KG, Saint S, et al. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med 2004; 117:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/86\">",
"      Zagler A, Azadpour M, Mercado C, Hennekens CH. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J 2006; 151:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/87\">",
"      Bagshaw SM, McAlister FA, Manns BJ, Ghali WA. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch Intern Med 2006; 166:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/88\">",
"      Kelly AM, Dwamena B, Cronin P, et al. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008; 148:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/89\">",
"      Gonzales DA, Norsworthy KJ, Kern SJ, et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med 2007; 5:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/90\">",
"      Hoffmann U, Fischereder M, Kr&uuml;ger B, et al. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004; 15:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/91\">",
"      Rehman T, Fought J, Solomon R. N-acetylcysteine effect on serum creatinine and cystatin C levels in CKD patients. Clin J Am Soc Nephrol 2008; 3:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/92\">",
"      Trivedi H, Daram S, Szabo A, et al. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. Am J Med 2009; 122:874.e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/93\">",
"      Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003; 349:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/94\">",
"      Marenzi G, Lauri G, Campodonico J, et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 2006; 119:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/95\">",
"      Cruz DN, Goh CY, Marenzi G, et al. Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Med 2012; 125:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/96\">",
"      Klarenbach SW, Pannu N, Tonelli MA, Manns BJ. Cost-effectiveness of hemofiltration to prevent contrast nephropathy in patients with chronic kidney disease. Crit Care Med 2006; 34:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/97\">",
"      Cruz DN, Perazella MA, Bellomo R, et al. Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Kidney Dis 2006; 48:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/98\">",
"      Lee PT, Chou KJ, Liu CP, et al. Renal protection for coronary angiography in advanced renal failure patients by prophylactic hemodialysis. A randomized controlled trial. J Am Coll Cardiol 2007; 50:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/99\">",
"      Hamani A, Petitclerc T, Jacobs C, Deray G. Is dialysis indicated immediately after administration of iodinated contrast agents in patients on haemodialysis? Nephrol Dial Transplant 1998; 13:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/100\">",
"      Tombach B, Bremer C, Reimer P, et al. Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. Radiology 2001; 218:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/101\">",
"      Arsenault TM, King BF, Marsh JW Jr, et al. Systemic gadolinium toxicity in patients with renal insufficiency and renal failure: retrospective analysis of an initial experience. Mayo Clin Proc 1996; 71:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/102\">",
"      Hoffmann U, Fischereder M, Reil A, et al. Renal effects of gadopentetate dimeglumine in patients with normal and impaired renal function. Eur J Med Res 2005; 10:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/103\">",
"      Rieger J, Sitter T, Toepfer M, et al. Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function. Nephrol Dial Transplant 2002; 17:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/104\">",
"      Hatrick AG, Jarosz JM, Irvine AT. Gadopentate dimeglumine as an alternative contrast agent for use in interventional procedures. Clin Radiol 1997; 52:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/105\">",
"      Hammer FD, Goffette PP, Malaise J, Mathurin P. Gadolinium dimeglumine: an alternative contrast agent for digital subtraction angiography. Eur Radiol 1999; 9:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/106\">",
"      Erley CM, Bader BD, Berger ED, et al. Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients. Nephrol Dial Transplant 2004; 19:2526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/107\">",
"      Thomsen HS, Morcos SK. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. Br J Radiol 2003; 76:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/108\">",
"      Thomsen HS, Alm&egrave;n T, Morcos SK, Contrast Media Safety Committee Of The European Society Of Urogenital Radiology (ESUR). Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol 2002; 12:2600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/109\">",
"      Erg&uuml;n I, Keven K, Uru&ccedil; I, et al. The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol Dial Transplant 2006; 21:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/110\">",
"      Sam AD 2nd, Morasch MD, Collins J, et al. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 2003; 38:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/111\">",
"      Ledneva E, Karie S, Launay-Vacher V, et al. Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. Radiology 2009; 250:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/112\">",
"      Katholi RE, Taylor GJ, McCann WP, et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995; 195:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/113\">",
"      Russo D, Minutolo R, Cianciaruso B, et al. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995; 6:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/114\">",
"      Erley CM, Duda SH, Schlepckow S, et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 1994; 45:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/115\">",
"      Chamsuddin AA, Kowalik KJ, Bjarnason H, et al. Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy. AJR Am J Roentgenol 2002; 179:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/116\">",
"      Kapoor A, Kumar S, Gulati S, et al. The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrol Dial Transplant 2002; 17:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/117\">",
"      Huber W, Schipek C, Ilgmann K, et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol 2003; 91:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/118\">",
"      Ix JH, McCulloch CE, Chertow GM. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant 2004; 19:2747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/119\">",
"      Bagshaw SM, Ghali WA. Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Arch Intern Med 2005; 165:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/120\">",
"      Huber W, Eckel F, Hennig M, et al. Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. Radiology 2006; 239:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/121\">",
"      Spargias K, Adreanides E, Demerouti E, et al. Iloprost prevents contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2009; 120:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/122\">",
"      Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290:2284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/123\">",
"      Wang A, Holcslaw T, Bashore TM, et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 2000; 57:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/124\">",
"      Dai B, Liu Y, Fu L, et al. Effect of theophylline on prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2012; 60:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/125\">",
"      McCullough PA, Larsen T, Brown JR. Theophylline or aminophylline for the prevention of contrast-induced acute kidney injury. Am J Kidney Dis 2012; 60:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/126\">",
"      McCullough PA, Tumlin JA. Prostaglandin-based renal protection against contrast-induced acute kidney injury. Circulation 2009; 120:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/127\">",
"      Teirstein PS, Price MJ, Mathur VS, et al. Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterization. Am J Cardiol 2006; 97:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/128\">",
"      Er F, Nia AM, Dopp H, et al. Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized pilot RenPro Trial (Renal Protection Trial). Circulation 2012; 126:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/129\">",
"      Bonventre JV. Limb ischemia protects against contrast-induced nephropathy. Circulation 2012; 126:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/130\">",
"      Margulies KB, McKinley LJ, Cavero PG, Burnett JC Jr. Induction and prevention of radiocontrast-induced nephropathy in dogs with heart failure. Kidney Int 1990; 38:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/131\">",
"      Kurnik BR, Allgren RL, Genter FC, et al. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998; 31:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/132\">",
"      O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/133\">",
"      Sugiyama M, Ohashi M, Takase H, et al. Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels 2005; 20:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/134\">",
"      Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005; 118:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/135\">",
"      Lev EI, Kornowski R, Vaknin-Assa H, et al. Effect of previous treatment with statins on outcome of patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 2009; 103:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/136\">",
"      Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol 2008; 101:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/137\">",
"      Xinwei J, Xianghua F, Jing Z, et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2009; 104:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/138\">",
"      Patti G, Ricottini E, Nusca A, et al. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial. Am J Cardiol 2011; 108:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/139\">",
"      Toso A, Maioli M, Leoncini M, et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol 2010; 105:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/140\">",
"      Lloberas N, Torras J, Herrero-Fresneda I, et al. Postischemic renal oxidative stress induces inflammatory response through PAF and oxidized phospholipids. Prevention by antioxidant treatment. FASEB J 2002; 16:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/141\">",
"      Durak I, Ozbek H, Karaayvaz M, Ozt&uuml;rk HS. Cisplatin induces acute renal failure by impairing antioxidant system in guinea pigs: effects of antioxidant supplementation on the cisplatin nephrotoxicity. Drug Chem Toxicol 2002; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/142\">",
"      Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004; 110:2837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/42/35498/abstract/143\">",
"      Onbasili AO, Yeniceriglu Y, Agaoglu P, et al. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures. Heart 2007; 93:698.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7221 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-59E8FFCE15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_42_35498=[""].join("\n");
var outline_f34_42_35498=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Types of radiocontrast agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Type of contrast agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Nonionic low osmolal agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nonionic iso-osmolal agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Carbon dioxide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Volume administration, mannitol, and diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Intravenous saline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Intravenous bicarbonate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Oral hydration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H588321811\">",
"      - RenalGuard system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Acetylcysteine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Intravenous therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prophylactic hemofiltration and hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hemofiltration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Contrast-enhanced MRI as an alternative",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Inhibition of renal vasoconstriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H607423301\">",
"      - Remote ischemic preconditioning (RIPC)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Atrial natriuretic peptide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Statins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Ascorbic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Trimetazidine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/10/32937?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32451?source=related_link\">",
"      Complications of mannitol therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42154?source=related_link\">",
"      Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/28/4553?source=related_link\">",
"      Renal and patient outcomes after acute tubular necrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_42_35499="Classification of toxic hepatocellular injury";
var content_f34_42_35499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F83839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F83839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of toxic hepatocellular injury",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Acute hepatocellular injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Injury predominantly to hepatocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Markedly elevated ALT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mildly to moderately elevated alkaline phosphatase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Cholestatic injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Injury to bile ducts or the mechanisms affecting flow of bilirubin from serum to bile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Disproportionately elevated alkaline phosphatase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Mixed injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Features of both acute hepatocellular injury and cholestatic injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pathogenic classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Intrinsic hepatotoxins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Direct chemical reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Predictable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Idiosyncratic reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Unpredictable",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ALT: alanine aminotransferase.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_42_35499=[""].join("\n");
var outline_f34_42_35499=null;
var title_f34_42_35500="Personnel and facility requirements";
var content_f34_42_35500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACCF/AHA/SCAI expert consensus document personnel and facility requirements for PCI",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Experienced nursing and technical laboratory staff with training in interventional laboratories. Personnel must be comfortable treating acutely ill patients with hemodynamic and electrical instability.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        On-call schedule with operation of laboratory 24 h/d, 365 d/y*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Experienced coronary care unit nursing staff comfortable with invasive hemodynamic monitoring, operation of temporary pacemaker, and management of IABP. Personnel capable of endotracheal intubation and ventilator management both on-site and during transfer if necessary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Full support from hospital administration in fulfilling the necessary institutional requirements, including appropriate support services (eg, respiratory care, blood bank)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Written agreements for emergency transfer of patients to a facility with cardiac surgery. Transport protocols should be developed and tested a minimum of&nbsp;two times per year.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Well-equipped and maintained cardiac catheterization laboratory with high-resolution digital imaging capability and IABP equipment compatible with transport vehicles. The capability for real-time transfer of images and hemodynamic data (via T-1 transmission line) as well as audio and video images to review terminals for consultation at the facility providing surgical backup support is ideal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Appropriate inventory of interventional equipment, including guide catheters, balloons, and stents in multiple sizes; thrombectomy and distal protection devices; covered stents; temporary pacemakers; and pericardiocentesis trays. Pressure wire device and IVUS equipment are optimal but not mandatory. Rotational or other atherectomy devices should be used cautiously in these facilities because of the greater risk of perforation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meticulous clinical and angiographic selection criteria for PCI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Performance of primary PCI as the treatment of first choice for STEMI to ensure streamlined care paths and increased case volumes. Door-to-balloon times should be tracked, and &lt;90 min outlier cases should be carefully reviewed for process improvement opportunities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        On-site rigorous data collection, outcomes analysis, benchmarking, quality improvement, and formalized periodic case review",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Participation in a national data registry where available, such as the ACC NCDR in the United States",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ACC: American College of Cardiology; IABP: intra-aortic balloon pump; IVUS: intravascular ultrasound; NCDR: National Cardiovascular Data Registry; PCI: percutaneous coronary intervention; SCAI: Society for Cardiovascular Angiography and Interventions; STEMI: ST-elevation myocardial infarction.",
"     <br>",
"      * Required for US facilities but may not be possible for all facilities worldwide.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     From: Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58:e44. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_42_35500=[""].join("\n");
var outline_f34_42_35500=null;
var title_f34_42_35501="Fewer ulcers with celecoxib";
var content_f34_42_35501=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fewer gastroduodenal ulcers with celecoxib",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 251px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Results of two trials in which the cumulative incidence of gastroduodenal ulcers as detected by four serial endoscopies over twelve weeks in patients treated with the COX-2 inhibitor celecoxib and either naproxen (study 3) or diclofenac or ibuprofen (study 4). Celecoxib was associated with significantly fewer gastroduodenal ulcers than naproxen or ibuprofen (p&lt;0.001).",
"    <div class=\"footnotes\">",
"     C: Celecoxib 200 mg BID; N: Naproxen 500 mg BID; D: Diclofenac 75 mg BID; I: Ibuprofen 800 mg TID.",
"    </div>",
"    <div class=\"reference\">",
"     Data from the Food and Drug Administration.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_42_35501=[""].join("\n");
var outline_f34_42_35501=null;
var title_f34_42_35502="Protective mechanisms in edema";
var content_f34_42_35502=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Protective mechanisms against pulmonary edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 268px; height: 400px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An osmotic gradient favoring fluid reabsorption from the interstitium is maintained by retention of serum proteins within the intravascular space. Fluid which does leak into the interstitium is transported to lymphatics from which it is returned to the circulation. Finally, tight junctions between alveolar epithelial cells prevent leakage of fluid into the alveolar space. Arrows represent lymphatic movement; small circles represent protein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_42_35502=[""].join("\n");
var outline_f34_42_35502=null;
var title_f34_42_35503="Ultrasound of gouty arthritis of the metacarpophalangeal joint";
var content_f34_42_35503=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F85635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F85635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Ultrasound of gouty arthritis of the metacarpophalangeal joint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 200px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADIAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDloCpUfalkWQDAwa0bWYLAoBJ+tZOoauv2pBGgZRUn2wSr5gG0H+H0oAv6hOTp116+WcVyGnag0c6pO21R61t3VwfslwfSM9a5yyhe7uQHUFCO1AEmrSFnaQHfCf4RWTslbDJKUU8bc10lxpkkceEQbewNU205phtnDRgcgjoaAF+xwQW0bu29m6gVsadZ2qKJHyATxmsW3sLuOQCNSyL0J71qiK/mj27ANvtQBq6ixMaLAoPv6VlyrdFt0uZMe3SqLHUbRuoK9fpUqeJ5IYmWeDcccECgDStZFlTbLbE+7U82xD/ufLSA/ezXIXnia4kyIwVGfSsmXUb2V8iSTb3GaAPSVvobI4gMbY/Oquo+NmigMCwHf64rmdJngWPzrjcZBV+cR3yBkiIT+/igCf8A4SXULq1CL8g9acmo6gsYJuiBVCSyUW2xWk47gU+w0K+nkO7eYOxagCaXUJ7lgtzcnYOeO9aN94qS4s4bZWK7BgMO9Ur3SI4owHfDCs5o7OJVMWJGXsaAN2I6jMFaS6wvb6U6d7iOM/6UzDHOTWTHr3mRmPAUKMCqZmluZgH8xEJoAvWtzeAN9nlYc84pt5eSiJmu5SzDpmrOY7SA/ZyDxk1i3jm8yzOAgPSgCmfEVxHlIpgIj270kOrsZg5nf0x2qCW0heXCxE5709rFVXAjOfagDYHia5X5FlKx+gNO/wCEqkX7qOW/vVix2PB3K231q6lveMgWGBWT1oA27LxKbdvPkG7PVR1rb07x1bSOVuLYbccbvWuU0vTcXG6aNi/dQMitxtFsFQPLCwOc0AaWo+JYbtR5tuJEH3QKyG8QSI5WK2eJT6Cr9lbacjDIZRVi8sY5whspEbbyQaAItL1p7V1LTyYb5sPV3xBr63LJkRnjOQax9SmXy/LubbL42qyiseLQ7i9LSAPGg460AOvNWFnIZYZTuHIxzXSeGvFcV3aD7Xlpc45rDhsI7UCGWHzc98VpWWnWRmCbWjJ7CgDsBbWuqW2+OVI5W469Kw9X0lLCAvPcROuMcGuw0Lw7p32dWed1PpmuS8YaPZ/aJVS8Ijz93NAGdaahHAitGFAPAYUrSw3jsJH8w/3QKxUtIomAWbco7ZrV04myYukauD2xQBJb6bblybDaJT13iq50l0kZpJVQ9TirZeKWTdzE7HkCtNdISWNW8zj/AGj1oA5e4uDGdgl3N0BNZk1tLdMPtDCUA8c9K6fVbOzi+WSNsngFaw7nTUhBZJ32nnFADjoYNjIRtbjtzXNLpDxyBwGIXtiug0+5mhysIkeP+Imuis9s0R+Vev3T1oA82vJ7i2cmMlcdgK1bHWFax23HzPwCMVtazDbC5+a3C+2K5y+VBISI9tAG1byDyxJAEXPrWrp0m194GZcfeFcK8l0Y8xDKdqfYazqVpKPLUNigD0CW6ntzvWHknqajvbqe4SMB1BPXPas3SvGVnJ+61SPbtrq9Pbw7fgtFKiN6ZoApzaat3FCXlYt6CrDeG4/sxfzCABmtWHTHuyBYXESovctVw+GNSkhYR3sRyMHLUAeb3NlAqsIUKkHrWWLF3beTvlU5XFd3L4WnspSt3KJsnOAeKZNpgjGYLcLjqc0AceJ7pR5cpMZPGCMYqX+2LiyQoJzNH3QVuT7cbZrQyN2IFZ1xEqKxjtlVvccigAsvEcqgSLbmP3PWuo0bXo5nV02+cepNczb2Es8QJhc574wK3tH0q3gIZ2VXPUUAXdV1m6lQpMGKA/wiuV1XX3ChLcSlgcYArtJpLNI9qyru965q5NubomJELZ5JoAp2vifUoQACwyMc9qln8W3tkuZJCzSfdx2rTu9NtruCPDqsnoKzZfCN6wLDYV6jJoAo3PibUrp98khYDpiihfC9xv5l2sOgFFAGPatviZjJlhnFaNnOfsybjk4pNK0AR7TM5lTuQai1Vo7fUJooOIVwFB7cUAXC32hTAW2iT5c1VSOfTpglsrMV/i9aj0yYPqdojEbWlANdJqWs2Vndtb+Wrke1ADNGsZ9SuALqYwqRnOa0tasY9Nsw0comwa5+61lgpeFeD29KyJ9SllJLuTn+HNAG7LcziLMZUcflVJLm9LMYLk57hqwI9QKSHdubPatLTpWYlpU2D+dAD7zUJ4ABckSE+lZ8rvfOAg8tAeRWrcBJ3jCxqQDyTWta2MeUFrH+8PcjvQBz50olQsUG52pkHha+NwrNhP8AZNdlcWOpx3USPb5B/iQdK07nQtQ8szGTMK8nHWgDDg0q0tbNo7tVL/3lFTQRWcdsRbyqW/umta2l0+OyZXGZf9rrXI33GrF7bj0HagDpNNs3mlXIiHsaZrs8umxbmcEf3V7Vn2884cFpMMeynmn3OlXlxF5jy/u2P8RoA5jUtWuLtSDEwGeKxlWaNixhfB45r0vTNDckFIo3PqavrpunSErdsm5OooA8pt7C8kJeOI8cjNa9uuq3oI8tFRODxzXXSXenWpkSMDA6Vy2r668chFggCn7x9KAKdwzWZMZ3lzxzUcUQKMLkhWPORVObU2lmQzrvOeavySJJHmJO3egBkNsidGZ4+5HatWEWX2QrET53vXPNf3UP7uKIbfzpzXkoi2iH992xQBsM58vbPt8sVNaSWZAUXfl/jxXD3seoM5lkeTb/AHQabbjePnLrQB6Quqx2bfuWjkI/WlvPE6GAYhy/cVwEJUy7bd3Mg6mtm13/AC/JuPegDai8SKB+8s2Ibjhaa2qOo32kTjn7pqxHPdLCoS2jYd8j7vvSGHhna4j3EZ2igCm+v6rNIqvYjaP4sU288Q3kWNgCrj5lqzaJPeLJtl4ToPWr+naF/aKFJISjHuwoA5VvE1/dybEiRQ3G6ui0aO5aMSySqZR05qTU/hjdQv8AaUuwFUZ8vNV9K0O8FwkbzeVEeoz1oA7i01WS200MzKZR71yut6kk26eePeT2Wum/4Qlbiy/d32GPbdXH674L1m1DG0uQ+OnNAGVHrMTPtWAAD86treSEboTgHtWFdaXq9pGDNb7ZO7461DFdTW+3zTluvTigDalvNViYtDCD71PpevahvxcuT7VHYeKIY1CTKoGMVBfXVrMu615Y8nFAHV2utQycXflk9OaXVLi0l/1MfJFeeBA0okDtgHOM1pjVpWKxxsqjpk0AdTawFrd0WPa7D5QO9SaeBYjbPAyz5yu6uTfVriwvIT5rSHOcg5FSarr93eSiQyDIHQUAdJqVncXkhmYp0zgGq8+lwjTy1ztznpWdouozzIIZWwCfvelWtQlt42aGW4Zz6mgDn54oRJ5aFlT2qSTTbB4AYLg/aO9NumgPSTAqrFK0svk25Tj+KgBp0R5ZMSqvl+tW59DMMStBKyH/AGWrTsrMFM3M+R6A1Pc6NPtVo7oBH6c0Ac3FfarZPtgnl/Otyx1XxAYyVuHwBzzSXHhq6t4/MWYOCMnBqrZwXYEgSU5XqvrQBs6dqt7cZW9nkR88HNTXE9xFMqR3MkqHrWZYpdTKVlUK3Ynqag1GO4tsq85BbpigDaMmoNOBbOuO+a6rw9ZmSZG1GBGOeSDXnmjaj5LiOeUlieDW+upTpdKsEzHPIoA9cnj0+CxJWAFPQCuQv7e0d2lhjdSezVg32vana2hyytjsDRpXiCO6VVuwwc9aAK+pWl4jtJ5IMZ9DUMDWz4EkLq2eTXRav9hWyE32iUBui1hW9tqF7IDbbDH2J64oAmuvJiWP7O53k8E1btrm+gjLXLGRMcYPaqt7pTyqiTXEcTA+uCTSTeHdUEObe5LKe27qKAL1nLFqTFoJRGyHkHvRXNS2Op2MoaKEkA5LUUAXPDFhqdygdbdkH91ga5nxmJLTxRewTJ5boVBHpkV7hBqsVhau0rRh15BA6V4F8R9U/tDxxqt3v3eYU+b220AVobl1mjaM/OGyPrV2eeQwfaZYt9wfWuetLrbdwODnDiuoS8+0DbIFAPoKAKcVyZUzcxsiH0FS6dLCl0xYb4yOAatPY3V0nlxMgjxkVRhsJPtBiJwV79qAL8TQrMzpbg5PHtUuqAmOMwNyew7VpT6ZLDZwsMbWOCRW3aWtjDbrLIBkDJzQBxiWzxvEZJG3HoK0r+XVLeS3eIhY15+tXNZ17SIYGIQbkIAbHQk4Gfzrm7nxHcTEx3AXB4TFAHeWfjae3hC3MIY464qyvjMXlu0a5UtXmfmXcabhtmHXk02K9mkkA2CFj6UAdJqzRyXe95cSeg4pkdozx+bHIWb0zXMX5uGnwZRu+tSadfajFdLBGVYH3oA2o57q0uvMETEg4y3Sreo+IbhrZY5mEYB/hrNvdTu2QwXEPHcrWJNGbldqsfoTQB01lr11aruW6Z1I6Csa8uru6uGeC5aNzyRmoIxFGmxRmQDmqd8qhFcZRvrQBZkkuLYAyyGTPWqFzeKzgyErjsO9VGvJZcrI3ToaakJjYeZiXJyKANFru3Kbk+8BxmqwvZmbDOQPQU+5029nXdEipGBVIRPGhDLlvWgDTF+9sCq8nsT0qhdarKzHbJ+87YHFVxKETZJyPUVEZEP+pjy1AGgdSma0w75m96sW8/2mARtGPN7sKxmZyPnT56s2PmiT92wVj2zQB3fhtbC1ctdquNuOaqvqVvBqcrRnEZPFczc292ybvtCn/ZzWewnU4ONwPJJoA9Gn1BHtt4n3bh0rkri4nSdjEHCk8nOajgvYH2rKdrrydtdv4Lm0S+lxf4Xb2PegDG0fUWtpIzh8ZyxxXaJ4ttRcQESDCgZHSusm03QdQjRLK3AyMEqKqS/C2ynDHYybuhB6UAUNT1xNUQLbXARiOMmquj6JdSSrM05kfsM1Hf8Awhlhl8+x1N1C9FLViy22v6FeApcs8aUAdxf6BraD7RbswQfwZqhcy31lZiacsz/3KxYvihqlvOLe4BEfdiK7Xw/4g0fVdr3zo0pHOelAHFX+veba/wCkI209iOlc5f6nZTRhEgVcd8V6p4h07SLvcLcRseyqa5C/+Gl1JGJ4ATGy5CjtQB55f21lcrhGMb/WoDbzeX+44C96TXdKvbe4aJ4TiNv4RzUmn3Fyq7SAQO3pQBWjnlRypUj14q2sccqkyv5bdh61Dc6rGzBfLXdnnis+5kMsqlsgDpigDbtEK/JMAQTwfSn3UEUbghn3HoBWdCbggSK4wO2a0rC6+cPcqH56UAXtE+a6UTI6xZ5YDiu4EOlz23kNECuc+Z3rPtdSt30xoorQA+pFUbSCc3QEsm21/u96AOq1DQNDudCWO3G66rz278NTwTERho0H8RrubDUbDRBLf30iraRrkk8n6Y7n2rQ8V+ReQlVcxr7daAPJ760uraNfImdnz3PFXbDU/kVb8tIy9Ap71sXdlHbRBjOjKexPNYH9nsbjfC6tz0zQB0um6i8jbBA7oenfFT6ray7ke0j2Z5biorF79IdtvFGuBy1QnVdTiLKYy474GaAFXdt3TOdy9MCs+4H22dW8wADqCeTV6O4aVSZoGUdSMdaijFs9wrRxSA+/SgAhtLVXy1szN/eqK4WSOQtC4VM9e4rdnvR9mNssGZG6MB0rMSxinHk3E+yY9aAIraZ5SBlnJ9a0tOuImu/J8lfNHXArRsrJLO0EYZHUfxVWFgIbj7U8ioh70APu7WeIF2cMh/hboKZYz+SzG3lYORjA6Co9RhvL6PZaTo+ORz2qDSHWSR7eQBJUGGYdzQAW8kEV1I9/M8rMcqPSr1/q93bGFrPd5PcnPSqlvbRLO5mTeFPBNXmvfNgeNUTaBjA7UAWx4liewkETKZNuMGiuOW2hV5NxMTsfWigDR8S6+t0Stm2xTnjPevK9ancapP5p+Y4z+Vb1vKgOS+V96iubGwvrkybMyMeuTzQBgWEnm31tHuwGkAJr0FYY4YdseJHHFc9HocEMiyLEN6nI+Y11thZiS1Vwdsh65oApx6iYzsdSB0wtTTMXMSpHNJLLIscccUZeR3ZgqqqgEkkkAAetOubCNFL27hpu4NP8HpKfH3hRpJSdus2OV7f8fMdAHS2Gm+IBGFufDfiUgdAdGuiP/RdLeaPrt0m0eH/EMa+n9i3f/wAbr7LooA+LvCngvV4/GHh6ZtE17ZHq1lI/naPcoioLiMszM0YUKFBJJPau5+MnwRjsZpdf8IWjPY5L3WmQrloR3eFR1HUlO38P90fTFFAHwnLotuthHdWl0stu4yGTmsG4htRktMfMHQ5r6R+Onwxhh07UvFPhmWCxkjVri/s5HEcMwGS0ik8LJ69A3seT8g3t+ZLwPhiDyDjFAHRJbxvMrSSfLV6CwSSYNasfY5qr4ZsV1C5j86bZEeoJr1zSvC2jRWgkFxn8aAPNZdP1JPm3bkrJuJJYJirxHcOuK9B8RXEEUrW1pMq471xMkd7fXLwRISf74HWgCsLqHZkrhz1rJvZvNcCQkqOmK6ObwXrCKJkYEN2rQsfDBWHN7hTg54oA4nT1i8z9+A654rZ1JFVEaC3KYGaj1C2tbG5zEQcHNbNpeW97BtkxlRgAUAYdvrDPbyLLvLngAcVlTG5BJdDg9BXSSWjyyFoIlyOgx1o/se+vpVjKhQeOaAOYjiaU+YQMdMVais2bDxYT1zXar4Ja0s2eeQeYOmDXPX+nXcKYjb5BQBiTwuspG8eZmla2jVd5Y+Z3q7aWsSnfKxaUe1TtEkpKqvNAGLcLII/lLA56immAyxqBMS/fNdlp1naIo+0gE1Ya0sbhisdttI/ixQByNhpsMkiCZ2UA8la9J8P6RoMdszbXeULnOe9c9d2CW4UpETzVi2uJII2+XChfSgDprPW20d3WGNgCeO9Xh8Q9Q80KmdoNcjpWqQz70umyegzUl1BB5gaKdQfSgD0fTfGiSsFuyC5962zq2jXpC3aRlT1rx9FSUhSwjcdKjnM9tMNrGY/7PNAHpfiDwtoGqW0jWMeHbpivO9W8F6ppcPnWxZbf261f0jxHqFuwj8vp2IrsLLxCbyJYrxQsfv0oA8s0zWLjTLrdJK5K4yrd69K8N/EJrkLDPKI0NZGuaNpl9M7xhFfk5rz/AFTR57OYmKTIB4INAHsWtJaahA0lqsRlYZLEV5PrGltbXEpyqljn5ah0TWru2k2Tu5j6DBrp7e5W+X5LdXLcZ9KAPNLq1ED7nO7PPFLFPDkbl3LXoN34PuZVd7ZQ/cgc4ri9U0iTTnYXUbqc+lADHeKQBYMoD1ot5BZzKSrN9azk+YhoWPFa+n3YaRYpYwxNAGjDrDvOFQ7R6CtOzv2N/HH880sjBEhRSzyMeAqqOSSazTaie7gtrK2ke8ncRQxRj5pHPQCvpb4RfDGDwfF/aWqmO68QTLhpAMpbKRyiep9W79OB18PPM8oZRR556zfwx7+vZGlKm6jOetfhnNY+BPEmp6tAbvxDcaVdJa2cS+YLUtC4CIB9+U5wWHrheMluVmjv5JQsmga88fc/2Pd5/wDRdfTFFfnWC4zxmGlUnUipubT1urW2S8jslh4uyR8o6poE922P7B8Q7OvGkXQ/9p1lXXh+5sbeW4fStdtbeFDJLLLpVyqIoGSxJjwAByTX2HXM/E7/AJJr4s/7BF3/AOiXr1KHHeIq1Y0/YxV2luyHhUle54Cng/X7eMPES6kcj2pIdK1G1VmuIRxzXYweLZbXEd4pCgYqpq/iOwu3RC5Tdwa/TTiOTWWS4mVWWNVBwRVu6iFv86xIyAclBzXQHQNGuE85Loq2MkbutZ9xpgZTHYz4PTBPWgDDbUI508u3i2yHgEisO7iuWujG0RMvZlrRv9K1yzuB5cSyYPYVUe51RZdslqyTHuBQBWNrqFu295mIH8FLFNNLJtmcsufu1bF7Kn+sieS475HFZl5Dqs8hkS3MYPtQBuw2ptk80uyAjpmot8Fi5mgbfI33gavaBo2pXSKt0pK4q7JpMenyFrmDjPBNAHKSyXNxL80jIrHt0q5Patp6I0U4LSDmtq/Fv5e5I1UYzxXMXEd7eO22IhFPB9qAKt1DLchmuJfu8giir9nBMkLDy/Mz1OOlFAHnkXmy/KEIJ4rZ06wlWHnhvX0qC0crycHFdNpd2cKfKQgepoAdpmksWWWZyy1pvHE5MSFl561GdWkRwqRxr6Lmp7a5n1B/KS3VHP8AFQBgagBZXRG8v7Cr3ha4S38VeH769aO2s4dWsZZJ5WCLGguYyWZjwABkknpVjUNClsmN0+JWz93rWrHaK1ijyEIT1A7UAfVP/Cx/A/8A0OXhv/waQf8AxVH/AAsfwP8A9Dl4b/8ABpB/8VXx5rkVtbopS6KsTWatzeJjYY3Q96APtq08feDry6htbPxZ4fnuZ3WOKKLUYXeR2OAqqGySSQABW5qd/aaXp9xfajcRW1nboZJZpW2qijqSa+IvDd/Da6zol/fXKQWlrqtjLM7nCoi3MZZj7AAn8K6/4p+Ob74h3ey2Z7Pw1bPvtrZxh7lh0llHp3VO3U89ACP4weN9S+IM4igWW08MRPut7Zvle5I6SyjsO6p26nnp5U+ipLciMBQzdMV3Nnp327SZGvLg7wMqF61madpE6Zlt4y4U/ec0AZtr4ZazlEhuCqr/AA1py6j9mtykdyW9qra1JfSSmF4ypPftXNX9lfIpWOCSWX+8o4oA3Iltbi5864dyxHIxXTaJeQ2swEMW9McbhXnFhd6rpziS4tWx33iuqs/GMUsaxC0BmHUjgUAemabdvM4Etv8Auyegrpb7w/YT6f5kh5Kniud0HxNp4sYvNhRZAOaj1K9ufEQMOlzeQUzk560AeN+NdOgs7yXyZARnpmuasHZWbYx4PGK7rxV4Qv45EedyxJyT60abodlkK4ZW9QOlAGbpNxezoTHEMDjmtmM3+4OzqjL0HrVjUrNdPkSGxlG2QdfSrWnWwinRLl/MLdxQBVk1K/mkELRGRj0xTzZXsilZ7Qoh7npXZJ4XnuStxYbQcdKg1fT7yCBormdt/oBQBxVxosvBiRM+tZsnha/nkLR/6zPQdK62zs76VhbgFo/XvV2TStVtYy8EigDsTzQByj/DzVzarKs2H64JrY0HwvrkDbPshkXpuNarRa1JEoaTvyQa6XSLXWEhDS3hVOwzQBRfwVqBhWS4ER77KwdfsbmygdTYKFC9QM12tzekDbPdMCPeuV13VktYJALjzQwIG45oA8ZvbySO6b91s+anpdCZh5khQ+xpniC7LXBYqrAtn5aw2vCzgxRkAUAdSXKuP3pZfUmrdpqE8LhLblc9Wrlo7rOOWBA4q7aNLNIMy8evSgDsYtSkebbJt8z1zitqPU0FsFZC798VwtxJbW0f76Qs2O3erFjqsiQq6OBEexHNAHXRM7sXAO09geasTab50OXjkrhY/E9zFeEQDjPU13Hh3x4F2x3sCtjg8UAcpremT6exlYERt0rPtNfOnSL+9xuODXreuaho9/ZAtCuWHFeUeJ9CUO8mBsJym2gD0Xwt4mhePibBI5BPWtDX7OPWLR2hiDYHJNeD2IvLS48wbgEPAJ7V3uleOZtiQXEe2IAKccZFAHPalpE+nrL5ce7n+HmsmwuDDcKZfkbPGa9KvtVt54z9ith5TD5s81w+sQwPKJPs2GU8GgCWe+WadGSRtyHcrISCrDoQR0IPevor4L/FltZWHRPFjrDqnCW12+FW67BW7CT9G7c8H5aW/aCX5YAQD1xV+21FbiUiVtoYY2kcCvIzjJqGbUfZ1tGtn1T/AMu6/U0p1HTd0foBRXzLo/xYN38PfEXhzxTcB7p9JuorK+Y8zHyWAjkP9/oA38XQ/N97zC1ttPE8YlsLbn7uYlwfrxX59guB69edSFepyOL0926a7p3R1yxKVrK5901zPxO/5Jr4s/7BF3/6Jevm1dO0loB/xJ9NYgdrVAf5VXltNHt4HM2hWZbti3T/AAr1KPAXsqkan1jZp/B/9sZvFXVrHT6hdQPdu0o+TGefWuR1O5tJJ9wmIIPbmozqUl6QgR1z/eHWnPYy2bYKRM0nOa/RDkIy9zc7WtblwEp/9q6jY87XkkHI561WuoNStWDxqoQ88VlTajdLcpJM5IXqOtAHeaD4+liKjU1CN3zXRxeJtJv7lZWKAnv2rx++v5NQywt029Nx4qnYfara7VgwMHXaDQB9AQ21hqkv7nywT0bHFLd+G75BttZYpQD92vL9P8VyptgSLy0B4bpXY+GdfuzcAmQMnXlqAPRtF0C/it0Lqgfb0rF8RaDeyK/2mMlByMVQb4k3MNx5EUeSpxnFXda+JcUdjDhFklbhhigDyTxFIbOUrIJFwcDjpWbperlHZZJWdD2r1bU0tdStBK0Eckk65AI6E15vqvg3ULBnuE2hGJYKOeKANrStWthG3lYIPBB6miuJs7meCU+dEI9p6kdaKAMy3SOZOXABHWtjTbS3h2uZiSPfircGn6W1qzDHmAdKox2hEgARhH60AXPsH9oXqrG2HbgHNX5nudHXy3cEjuDWdGs0E/7g4GPvelW/OhkkxetvPc0AEeq30z7i2Yz61LZ6s6TsJ1Pl+prPuUMpK2OW9BWrbeG9SktkkmYFW4Cgc0AR6ta2l1Ejhy2TnBNUxHFsCrEygcA+td7oHw5nvXQ3Uhij613E/g7Q9Jto3uXWRgOBmgDxjRNHlvNwNqJIgwJBGRwcj9QK7KWC0SDbNalGxW3d+IdK0wFNLiVieDxWHNrklxlnRSD2xQBFZWjSRlLKMiI8FielbOk+DmuP3ovjgHlOmawZNUZY2Kt5b+gPFN0rxDJBKHuLggDtnrQB1d3odlBN5Ew3P71saYum6fbCFLeIyjn5q4LV/F9rcXYCszse4rNv/EMRtjEhkSb1NAHpuo6b4cv4yb5UEjdVWuY1j4f6A1v59vP5KHpivP4dSZpMm6bzPVjW9Z6q86iGe7SRB0U0AZ9/o0lsfK015JAp+961JZwa1pe2W1UOzHkE11NkTL8qyxxjoCKs3mgSSIskd7k9eDQBy+sXGtX0CCePGBzWdpVxLaLKjRjLcZauntfPEjQHc3OCSM8VqnwPb6hLE0c5Un7wPFAHEWlss86yXHKg84Nd5o2h6NdBZPNZXH8JrXHw2jtmRjdqFA5G6n3vh+0gBMV0AB12mgC1LcQaTasVw0a9WB5Fcnqviqyk3Sqm/wCtZ/iJ1tt0IumZD71xF3dWiyFDJ+GeKAO0s/ENj5wmfgnooFVNU1M3MzPFIVQ8Vy0WrafbHG1WPrVdtYiaZnjGF/u5oA7C21mG3A3SFm75qefxhBBD88g57ZrzyXVkdyNo6Vh6jcK+cH3oA6+TxEs88zNKWznHtXPX2rxkyCeQtu6Adq5WS4ZSQrnn0qFJ9uSwJJ7mgC64iXc0TEgnJzUCBZFIVSD2NUXnw1Oa6Y8AkUAXY4AqESvhu1MKeUuRMxPoKpl+cFi3vT1Kt/EQaAJxcMF3H5j6GrEWpkp5ZQDFZ5xvzn5akLqFztoAtG6VDuC5apRcNhZGYqKzJCZBgELTo23gJI24DtQB0TatcRxINxKEjvXQ2rWt7bp5tx83cE1xEzny1UEDHFS2koiGZHPtigDqb/T0CMYXD9hg1zVwn2SQeee/G01fW5E4wHKD271Turddw5ZyT1PagDb0jV0jTaBmk1OU30wKkIrdq5mUPBMCDxnnFbukJHczI0pGPegCjc2MsS4j+ZB3qvCiwAu/3h6969FOiwNZs6MDXF6vamOYrj92O9AGNc3fnEhI93bb610WlfabgDMH05rlrjKH5GHHStLQ724ikULISPQdKAPQElEcMYkWWNl6kd60hcx3Nvu837vHIxWz4FSPUI9l0bdspkAnkVV8Q6XbQSMIwoGf4TQm0BWsrSO7KqzooPGa6QfDb7fFHMl85KDPWua0yKCzdWJHHvmu/wBG8V28CrGxAHA4oA5DxF4Ov4oSI7k7VHQ9a4U291Ybo5bVpufv4zX0TJJaa2o2SoOMdadb+CbQIWMylDyc96APm9zHLGyvC6A9ccVV+z2QjMUEzCY9Mmvom78E+H3uAZZkUdwTXCeKPh3pr6izaZMvTgqaAPIZ5Xhk8l2yR3BrY0rXFhVYvMIx6Vs614CEFu3nz4wOWzzXNt4YjiQfZ7je3pnmgDtNN1TTeHmcscc+tUb25jlmJtiAAc/NXJLaSwfKFdGHU1pWtqzBTdN8vqDzQB0ll4hEPEkjMw6ema39M8Qx3Mbi6STaBwa52DRLe5hDQSgFRnFPt5mtkkiC7j0PpQBsLpdlrkjMrDOeB0orF0c3MUpuI/lVDuIzRQBi2l1pijAJWQdDUsupggooL/QVoaf8NNado5bhFVRgkDvXp/hHwTYW4V76JN69d3egDzDT4XvbTYsEqg99tWbfw5d3J8hIGB9WFe9XVxZaXaMtpZQMq9PlFcNrviAOGaBUhlPZe1AGFpPhj7KVViqzd6622+z2MQ80pkd687n1+WOdmeUlvas6+1KW/G0XW09evSgD1HWPFDW9uoedVjHTbxXDal4kuL9wsJZiD1Jrnkljn/d3N1vVfU1Xl1C0tjiCTpQBtzmWccxqh7n1quoCZDzbTXPza8kmVEhFY+pamSw8iQk+lAHVX5U8+fkfWsS61GCA+WzE+/WsEahNI4Fyx57DvU8jxFcNFlfU0Aa0OrQQgSxEMw9qSXWZLs73jGPXbg1zs90kS7IECtTLfUZgNsnJ9qANhpopZiGYp61pW9jbqolS6YH0LVyUlyBPvlBxnpV+0nSQjJKr29qAOvsLPUZJP3MzbCeDmvRfDEEuVW6ugwB5Ga8uj8RSWVqiW+DjgmiLxDqER8yIkF+uaAPrLRp/C0duofyGlxyfeqPi3WtAtYwbaWJSBwFPevl2LWLtJNzyuM8n5qmvNbtpYwsjyFsfxGgDvfFXjIzu3k3bKoHQN1ripfHt1ZBo4i0gPdjXN3F3DsYopPvXPXlx5rMRQB1Go+MLi+BMrhT6Vzd3fyzyHuDzxWQSQc44oMp7cUAaAkdH3s5I9DTnvCSTGWU96zVlbd8xJFTiTcu3Ax60AXVkkI3ljk96py3Eu87+RTXdlH3/AMKrs7MeTQBN9oMf3OvuKbJcSN94j8KjJ4puaADk5NAJoyfWgcUAOVio4HWmg4OadvOCOxptAHceIvh9q+ieCNF8U3LWkul6qAYxA7M8OQSokBUAZ2tjBP3TSX/gDWtO+HNl4yu5bRNMu5xBFAXbzznftcrtwFOxsHPPpXplzrulWOleCdE8VyyReGda8LRw3ckalmgdJ5WimUAEkqwxwOjGqev+IofEnwi1vUpITDpi+KLWG2tR0htY7crHGB7IBn3ye9AHK6P8HtavdGtNU1nV/Dvhu2vU8y1GuagLZ50P8SrgnH1xwQah034Ta9P4zuvDz6holrNBYNqTXs13m1a3UgFxIgbA69QMYOa0/wBpiz1AfE++1KeOV9Kvo4ZNNuQCYZIPKXaIz0wOeB3575Nn4AWK2HiPxQniO11C2sn8L30kypHsmaDChjHv4JwGwTxkUAc94x+G2r+HNEGtJqeia7pAkEMl5o16LmOGQ9FfgEE+uMcjnJFcTAXc/OflFei+JvF/hKw8EXvhf4fafrK2+pzRTaheazJGZWERJREWP5QMnOevbB6jzUSFehxQBoQ3QRlCkccc1tR5uIwBImcVy3yHrwfpU9rI6TL5RI9aAL+oW8luDufP4VQt7ho5MlmUZrp9zyRASorrism/jt1DHhT6UAbek6jJcosSzsB6mrmo6HLNbM8dzn2rjbS5MXMJwewrrtBlvb+MIPlU9zQByV3pdxHLtbp61JZySW+Fi27x3rsdW8PXyKZS4aM9hXKXFqElxghx70AWLfVb6xkMkTSRlupHQ1u2fiG5KjzWLg9TnOK5qW/DxpDJggdc1saPb20oO1yW64oA6jS7iHa8nmFyw5U015xPKWjV02nms9LVLYkszrnoRTjJPH+7U793Q96AOy8P62LQBcnd9a65PEV7NHtjyyY/hNeMS6ddLIJJpGjJORW9peq3lkuIpA0Q60AejjTZL+I3NxO0ZH8Oaqo1pZSczsXHU5rFtPFtzOvleXhD3xWjLcR3VkVjtw8x6NQBmaxqolvHjRTcA/wHpWd/ZUl2d1nbmG4I7jit3R1s7OZGvmRJR1refVdPZcWy7m/vAUAeZT2N1bu32yJnx1IHWsO9nVXKxBhg9DXsV7EjQeaxyrc4IrkdZtLGYH7PbES55IFAHEpd3FthrZzluoatOzluGGXBGeuaSS1feRcRsqjhTjFR3VvKihvtPygdAaALy6x9jUxlQVbg8UVyV7fByQrZwcH3ooA9on8dRxFQm98AdKxdU8Z3FxLugLoPriuIh11ihHlJ04qjdakzvlu1AHayeK71oShmLZ/hzVB5pLj9/MW57VyC6gvm5X5T6mro1cyfuvM3Z9KANG6ngjfcwIzxuNVZntLZROkm9m6rmsnULiR0KnlQarGeLyQpTafU0AbF7eWTwKYh8/VsViS6laElYkO7oSahuJI0TdkGs2eSJvuqAaALUsyocph93X2oSVBjHBNZYfOeSo9qaZcnnPtQBru8SkOz5Ipkty87b43AQdjWYZmxgYxTN2O/NAFi5kJlyDxSpOqjgfN61UzRnigC410D1XJNIs5LZLFfaqoIHTrTlweW60AX47hc/M5wPWrN1qJEKCJiSOtZUsvAUoAKam36UAbkWqKVAGS3ofWobm4nm+afC46AVThXgNIAB7VFcOpcBCx+poAuLckRsp5qm0iE+hpCdgyw/Wo2bfzgA0ALIRjg1FTuo5IptAADg07zG6Dim0UABJJyaKKKACl+X3pOKKACiiigAoorrvhHo9j4g+JXh7StXg+0WF3dLHNFvZN64PGVII/A0AYmr65qOsW+mwajcedFp1uLS1XYq+XEGLBeAM8seTk806PX9Sj8NzaAlzjSZrlbx4PLXmVVKht2N3QkYzj2rqvFPwn8ZaJpV3rt14durbQ0kYiRnUsibiFLJu3qOnJFU/CHwv8AGfjDS31Hw7oU93YoSvnGSOJWI6hd7Ddj/ZzzQBZ8KfFvxz4U0xdO0LxDcQWK/chkjjnWMei+YrbRz0GBWZN4/wDE8+sajqlxrE89/qFm+n3M0yq5e3cYaMAghR/u4I7Uvhv4f+KfEniC90PR9Hmm1WyDG5t3dIjFg4O4uQBzx1qHxn4J8R+C9QgsvE2lTWNxOu6EFlkWQcZ2shKkjIyAcjIoA53NITzXt/w7+CWvrdT6h438NTR6J/Z1zMjSXAVllEZaMsqPvXkdGAHrXiFAExlJXAXpSQyMCckgHvUIJBpzMD0GPagDSgupFdQspIrYS2huLUu5+auZgIVg1aaagdmAMgUAQy2/kSeaDwprT0rWpkkCwjj0zWVcyGdSR8vrVNSYSGBwR0xQB6lBrdxPYiF0GT3Jrj9YS6Fy7soCnuKr6RfzSzKkk+xB3NaGrQ+bbjZchz7GgDm41bzt20uTXUaBpt+W81BhPSsm2fy22lefWt7S9aMLbQT6GgDpoZ3eJkuIlJQda5i9vZIrtTGTndxjoK1o7z7YCIFyO+K1NEg02CKZr6Lc5HANAENnfvLbFrpPNIHGO1YF7fxm4CgmNScFa3Z9WgtI3jjtxHGe/fFc3eS2t0rSRDL9eR0oA6bRbhGCwrLgHua17pbq1X9zcgL1Bryd7i5tzuRz9atR6xcPbEPcMx9KAO8Y+Zl7iYySHvmtHR3uLa4Enmo0PZK850rUJzOolyI/etKTW0ikKwTfvB6nigD0DWtYujb5hAxnpWZH4lCKFeIeZ34rGs9baRFE8e7A5NZd7eR3Nztg3I+6gDt7e7Gp7hPGUAGQcVhajEjrL5RPGRipDaX8lqn2a5T7vPNc3qLalYsfMdWyaAMxlIZ1eIA56mioJnkncNKcYOeKKAK8V4wIwpOKmN2zn7mRVAykE8cU0zsOB0oAuCbc5XYAO5oR3hm3R4K9yaomUhs80NMXOBmgC3PcyFyd457ZqrNNJKNjNxmmgknpTWRjzyKAHIDjDEmopGAOBUnnYXbmoHPzEgCgCQA4yOT6Go3yW5FCPgEGkPXrQAhzRRRQAUdDRRmgBxJY9AKQgjvSUCgBcrjqc0oI96TJpRtP3qAJVwnYnPvUZyW4Uimlzng8UqscjJOKAJSgxlnph2DjrmnM0Y6HNNZlHQUAM2jFJRnmigAooooAKKKKACiiigAooooAK774Cf8AJY/Cf/X8v8jXA0UAeyfDS8ur3Xviu15cz3DS+G9SkkMshYuysm0nPUjsT0r0bQLPT/GXgLwc+ieBIvF76Xp8dtMIvEradJZzqTvzDkDkncHHJz7CvlWigD6at9LtPFXxO8d30nhrSNX8WW0Vl9h0OXVRNBIfLVZZPNOwSlQFyDwCTyTzVzxjef2Vb/Cu68XaX4d0gWWvyG6tNGVRbWwBiY7grMAwPzMAT0r5ZooA+pfCvgDxXo/xL8UeJfEM9tLY31jf/Z7v7ckjXqtGxUxqCWICheCBgYxxXy4OvNNpaAB8Bvl6UhPbFPXJOBT/ACzkfITQA1cocgAigvz8g2t7VKyEAYQ0gjbHzKw96AAISuZCSKJfLCYUnNPjjIAwxx6GmuyMdmzB9aACz2OwR84NdDbaY0sKiCQAe55rnkVUP3ifoK6DRiGYABzQA8afOsm3bvHrXSQWdoLQFyivjketVP7OvHG6OYKp9ahksZWZFZizE8kGgB2mXEUF0yklQTjgda6TUp7GO0DLFmTHFLpfhma4g81gAFGQTWVq1q8JMcsh44oA5m4v3lmKzKTzwB3qKZnVflURqauGxTeSshZj0BrTtvDd1fQeYDuQdu9AGAklqbZhI+6XqBVcKqW5YIAexrtNO8HQTTKl0rop6sa7n/hX2iw6KzCfdgdM0AeDSC7J3Idye1SxpHMu0jbN3LGu8vPC9kspWG5CL7msK70S0jdk+05YdwaAKFvLLGoijmUsOOTUDzy2khfcrs3XHatKHw1FJzHcEn61l3WkPDKwMpIB6ZoA17HUZWUFpCi+gNJqGo27bRLukI6YqlZaTLMCPN2j3qzNoE0Y3ecp9aAKFzdqARbx9aKvQaGk/wDrLsJ+NFAHMyS5ORTN5XlaUyr/AHMCnDy+uDmgBqszDJwKjYlHzSvJk8Dim7h6UASpLx1AprSN3Oaj4zyKGIxgCgBTtPGPxpX2gfLSJjq3Shih+6uKAG5oo/EUUAKpxQxyeOlJRQAUUUUAFFFFABk0lLRQA5B9KN3rg02igBzsDwABTRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAoYjocVNFKcjc4AqCigDXhlj/vipTIjDBK4rDqWGVUHK7jQBpmGNhkN+VONuhj3Ag4NUlvWUjbGNvpVqO+X75iOKAECgnCoR71saWJk2+UuTVWGeKZBlQtamn3scPGBtoA6G3hvbqFVEXK9eahObaULPGynPUVZ07xJYSfuYpGjkH3veq82s6YshInWZ88gnpQB22lKkkCFb6NF28gmoNZsdOnx5U3nydwozWfo7aPe8tkEDOFavaPhLo3hy/SVmiUunTf3oA8Qt9C86QBLGY5P8Kmuo0vwX4gkT/iWWsiqP4XB5r6ss9L0y2QfZ7a3VR32ipJL2xtUJaWFAOwxQB8vn4XeOL1gW2RenFb9h8GPEzWgS81GMHrgGvYtU8c6PbZj+1IXI4ANYkXj+A3Cqsylfc0AeW3fwE1Wbrdoxrn9S/Z712JS1vIkjema+i4vGdiU3SzIv/Aqn/4S/SvLDNeonuTQB8my/CDxjbOfJtm49KpzfDrxJGD9qsHU92Ir7Ji8UaS0IYXsT/8AAq5/xJ4n0dowJZ4xnuCKAPlOH4YeIrs/uSOOw4IrY0n4JeLr9j+9VUHXmvc5tV0qCEyae6lyMkhqw7D4hPptw6M24MeMGgDibb9nfW9hM91GDjoDRXr1t46jvY8m4VSB/eooA+AV54pdrdAaeHiA6HP0pN6ZyQTQA5IgyeppPJZec00zHGF+UelNMjHvQAu0s+M1L5AUZfpVfP1zUiyALzkmgBoVWYgHim96e0mfugCmZ55oAU5xnnFIBnpSliRjPFJ3yKAHMjAc02gknqaO1ABRRRQAUUUUAFFFFABSUtFACUtFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAKACc5oDsOAeKSigB6TOn3TVmO+devFU6MmgDodPu4CcyJjjrVTUY7VmDW4ZW71RhuCvGKurIxTPligDR03UjatH5ZCAHJJ7ivafh14ysIF+SUggDd81fPdwHfHGPatDRZ5bZsRjk8UAfZEPxDsjb7Fnxxz81cp4m8YwzxOsEp57g14hbaz5ICzhsn9Kurrls6bSTk0ALrF/dS3m+GZs8kc0sOrahCgaVyW9Qay7/UIlB2ZL44rNh1OYsA6/L9KAOytNd/eh7q7kC9xmp9S8SafJaCMTSMM8bWribmVZFO5fl9qpWssKXOWT5fQ0AehQausNsrxXUoQjgFqz7/Urm7xumcp25rmrvVIfJ2QryO3aqB1e5b5QQoHQUAd7bXl35BVJ2UYxyaxpbi8jlbzbgnnsawV1u5xtYnniqtxeXIYO3I60AdPc6ldwunlzvn2NFc4urpkZySO9FAHMCigUtACUtFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQACplncDA5FQ0oYigCQzNnnrT4pmD5EpWoB1yaMjPIoA24ryYjqHHvUVxdSNIGA24qvbXESrtbIqw8YnXMbAfWgAW5ldt5fgVK1xJLjafwrPZJIpMMwxVhAeArdaAJzJPjBcCqk8knY1Y8lyDkhvxqNkCj5higCH7QQmDHk+tR+bKT8oAPpT9isxwxqEjy2JDEn3oAs7pEA81wM9KcJDtIZy9U3JdeXBpoZ0+lAEry7H5UEUVA77+oooAZxS0UUAFFFFABRRRTAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACgHFFFADo8bstU6OC6/MQBRRQBZJjD7i2frVuCSN0wFzRRQBMIo2GdxBqnPA28gSZ+tFFAEDvJEOMVWkn8wfMOaKKAID0ooooAKKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This longitudinal dorsal ultrasound scan of the second metacarpophalangeal joint shows thickened synovium with hyperechoic deposits (white arrow) indicative of crystalline arthropathy. The double contour sign at the metacarpal head (yellow arrow) represents crystal deposition on the articular cartilage surface. The findings in this 56-year-old man with polyarthritis are consistent with gout.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; 2012 American College of Rheumatology. Used with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_42_35503=[""].join("\n");
var outline_f34_42_35503=null;
